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Abstract 
Senescence is a cell stress program characterized by a stable cell cycle arrest and 
thus aims to protect against replication of potentially harmful cells. In oncogene-
induced senescence (OIS) the cell cycle arrest is brought about by activation of an 
oncogene. This in turn initiates a DNA damage response and subsequently, the DDR 
induces p53-p21 and RB tumour suppressor pathways. The metabolism of senescent 
cells is highly altered, notably there is increased secretion of proteins and increased 
functional activity of certain metabolic enzymes. There have been many recent 
studies investigating the role of specific metabolic pathways in OIS and how they 
may be targeted for therapeutic benefit. This thesis aims to identify novel metabolic 
regulators of OIS, by combining high throughput RNAi screening and LC-MS based 
methods. This thesis has identified and validated 17 essential OIS metabolic genes; 
in this list, there was enrichment for genes involved in lipid biosynthetic processes. 
Lipid metabolism was an attractive focus for this thesis as it has not been extensively 
studied in current literature. Next, ceramide synthase 4 (CERS4) was extensively 
validated as a key enzyme for both OIS and replicative senescence. Using LC-MS 
based lipidomics, CERS4-driven rewiring of lipid metabolism in OIS was revealed 
and this corresponded with an accumulation of ceramides due to increased de novo 
ceramide synthesis. It was then confirmed OIS-related ceramide is mechanistically 
linked to cell cycle via the PP1-RB-E2F axis. Ceramide activates PP1, which 
physically binds to RB in a CERS4-dependent manner. PP1 is then able to 
dephosphorylate and activate RB, which inhibits transcription of E2F targets (cell 
cycle genes). Overall, this thesis identifies a metabolic checkpoint that links altered 
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Lay Summary 
Senescence is a biological process cells undergo when they encounter stress – cells 
will stop dividing and undergo numerous physical and chemical changes. In 
oncogene-induced senescence (OIS), a gene suffers a dangerous change (mutation) in 
its sequence that will pre-dispose the cell to increased pre-cancerous cell division. 
This altered gene is termed an oncogene, and OIS will be activated when an 
oncogene is mutated. When the cell gains an additional oncogenic mutation, it will 
convert from a pre-cancerous to a cancerous state. OIS is a fail-safe mechanism that 
attempts to prevent the pre-cancerous cells from replicating and therefore converting 
to cancer. 
Metabolism is the set of chemical reactions that occur in a cell that allows it to 
function and remain alive. These reactions involve many different metabolites, such 
as sugars, fats and proteins, and are controlled by proteins called enzymes. Normal 
cell metabolism has been extensively studied and in recent years there has been 
increased interest in how metabolism of senescent cells is altered. Due to the 
involvement of senescence in cancer, it is thought the altered metabolic pathways 
could be potential targets for new cancer therapies. Therefore, the main aim for this 
thesis was to identify new metabolic regulators of OIS, that could one day be 
therapeutic targets for cancer treatment.  
In this thesis, large-scale changes in fat content of OIS cells were shown and a role 
for an enzyme involved in fat metabolism in OIS was identified. This enzyme 
synthesizes specific fats known as ceramides, that are vital for cell function. It was 
found OIS causes increased levels of ceramides and this was due to increased activity 
of a metabolic pathway that makes ceramides from scratch. Further investigation of 
this pathway demonstrated activation of a cell division protein essential for OIS by 
ceramide, thus linking the altered fat metabolism to cell division and OIS. In the 
future, it is vital to confirm these results using a model more relevant to humans so 
the therapeutic benefit of targeting this metabolic pathway can be established. 
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Chapter One: Introduction 
1.1 Cellular senescence 
Senescence, derived from the Latin word senescere (meaning ‘to grow old’), is 
typically associated with organismal aging. In concept, cellular senescence 
(henceforth, ‘senescence’) is biological aging at a cellular level. However, over the 
past 20 years, senescence has been implicated in biological situations other than 
aging, such as cancer and tissue repair. In this section, all concepts of senescence are 
explored, including: a historical overview of senescence research; markers used to 
identify senescent cells in vitro and in vivo; types and triggers of senescence; and the 
role senescence plays in health and disease. 
1.1.1 Discovery of senescence 
The concept of senescence was first postulated in 1891. August Weismann suggested 
in his collection of biological essays “death takes place because a worn-out tissue 
cannot forever renew itself and because a capacity for increase by means of cell 
division is not everlasting but finite” (Weismann et al., 1891). This view was 
challenged in 1921 by Alexis Carrel and Albert Ebeling, who reportedly cultured 
chick heart fibroblasts continuously for 34 years (Carrel and Ebeling, 1921). This 
work created a dogma in the tissue culture community that cells grown in culture, 
provided with nutrients, were immortal. However, this work could not be reproduced 
by anyone and was likely due to experimental error. In 1961, the pioneer of the 
senescence field Leonard Hayflick, along with Paul Moorhead, published work 
contradicting the widely-accepted dogma (Hayflick and Moorhead, 1961). They 
indicated the limited proliferative capacity of primary human cells in culture 
occurred in three phases (figure 1.1): primary culture (i.e. pre-passaging), phase I; 
exponential growth, phase II; slowing and arrested growth (i.e. senescence), phase 
III. Hayflick published work in 1965 further supporting the limited in vitro lifetime 
of primary human cells and concluded this phenomenon “may be an expression of 
aging or senescence at the cellular level” (Hayflick, 1965). These two seminal 
papers have been collectively citated over 6000 times (as of July 2017), which 
reflects the significance of Hayflick’s work to the senescence field. Hayflick has 
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been further recognised for his founding work, by naming the point at which cells 
begin to senesce in his honour: the Hayflick limit. It is important to introduce here 
that senescence is implicated in cancer biology due to the unique ability of cancer 
cells to overcome the Hayflick limit and grow indefinitely (figure 1.1).  
Senescence is now defined as a failsafe mechanism that initiates a stable cell cycle 
arrest and halts division of harmful cells. It is driven by multiple different stresses 
(such as telomere shortening or oncogene activation) and results in a diverse 
collection of phenotypes (collectively known as senescence markers). Since 
Hayflick’s seminal work, the fundamental mechanisms of senescence and role of 
senescence in human health and disease have been established and will be reviewed 
in the rest of this chapter. 
 
Figure 1.1 Hayflick’s three phase phenomenon of primary human cell growth 
in vitro 
Hayflick theorised the following three phases of cell growth in culture. Phase I comprised of no 
growth of cells before passaging started. Phase II was exponential growth of cells during 
passaging. Phase III was a slowing and eventual arrest of cell growth, even though passaging 
was continued. Hayflick found these phase III/senescent cells could remain in culture for up to 
one year before dying (Hayflick, 1965). The point between phases II and III is termed the 
Hayflick limit. Cancer cells can grow exponentially beyond the Hayflick limit and thus bypass 
senescence. Adapted from Shay and Wright (2000). 
   
   25 
1.1.2 Senescence markers 
As described in the previous section, growth arrest is the hallmark feature of 
senescence and is used for preliminary identification of senescent cells in vitro and in 
vivo. However, as stable growth arrest (or G0 phase of the cell cycle) can be 
attributed to quiescence or terminal differentiation, cell cycle exit cannot be used 
alone for the identification of senescence. Senescence results in a heterogeneous 
phenotype that is unique due to multiple effector programmes (reviewed by Salama 
et al., 2014). In addition to cell cycle analysis, the senescence markers summarised 
below can be used to confirm the presence of senescence, phenotypically and 
molecularly. 
1.1.2.1 Cell morphology 
Morphological changes due to senescence can be quite prominent and are used as 
initial identification in cases where senescence is not originally expected. Although 
morphology depends on the senescence trigger, senescent cells are generally flat and 
enlarged with vacuoler and nuclear modifications. H-RasV12-induced senescent 
fibroblasts have this general phenotype, with increased cytoplasmic vesicles (Serrano 
et al., 1997). In contrast, BRAFV600E-induced senescent melanocytes have a spindle-
shaped morphology (Michaloglou et al., 2005). 
1.1.2.2 DNA damage 
Senescence can be induced by a variety of different triggers and mostly DNA 
damage and the activation of DNA damage response (DDR) pathways are an 
essential post-trigger mechanism of senescence induction and maintenance (Fagagna 
et al., 2003). First, the DDR is induced by senescence triggers such as: telomere 
shortening (Harley, Futcher and Greider, 1990), ionising radiation (Di Leonardo et 
al., 1994), drugs (e.g. etoposide and cisplatin (Chang et al., 1999)) or oncogene-
induced hyperproliferation (Gorgoulis et al., 2005). DNA damage, such as double 
stranded DNA breaks, is sensed by specialised protein complexes. The sensor 
complex recruits and activates ATM apical kinase, which phosphorylates histone 
H2AX at Ser139 to form γH2AX (this phosphorylated protein is often used as a 
DDR marker). γH2AX is a vital component of the DDR signal transduction cascade, 
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acting in a positive feedback loop to recruit more ATM to the DNA damage lesion 
(Celeste et al., 2002). The positive feedback loop is enforced by DNA damage 
mediators MDC1 and 53BP1 (Abraham, 2002; Lou et al., 2003). ATM only 
phosphorylates serine or threonine residues if they are followed by a negatively 
charged glutamine (SQ/TQ) (Kim et al., 1999). Another marker commonly used to 
detect DDR are these phosphorylated S/T Q residues (or pS/TQ) on DNA damage 
mediators. When the DDR kinase activity reaches a specific threshold, downstream 
DDR factors, such as checkpoint kinases 1/2 (CHK1/2), are activated by 
phosphorylation (Buscemi et al., 2004; Bekker-Jensen et al., 2006). Effector 
proteins, such as p53 and subsequently p21CIP1, are activated by CHK1/2 and initiate 
cell cycle arrest to allow the cell to attempt DNA repair (d’Adda di Fagagna, 2008). 
1.1.2.3 Tumour suppressor activation 
Tumour suppressors are effector proteins that mediate the stable cell cycle arrest in 
senescence and are activated by many different pathways. For example, in some 
types of senescence the DDR is a vital trigger for tumour suppressor expression. See 
figure 1.2.A for an overview of the most common tumour suppressors activated in 
senescence. p53 (encoded in humans by TP53) is commonly known as the ‘guardian 
of the genome’ (Efeyan and Serrano, 2007) and is heavily implicated in senescence 
signalling. The p53 node specifically modulates the activity and expression of cyclin-
dependent kinase inhibitor (CDKi) p21CIP1 (encoded by CDKN1A). Other commonly 
measured CDKi for senescence detection in humans include p16INK4a (encoded by 
CDKN2A) and p15INK4b (encoded by CDKN2B). Inhibition of CDKs and cyclin 
complexes results in the critical step of senescence induction: the 
hypophosphorylation and activation of Retinoblastoma protein (encoded by RB), 
which in turn inhibits E2F-promoted cell cycle gene transcription (Chicas et al., 
2010). The regulation of RB phosphorylation is critical for cell cycle progression, 
which is mediated by protein phosphatases and CDKs (see figure 1.2.B).  RB activity 
can be measured as an indicator of senescence, by analysing E2F target gene 
expression and RB phosphorylation state. 
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Figure 1.2 Tumour suppressor networks activated during senescence 
(A) Tumour suppressors are essential for senescence signalling. Senescence can have a variety 
of different triggers; generally, there is activation of p53/p21CIP1 and p16INK4a/RB tumour 
suppressors, with reciprocal regulation between the two pathways. p16INK4a and p21CIP1 are CDK 
inhibitors and result in activation of RB to repress E2F-promoted cell cycle genes.                      
(B) The regulation of RB is essential for cell cycle control. In proliferating cells, RB is 
phosphorylated by CDKs and inactivated; pRB frees E2F transcription factors to initiate the 
transcription of genes essential for cell cycle progression (left schematic). In non-proliferating 
cells, RB is hypophosphorylated by protein phosphatases (PP) and activated; RB prevents 
transcription of E2F target genes (right schematic). 
Red lines indicate inhibitory functions. Grey lines/arrows indicate inhibited pathways. Black 
lines/arrows indicate active pathways.  
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1.1.2.4 Senescence-associated heterochromatic foci 
Senescence causes an unusual nuclear phenotype due to gene expression patterns and 
regulation of senescence markers, ultimately leading to global changes in chromatin 
structure (reviewed by Adams (2007)). One of the well characterised and unique 
gene regulation mechanisms in senescence is that of the murine and human INK4A-
ARF locus (which encodes senescence marker p16INK4a). The locus is repressed by 
H3K27 trimethylation and associated polycomb proteins (Jacobs et al., 1999); this 
negative regulation is counteracted by Jumonji Domain containing 3 (JMJD3) driven 
H3K27 demethylation (Agger et al., 2009; Barradas et al., 2009). Although 
chromatin regulation had been previously postulated (Rogakou and Sekeri–Pataryas, 
1999), it was not until 2003 when senescence-associated heterochromatic foci 
(henceforth, SAHF) were fully characterised. Narita and colleagues found DAPI-
stained nuclei of human senescent cells had a punctate staining pattern, differing to 
the diffuse DNA distribution of proliferating and quiescent cells (Narita et al., 2003). 
The authors also found SAHF chromatin was more compact and resistant to nuclease 
digestion. SAHFs are enriched in heterochromatic marks (e.g. H3K9 methylation), 
chromatin-binding High Mobility Group (HMGA) proteins (Narita et al., 2006) and 
transcription-silencing histone macroH2A (Zhang et al., 2005); and lack euchromatic 
marks (e.g. H3K9 acetylation and H3K4 methylation). Formation of a single SAHF 
is a multi-step process involving the condensation of a single chromosome (Zhang, 
Chen and Adams, 2007). SAHF formation is driven by chromatin regulators Anti-
Silencing Function 1a (ASF1a) and histone cell cycle regulator (HIRA) (Zhang et al., 
2005). The function of SAHFs is thought to contribute to the stable transcriptional 
programme of senescent cells; specifically, stable transcriptional repression of 
proliferation-associated genes (such as cyclin A). The tumour suppressor RB and 
HGMA proteins are required for SAHF function by cooperating recruitment of 
heterochromatic proteins to E2F-driven promoters and resulting in the repression of 
E2F target gene transcription (Narita et al., 2003, 2006). 
1.1.2.5 Senescence-associated β-galactosidase 
Senescence-associated β-galactosidase (SA β-gal) was one of the first characterised 
features of senescence and can be easily measured in vitro and in vivo (Dimri et al., 
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1995). The β-gal is encoded by the gene GLB1 (in humans) and is localised to 
lysosomes (Lee et al., 2006). Non-senescent β-gal activity occurs at pH 4 but 
lysosomal expansion during senescence (Kurz et al., 2000) results in increased 
activity of the β-gal that can be measured specifically at pH 6. It is unknown if SA β-
gal has a role for induction and/or maintenance of senescence. In recent years, there 
have been multiple studies showing senescent cells have highly altered metabolism 
(see 1.2.3). Increased activity of lysosomal β-gal, together with its implications in 
autophagy (Gerland et al., 2003; Narita et al., 2011), may reflect the changing 
metabolic environment senescence generates. The use of SA β-gal as a marker for 
senescence may be limited as it is also detected in quiescence induced by confluency 
and serum withdrawal (Yang and Hu, 2005). Nonetheless, when used in combination 
with other markers, SA β-gal is a good initial indicator of senescence.  
1.1.2.6 Senescence-associated secretory phenotype 
Senescent cells have a diverse secretome, used to enforce a complex response on the 
cellular microenvironment, utilising both autocrine and paracrine pathways. 
Historically, individual secreted factors were implicated in replicative senescence, 
including extracellular matrix (ECM) factors such as fibronectin, collagenase and 
gelatinase (Mann, McKeown-Longo and Millis, 1988; Millis et al., 1989; Sottile et 
al., 1989; Zeng and Millis, 1994). Microarray analysis was used to identify a strong 
inflammatory response present in the senescent transcriptome, that mimicked wound 
repair processes (Shelton et al., 1999). More recently, the composition of the 
senescence-associated secretory phenotype (SASP) has been characterised using 
gene expression profiling, antibody arrays and proteomics. The SASP is composed of 
cytokines (interleukins: IL6, IL1α, IL1β), chemokines (IL8 and immune cell 
attractants: MCPs and MIPs), growth factors (transforming growth factor beta 
(TGFβ)), ECM components (matrix metalloproteases) and proteases (Acosta et al., 
2013). Expression of the SASP is mediated by transcription factors C/EBPβ and NF-
κB (Acosta et al., 2008; Kuilman et al., 2008; Chien et al., 2011; Jing et al., 2011); 
specifically, chemokine signalling is regulated via these transcription factors and 
subsequently through the CXCR2 receptor (Acosta et al., 2008). C/EBPβ also has a 
role for regulating the composition of the SASP. Hoare et al. (2016) found NOTCH1 
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represses C/EBPβ in an ‘early’ TGFβ SASP response and vice versa in a ‘late’ and 
classical NF-κB-C/EBPβ-IL6-IL8 SASP response. In addition, persistent DNA 
damage is essential for the regulation of some SASP factors, such as IL6 and IL8, in 
many different types of senescence (Bartkova et al., 2006; Di Micco et al., 2006; 
Coppé et al., 2008; Rodier et al., 2009). More recently, IL1 signalling activation, via 
the inflammasome and caspase-1, has been implicated in SASP expression 
(particularly IL6 and IL8), upstream of C/EBPβ and NF-κB (Acosta et al., 2013). 
Furthermore, IL1α has been proposed as a master regulator of senescence, through 
mTOR activity (Laberge et al., 2015). Finally, inflammasome-mediated SASP 
expression is linked to oxidative stress activation and the DDR (Hubackova et al., 
2012).  
The SASP can have both autocrine and paracrine functions, which result in complex 
and paradoxical outcomes. There is debate whether the function of the SASP is 
beneficial or detrimental for human physiology and pathology. SASP pro-
inflammatory factors can threaten neighbouring cells with harmful outcomes, such as 
cancer and fibrosis. Whereas, SASP factors also have an essential tumour 
suppressive role for the induction and maintenance of the cell cycle arrest. The roles 
of senescence and the SASP for human health and disease, good and bad, are further 
discussed in 1.1.4. 
1.1.2.7 Summary 
Senescent markers described here are hallmark features of many different senescence 
scenarios. They provide a useful tool for identifying senescent cells in vitro and in 
vivo, particularly when measured together using High Content Analysis (Acosta et 
al., 2013). The presence or absence of an individual senescent marker is highly 
dependent on the context of the cellular senescence, such as genetic background and 
tissue microenvironment. In the next section, the triggers and mechanisms of the 
three main types of senescence are described. 
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1.1.3 Types of senescence 
1.1.3.1 Replicative senescence 
The senescence Hayflick observed in cultured fibroblasts is now recognised as 
replicative senescence, typically associated with aging. During the 1970s, work on 
DNA replication and chromosome structure drastically changed the field’s 
understanding of the causative mechanisms of replicative senescence. First, James 
Watson described the ‘end-replication problem’ (Watson, 1972), resulting in the 3’ 
end of the lagging strand not being completely replicated. This occurs because there 
is no lagging strand priming DNA available for a polymerase to bind and initiate 
replication of the next Okazaki fragment. Next, Alexey Olovnikov hypothesised the 
‘marginotomy theory of aging’ (Olovnikov, 1973): the end of DNA molecules were 
composed of ‘telogenes’, prone to shortening during each division (according to 
Watson’s end-replication problem). Olovnikov realised this could be an explanation 
for Hayflick’s observation of human cells having a finite number of replications 
when cultured in vitro. 
Telomeres are sequences of DNA composed of tandem repeats (in mammals: 5’-
TTAGGG-3’) found at the end of every chromosome. They function to protect the 
genome from DNA metabolising enzymes and are often referred to as ‘molecular 
clocks’ that record the replication of cells (McClintock, 1941; Blackburn, 1991; 
Muñoz-Espín and Serrano, 2014). Once the telomeric sequence length was 
determined, many studies proved Watson’s and Olovnikov’s hypotheses were correct 
by showing telomere length changed depending on tissue type (Cooke and Smith, 
1986) and human telomeres shortened in vitro (Harley, Futcher and Greider, 1990) 
and in vivo (Lindsey et al., 1991). Meanwhile, Carol Greider had also used the 
telomere-enriched protozoan Tetrahymena thermophila to identify an enzyme (now 
known as ‘telomerase’) that maintains telomere length (Greider and Blackburn, 
1985). Telomerase elongates telomeric regions using an innate RNA template and 
reverse transcriptase activity (Feng et al., 1995). Telomerase research was a turning 
point in the field, as it allowed definitive demonstration that telomere shortening 
could specifically induce senescence, rather than it being an effector programme; 
expression of the telomerase catalytic subunit in primary human cells resulted in 
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senescence bypass when the cells were passaged (Bodnar et al., 1998). The ectopic 
expression of telomerase is now often used for cell immortalisation and this 
discovery has been fundamental for industrial and clinical R&D in recent years. 
As stated previously, the DNA damage response (DDR) is a key mechanism for 
senescence induction and maintenance. Human cells detect telomere shortening as a 
type of DNA damage, and as telomeres are not easily targeted by DNA repair 
mechanisms, the DDR eventually occurs. In recent years, the molecular mechanisms 
of telomere regulation and function relative to the DDR have been examined. 
Telomere structure was determined in 1999 using electron microscopy; Griffith and 
colleagues demonstrated the 3’ single strand telomeric DNA loops back to form a t-
loop (Griffith et al., 1999). Telomeres recruit a multi-protein complex collectively 
known as shelterin, composed of six proteins: TRF1, TRF2, POT1, TIN2, TPP1 and 
Rap1, that recognise and protect the telomeres (Palm and de Lange, 2008). Shelterin 
proteins have been shown to have contradicting functions, depending on an unknown 
threshold for telomere length and shelterin recruitment. Shelterin proteins contribute 
to persistent telomeric DDR by inhibition of DNA repair at telomeres but also inhibit 
DDR kinases ATM/ATR when present at sufficient levels (van Steensel, 
Smogorzewska and de Lange, 1998; Fumagalli et al., 2012). In addition, telomere 
shortening can trigger a DDR through ATM to p53 and p21CIP1 tumour suppressors 
but not p16INK4a (Herbig et al., 2004). In conclusion, the molecular mechanism that 
links telomere shortening to replicative senescence is complex and depends upon a 
balance of multiple factors, that is disturbed when telomeres shorten below a certain 
threshold.  
1.1.3.2 Oncogene-induced senescence 
H-Ras (a member of the Ras superfamily of proteins) was first identified as an 
oncogene by Jennifer Harvey’s work on sarcoma-causing viruses in rats (Harvey, 
1964) and subsequently, the human H-Ras gene was identified in cancer cells 
(Cooper, 1982; Parada et al., 1982). Since their discovery, Ras genes have been 
extensively studied and shown to be mutated in many different types of cancers 
(Prior, Lewis and Mattos, 2012). 
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In 1997, Serrano and colleagues identified a cell cycle arrest in human primary cells 
with oncogenic H-RasV12 expression, that was phenotypically identical to replicative 
senescence (Serrano et al., 1997). They characterised oncogene-induced senescence 
(hereafter, OIS) by an activation of p16INK4a/RB and p53/p21CIP1 pathways, in 
addition to classical senescence markers (such as morphological changes and SA β-
gal). This was the first indication that Ras oncogene expression could primarily be 
involved in cell cycle arrest and not transformation. It was also a pivotal study for the 
field as it exposed a type of senescence independent of telomere shortening. This was 
confirmed shortly after by showing telomerase: (1) is not essential for OIS (Wei, Wei 
and Sedivy, 1999) and (2) is highly expressed in cancer cells (Shay and Wright, 
2006). Conversely, recent work has shown that derepression of telomerase can 
bypass OIS in vitro via epigenetic and transcriptional regulation of activity (P. L. 
Patel et al., 2016). Additional mutations in OIS-essential genes (such as p53 and RB) 
are required to bypass senescence and allow progression of cancer (Dirac and 
Bernards, 2003; Sage et al., 2003). Since Serrano’s original work, OIS has been 
established as an ‘emergency brake on cancer’; in response to oncogene-induced 
hyperproliferation, OIS acts to halt division of cells vulnerable to transformation (in-
keeping with the classical definition of senescence).  
There are approximately 50 oncogenes recognised to induce senescence in vitro and 
in vivo, many of which are part of the Ras signalling pathway (reviewed by 
Gorgoulis and Halazonetis, 2010). In 2005, multiple groups published the first 
evidence of OIS in vivo (mouse and human), using a variety of different oncogenic 
drivers: KrasV12-driven lung adenoma in mice (Collado et al., 2005); BRAFE600-
driven melanocytic nevi in humans (Michaloglou et al., 2005); and Pten-/--driven 
prostate intraepithelial neoplasia (PIN) in mice (Chen et al., 2005). OIS was 
exclusively observed in pre-malignant lesions, along with tumour suppressor 
expression and SA β-gal activity, and was absent in more advanced cancerous 
lesions. In addition to Pten inactivation (Chen et al., 2005), other tumour suppressors 
have been implicated in OIS after loss in vivo including: neurofibromin-1/NF1 
(Courtois-Cox et al., 2006), von Hippel-Lindau/VHL (Young et al., 2008) and 
Retinoblastoma/RB (Shamma et al., 2009). Oncogenic BRAF and K-Ras have also 
been implicated in mouse and human serrated colorectal cancers (Bennecke et al., 
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2010; Carragher et al., 2010). These in vivo models have helped establish the role of 
OIS in cancer biology, and in recent years its use in the development of new cancer 
therapeutics has been explored (reviewed by Acosta and Gil, 2012). OIS and cancer 
pathology is further discussed in 1.1.4.1. 
OIS is typified by upregulation of p16INK4a and p53 pathways but expression and 
function of these pathways vastly depends on genetic context of the OIS. In mice, 
inactivation of p19ARF is capable of bypassing OIS and allow tumour development 
driven by Ha-ras (Kamijo et al., 1997). This p19ARF tumour suppression is mediated 
upstream of p53, independently of DNA damage and the DDR (Christophorou et al., 
2006). In humans, OIS is more susceptible to bypass by p16INK4a inactivation, 
upstream of RB, rather than p14ARF (the human ortholog of p19ARF) (Wei, Hemmer 
and Sedivy, 2001; Ben-Porath and Weinberg, 2005). Also, tumour suppressor 
activity of p53 is essential for OIS induced by Pten inactivation in mice. Pten-/- mice 
with p53 knockdown exhibited a lethal invasive prostate cancer, similar to human 
pathology, due to bypass of OIS at the PIN stage (Chen et al., 2005). Finally, 
although Pten-loss induced cellular senescence (PICS) does not present with DNA 
damage (Alimonti et al., 2010), the DDR is an established mechanism for OIS-
related tumour suppressor activation. For example, H-RasV12 expression in human 
cells results in an increased number of prematurely terminated replication forks and 
double stranded DNA breaks and inhibition of DDR kinase ATM bypasses OIS 
(Bartkova et al., 2006; Di Micco et al., 2006). 
1.1.3.3 Mitochondrial dysfunction-associated senescence 
Mitochondria were first implicated in senescence by Denham Harman, who 
hypothesised reactive oxygen species (ROS), produced as a by-product of 
mitochondrial redox metabolism, cause the damage to DNA, lipids and proteins 
typified in aging (Harman, 1972). Since this ‘Mitochondrial Theory of Aging’, there 
has been much work done to determine the role of mitochondria in replicative 
senescence (reviewed by Passos, von Zglinicki and Kirkwood, 2007). In recent years, 
there has been progress in understanding the mechanistic role mitochondria and ROS 
play in senescence, coinciding with many studies also implicating rewired 
mitochondrial metabolism (described in 1.2.3.1). Dysfunctional mitochondrial 
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activity and content have been analysed in a variety of models, to determine whether 
mitochondria can affect senescent features, such as the SASP, and therefore are 
effectors of senescence.  
First, Correia-Melo et al. (2016) targeted human fibroblasts for mitochondrial 
depletion using Parkin-CCCP mediated mitophagy (Narendra et al., 2008) and 
assessed the senescent response, induced by radiation. The authors found 
mitochondrial depletion increased glycolysis-generated ATP, indicating senescence 
is dependent on mitochondrial oxidative metabolism (similar to the essentiality of 
pyruvate dehydrogenase during OIS (Kaplon et al., 2013)). Mitochondrial depletion 
also caused a reversal of senescent-specific transcription, particularly pro-
inflammatory factors of the SASP. Importantly, the authors also found a mechanism 
that linked senescent-associated mitochondria accumulation to the DDR via 
transcriptional activation of mitochondrial biogenesis regulator PGC-1β and 
upstream regulators ATM, Akt and mTOR. Overall, this study revealed senescent 
cells increase their mitochondrial content to accumulate ROS and promote a 
persistent DDR, thus creating a positive feedback loop for reinforcing senescence.  
Second, a similar study utilised RNAi (for depleting sirtuins 3/5) and 
pharmacological inhibition (rotenone and antimycin, electron transport chain 
inhibitors) in human fibroblasts to disrupt the function of mitochondria. Using these 
approaches, Wiley et al. (2016) characterised a distinct type of senescence called 
mitochondrial dysfunction-associated senescence (MiDAS). During MiDAS, a 
decrease in NAD+/NADH ratio activates AMPK-p53 signalling that enforces a 
growth arrest. In addition, MiDAS is characterised by a lack of IL1R-dependent pro-
inflammatory factors of the SASP, indicating the composition of the SASP depends 
on the context of senescence. The authors also found senescent cells in a mouse with 
increased mitochondrial DNA mutations had a MiDAS-type SASP, confirming 
MiDAS is exists in vivo and is likely to be physiologically relevant to humans. 
Together, these recent studies have revealed mitochondria are central effectors for 
the maintenance of traditional senescence and the induction of a distinct type of 
senescence (MiDAS). How these findings are implicated in human health and 
disease are still being assessed. Finally, the mechanistic effects of altered 
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mitochondrial metabolism and other rewired metabolic pathways during senescence 
are discussed further in 1.2.3; and identifying novel senescent-induced metabolic 
rewiring is the focus of this thesis (1.4).  
1.1.3.4 Summary 
Senescence can be triggered by a variety of different mechanisms; the best 
characterised, described above, include telomere shortening, oncogene activation (or 
tumour suppressor loss) and mitochondrial dysfunction and ROS. In this section, it 
has been described that the type of senescence and the resulting phenotype vastly 
depend on the trigger; how these different types of senescence responses positively 
and negatively affect tissue biology is discussed next. 
1.1.4 Role of senescence in health and disease 
Senescence has a complex role in human health and disease (reviewed by Muñoz-
Espín and Serrano, 2014). Over the years, senescence has been associated with many 
diseases and current efforts are focussed on delineating the underlying senescence-
related pathological mechanisms. In addition, senescence has recently been 
implicated during embryonic development and normal physiological settings. This 
section reviews the role of senescence for human health and disease and how it can 
be therapeutically manipulated. 
1.1.4.1 Cancer 
Oncogene-induced senescence plays a pivotal role in cancer prevention, as 
introduced in 1.1.3.2. OIS is detected in benign stages of both mouse and human 
tumorigenesis and must be bypassed in subsequent cells to allow progression of 
malignant lesions. Remaining senescent cells in a tumorigenic lesion are permanently 
arrested and are cleared by immune cells (some examples of immune clearance 
mechanisms are further discussed below). A key effector programme of OIS, the 
SASP, can contribute to both anti- and pro-tumorigenic outcomes. The SASP is a 
complex signalling network of secreted factors, with both autocrine and paracrine 
functions (see 1.1.2.6). Acosta et al. (2008) and Kuilman et al. (2008) showed SASP 
factors IL6 and IL8 reinforce both replicative and oncogene-induced senescence by 
maintaining the cell cycle arrest via tumour suppressor regulation and therefore work 
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as an autocrine feedback network. As an example of paracrine senescence, vascular 
endothelial growth factor (VEGF) and other TGFβ ligands were identified to regulate 
tumour suppressors p15INK4b and p21CIP1 during paracrine senescence; via this 
pathway, the SASP can mediate the paracrine spread of tumour suppressive 
senescence to normal cells (Hubackova et al., 2012; Acosta et al., 2013). In contrast, 
murine senescent fibroblasts have been shown to promote tumour vascularisation and 
tumorigenesis via VEGF (Coppé et al., 2006). Other pro-tumorigenic effects of the 
SASP include promoting: proliferation and transformation of mammary epithelial 
cells (Krtolica et al., 2001); motility of cancer cells in vitro (Ohuchida et al., 2004; 
Coppé et al., 2008); differentiation of mammary epithelial cells (Parrinello et al., 
2005). In conclusion, some would argue the anti-tumorigenic benefits of senescence 
outweigh the detrimental pro-tumorigenic effects. However, there is a fine balance 
between the two outcomes of OIS, depending on the context (e.g. cell types 
involved) and the effect on the whole tumour microenvironment. 
OIS has a vital role for the immune surveillance of murine liver cancer 
tumorigenesis, specifically hepatocellular carcinomas (HCC). Xue et al., (2007) 
showed the SASP can signal, in a paracrine-manner, for immune clearance. This 
activation of the innate immune response was p53-dependent and resulted in natural 
killer (NK) cell-mediated clearance of senescent cells from pre-malignant liver 
lesions. This was further supported by work showing NK cell recruitment to p53-
induced senescent liver lesions is dependent on the chemokine CCL2 (Iannello et al., 
2013). CCL2 is also secreted from senescent pre-malignant hepatocytes to recruit 
CCR2+ myeloid cells (Eggert et al., 2016). When differentiation of immature 
myeloid cells into macrophages occurs, senescent cells and pre-malignant lesions are 
cleared; however, when differentiation does not occur, immature myeloid cells 
promote HCC growth through NK cell inhibition, indicating the protective function 
of senescence against cancer is context-dependent. In addition, GR-1+ myeloid cells 
deregulate senescence in prostate lesions by interfering with the SASP, and thus 
protecting surrounding tumour cells from senescence (Di Mitri et al., 2014). Lastly, 
CD4+ T cells have been implicated in the clearance of senescent cells from pre-
malignant liver lesions (Kang et al., 2011). Together, these studies show there is a 
requirement for immune clearance of senescent cells to prevent development of 
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cancer, but this largely depends on the correct differentiation and stimulation of 
immune cells. However, ‘senescence surveillance’, utilising both innate and adaptive 
immune systems, can promote a controlled elimination programme of pre-malignant 
senescent cells. If the appropriate disease context is evident, senescence surveillance 
could specifically be harnessed to provide an attractive target for cancer therapy. 
In recent years, many pro-senescence therapies have been explored experimentally 
and clinically, with an aim to replace conventional cancer treatment strategies, 
chemo- and radiotherapy. Historically, cancer drugs and ionizing radiation are both 
known to cause therapy-induced senescence (TIS), which requires engagement of 
p16INK4a and p53 tumour suppressor pathways (Schmitt et al., 2002). Genetic 
depletion of p16INK4a and p53 results in drug resistance, therefore TIS is required for 
a robust response to chemotherapy. This indicates senescence could be 
pharmacologically upregulated for therapeutic gain in cancers. However, caution 
must be used when developing pro-senescence therapies due to its finely balanced 
anti- and pro-tumorigenic features. In addition, there is risk of DNA damage when 
inducing senescence, that can cause detrimental genetic abnormalities. Indeed, 
analysis of human prostate tumour microenvironments identified DDR-NF-κB 
activated WNT16B (a secreted factor), which attenuated the effects of conventional 
chemotherapy and promoted tumorigenesis (Suvn et al., 2012). In contrast, Pten-loss 
induced cellular senescence (PICS) in a murine prostate cancer model does not 
exhibit DNA damage (Alimonti et al., 2010); therefore, inhibition of Pten and 
activation of PICS could be a possible pro-senescence therapy for prostate cancers. 
Alimonti et al. (2010) showed Pten inhibitor VO-OHpic induced PICS specifically in 
Pten+/- tumours. This further highlights the importance of genetic context when 
evaluating pro-senescence therapies. Another promising target for pro-senescence 
therapy is the inhibition of CDKs; particularly, inhibition of CDK4 with PD-
00332991 and LEE-011 induces senescence in glioblastoma, neuroblastoma and 
breast cancer in in vitro and in vivo models (Michaud et al., 2010; Thangavel et al., 
2011; Rader et al., 2013). These proof-of-principle studies have been followed up 
with clinical trials (Finn et al., 2015), and PD-00332991 is now approved for use in 
ER-positive breast cancer (Inman, 2015). In addition, senescence markers can be 
used as a prognostic tool for human cancer; for example, increased p21-positivity, 
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stabilised by mTORC1/4E-BP1, indicates better survival in head and neck squamous 
cell carcinomas (Llanos et al., 2016). Overall, development of pro-senescence 
therapies for cancer will depend on evaluating which mechanistic pathway to target, 
how this will affect other pathways and assessing the genetic context of individual 
patient tumours. 
1.1.4.2 Aging 
It has been proposed senescence and aging are associated since Hayflick’s seminal 
work in the 1960s. However, the causal mechanism linking senescence to aging 
biology is still a current topic of research, and is discussed below. Many studies have 
shown aged mammalian cells and tissues have accumulated senescent cells with 
different markers. For example: DNA damage is progressively accumulated in aged 
primates (Herbig et al., 2006; Jeyapalan et al., 2007); telomere length and resulting 
dysfunction is implicated in aged murine stem cells (Flores et al., 2008); and SA β-
gal activity is increased in cultured human cells and aged human skin tissue (Dimri et 
al., 1995). Cell cycle inhibitors such as p21CIP1 and p15INK4b are not usually 
upregulated in aging-related senescence but accumulated p16INK4a is consistently 
implicated (Krishnamurthy et al., 2004). Furthermore, telomere shortening triggers 
senescence through ATM, p53 and p21CIP1, not p16INK4a (Herbig et al., 2004), 
suggesting accumulated p16INK4a in aged tissues is triggered by a telomere-
independent aspect of aging. 
Due to accumulated p16INK4a prevalence in aged senescent cells and tissues, it is 
believed to be a functional biomarker for aging-related senescence. Indeed, in 2006 
three studies were the first to show senescence plays a casual role in aging, via 
p16INK4a accumulation. These studies showed age-dependent increased p16INK4a in 
tissue stem cell/progenitor compartments: neural stem cells (Molofsky et al., 2006), 
haematopoietic stem cells (Janzen et al., 2006), and pancreatic islet cells 
(Krishnamurthy et al., 2006). In all these cell types, senescence led to decreased 
regenerative capacity in aged tissues that could be rescued with genetic ablation of 
p16INK4a. p16INK4a is also essential for accelerated aging in a progeroid mouse model 
with mutated checkpoint protein, BubR1 (Baker et al., 2008). Recently, two other 
papers from the van Deursen group have presented further evidence for the function 
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of p16INK4a during aging-related senescence. Baker et al. (2011) developed an 
innovative mouse model, by introducing a transgene, INK-ATTAC, into the mutant 
BubR1H/H background. The INK-ATTAC construct has an AP20187-inducible 
caspase-8 (apoptosis activator) controlled by a p16INK4a gene promoter, that is only 
transcriptionally active in senescent cells. Therefore, upon AP20187 treatment, the 
INK-ATTAC can selectively induce elimination of p16INK4a-positive senescent cells 
by apoptosis. The authors used this model to show lifelong or late-life clearance of 
p16INK4a-positive senescent cells delays the onset of age-related phenotypes, such as 
eye degeneration, exercise ability and adipose content. However, BubR1H/H;INK-
ATTAC mice do not have extended lifespan as the progeroid mice died of p16INK4a-
independent cardiac failure. This study was repeated in wild-type mice, to analyse 
the effects on naturally-occurring p16INK4a-positive senescent cell clearance. Both 
male and female INK-ATTAC mice have extended median (not maximum) lifespan, 
delayed tumorigenesis of age-related cancers and reduced deterioration 
corresponding with increased functionality of tissues, such as: heart, kidney and fat 
(Baker et al., 2016). These studies and others (Xu et al., 2015; Hashimoto et al., 
2016) highlight the benefit of therapeutically removing senescent cells to extend a 
healthy lifespan. 
As described previously, immune clearance of senescent cells is a vital mechanism to 
prevent persistent senescence in a tissue, that can lead to detrimental pathology. It is 
widely known the immune system declines with age, perhaps explaining the presence 
of persistent and detrimental senescence during aging. Therefore, genetically 
targeting the clearance of senescent cells is an attractive method to delay aging, and 
is currently being assessed for therapeutic viability in mouse models (as discussed 
above). Further, a recent study revealed therapeutically activating senescent cell 
apoptosis by perturbing FOXO4-p53 interactions can restore tissue homeostasis in 
aged tissues (Baar et al., 2017). Senescence also has a role in age-related diseases, 
and there is potential in targeting senescent cells to counteract them (reviewed by 
Childs et al. (2017)). These pathologies include: atherosclerosis (Vasile et al., 2001), 
type 2 diabetes (Tchkonia et al., 2010), glaucoma (Liton et al., 2005), osteoarthritis 
(Martin and Buckwalter, 2003) and lung disease (Noureddine et al., 2011). Recent 
studies have shown the reversal of atherosclerosis and osteoarthritis in mice after 
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genetically ablating p16INK4a (Childs et al., 2016; Jeon et al., 2017, respectively). 
Finally, many ‘senolytic’ therapies have been explored to promote elimination of 
senescent cells in aging humans, using small molecules. For example, inhibitors of 
the BCL-2 family, ABT-737 and navitoclax, allow senescence-specific apoptosis in 
age-related diseases (Childs et al., 2016; Yosef et al., 2016).  
Ultimately, aging is not considered a disease, and although it does increase the risk 
of developing many associated diseases, through a mechanism involving senescence, 
it is likely aging will never be prevented in humans. Instead, the use of anti-senescent 
therapies for delaying or maintaining specific age-related diseases is more likely to 
be clinically assessed in the future.  
1.1.4.3 Fibrosis 
Senescence has been implicated in fibrosis (the accumulation of fibrotic lesions 
usually coupled with a loss of tissue function) of many different tissue types. The 
best characterised is the formation of senescent fibrotic scars in response to chronic 
liver damage. Hepatic stellate cells (HSCs) are damage-activated to proliferate as 
myofibroblasts, which eventually form a fibrotic scar with collagen and a unique 
ECM. In humans, the periphery of the scar stains positive for SA β-gal and founding 
HSCs express p53, p21CIP1 and p16INK4a (Wiemann et al., 2002; Krizhanovsky et al., 
2008). The senescent cells within the scar produce a SASP to eliminate the scar and 
allow tissue repair; particularly, CCN1 is a key mediator of this process and 
treatment with recombinant CCN1 can promote HSC senescence to reverse liver 
fibrosis in mice (Kim et al., 2013). In addition, activated HSCs secrete IL22, which 
mediates senescence through STAT3/SOCS3 p53 activation. IL22 overexpression in 
mice livers accelerates recovery of fibrosis by inducing HSC senescence (Kong et 
al., 2012). Together, these studies indicate the efficacy of pro-senescence therapies 
for the reversal of liver fibrosis. Additionally, fibrosis in response to renal injury has 
been shown to beneficially induce senescence in mice and human kidneys, with 
increased p16INK4a, p21CIP1and SA β-gal (J. Liu et al., 2012; Clements et al., 2013). 
Furthermore, p53-positive senescent myofibroblasts are present in areas of the heart 
after myocardial infarction (Zhu et al., 2013). As pro-senescence therapies have had 
some success with liver fibrosis, there could also be a future use for them in 
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preventing fibrosis post-renal and -cardiac injury and improving recovery. Finally, 
senescence can also be detrimental in certain fibrotic environments. For example, in 
a mouse model of idiopathic pulmonary fibrosis (a chronic disorder affecting lung 
function), SA β-gal positive cells concomitantly activate NOX4 to generate oxidative 
stress and inflammation in fibrotic lesions (Hecker et al., 2014). This response can be 
attenuated and damage reversed using the anti-inflammatory drug rupatadine (Lv et 
al., 2013) and drug combination dasatinib/quercetin (Schafer et al., 2017).  
1.1.4.4 Wound healing 
Senescence has also been implicated in the fibrotic response during wound healing. 
Jun and Lau (2010) found the SASP factor CCN1 can mediate senescence in the 
granulation tissues of healing wounds and subsequently expression of anti-fibrotic 
genes (like its implications in liver fibrosis). The authors found senescence is 
established by CCN1 binding to integrin-α6β1, initiating DDR activated p53 and 
RAC1-NOX1 activated p16INK4a/RB. This process was lost in a CCN1-mutant mouse 
(with no integrin-α6β1 binding domain) and fibrosis of the wound was exacerbated. 
Furthermore, topical recombinant CCN1 treatment reversed the harmful effect on 
wound healing in the CCN1-mutant mouse. Additionally, a more recent study, 
utilising a model like the INK-ATTAC mouse described in 1.1.4.2, has shown 
senescence is involved in tissue remodelling in a healthy in vivo context (Demaria et 
al., 2014). In this study, the p16-3MR mouse was used to specifically eliminate 
senescent cells by apoptosis. The resulting response to a wound was delayed due to a 
reduced transient presence of senescence in the early stages of wound healing. 
Senescence fibroblasts and endothelial cells were found to express platelet-derived 
growth factor AA (PDGF-AA), and topical treatment of PDGF-AA restores normal 
wound healing. Finally, senescence has been positively associated with tissue 
damage, due to the concomitant activation of cellular reprogramming by IL6 
secretion (Mosteiro et al., 2016). From studies like these, there is now evidence to 
support the theory that senescence is a vital and beneficial process for tissue repair. 
However, senescence is a double-edged sword; as discussed earlier in this section, 
beneficial outcomes of senescence depend on sufficient clearance of senescent cells 
from areas of tissue damage (such as pre-malignant lesions). This must be considered 
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when developing therapies targeting senescence, to ensure tissues return to pre-
damage conditions rather than develop chronic damage.  
1.1.4.5 Embryonic development 
In 2013, seminal papers from the Serrano and Keyes groups described programmed 
senescence present in developing mouse embryos (Muñoz-Espín et al., 2013; Storer 
et al., 2013). Observations were similar in chickens and humans, indicating this is a 
conserved process between vertebrates. Embryonic structures implicated in 
developmental senescence include, but not limited to: the mesonephros (the 
temporary embryonic kidney); endolymphatic sac (an inner ear tube); and the apical 
ectodermal ridge (AER, a transient structure in limb buds). These structures 
exhibited non-proliferative cells with SA β-gal, tumour suppressor expression and 
heterochromatic markers. Senescence in the mesonephros and endolymphatic sac is 
dependent on p21CIP1, not p53 or DNA damage, and was regulated by TGFβ-SMAD 
and PI3K-FOXO pathways (Muñoz-Espín et al., 2013). Senescence in the AER is 
characterised by a SASP that activates Erk in the mesenchyme proximal to the AER, 
and instructs the structure to remain senescent. The SASP also feeds back to the AER 
to mediate immune clearance of senescent cells at the correct development transition 
(Storer et al., 2013). Apoptosis is generally important for development (Fuchs and 
Steller, 2011) and from the two previous studies, apoptosis is a known compensatory 
mechanism if senescence fails during embryonic development. Despite this, 
morphological defects in adults occur if senescence is absent during development 
(Muñoz-Espín et al., 2013). It is interesting to note here that senescence has also 
been observed in two specialised adult cell types, megakaryocytes (Besancenot et al., 
2010) and placental syncytiotrophoblasts (Chuprin et al., 2013). These two cell types 
are the only naturally polyploid mammalian cells known to undergo 
endoreduplication during differentiation (Ullah et al., 2009), and thus senescence 
could be underlying cause of this developmental programme.  
1.1.4.6 Obesity and diabetes 
Senescence has been identified in obese murine and human adipose tissues, 
associated with type 2 diabetes. Minamino et al. (2009) found a vital role for 
oxidative stress and p53 activation in adipose tissue of diabetic mice on a high fat 
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diet. The senescent adipocytes presented with SA β-gal, p53 expression and SASP-
like pro-inflammatory response. Importantly, targeting p53 expression in the diabetic 
mice reversed the senescence phenotype and improved insulin resistance. Further to 
this study, obesity-related protein HMGA2 has been implicated in human adipose 
tissue senescence characterised by CDKN2A expression (Markowski et al., 2013). In 
addition, when CDKN2A expression is ablated in a progeroid mouse, adipose tissue 
does not senesce (Baker et al., 2008, 2011). Although adipose tissue senescence is 
detrimentally linked to obesity and diabetes, it is preventable with low fat diet and 
reversible by introducing exercise (Schafer et al., 2016). This study identifies a novel 
cellular mechanism that demonstrates exercise is beneficial for disease prevention.  
In similar context, a recent study has implicated senescence in age-related resistance 
to white to beige adipocyte differentiation. This process is induced by cold 
temperatures and results in beige adipocyte thermogenesis (or ‘beiging’). Berry et al. 
(2017) found aged murine and human adipocytes were incapable of beiging due to a 
SA β-gal-positive senescence phenotype, activated through p38-MAPK-p16INK4a 
pathways. The authors showed targeting senescent cells with a p38/MAPK inhibitor 
restored beiging in aged human cells. Therefore, combining senescence inhibition 
with hypothermia-induced beiging may be a potential strategy for reversing obesity 
and diabetes in aging humans. In addition, pancreatic β-cells have been implicated in 
age-related insulin resistance and diabetes pathogenesis (Aguayo-Mazzucato et al., 
2017). In response to aging, β-cells exhibited heterogeneous expression of senescent 
markers SA β-gal, p16INK4a and p53, which correlated with rapid decline in function. 
These studies suggest targeting senescence in aging-related metabolic dysfunction 
could be a novel therapy for diabetes. 
1.1.4.7 Summary 
The basic function of senescence is to clear unwanted and/or harmful cells. This 
function in normal physiological and pathological environments has revealed a 
general mechanism for senescence in tissue remodelling, as follows: (1) senescence 
establishment; (2) clearance (i.e. senescence surveillance); (3) regeneration of tissue. 
The clearance of senescent cells by innate and adaptive immune systems is vital for 
the transient nature of protective senescence. When senescent cells persist, tissue 
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dysfunction occurs in the senescent microenvironment and aggravates pathology of 
initially protected tissues. 
1.1.5 Cellular senescence summary 
Senescence is a stable cell cycle arrest that is utilised in environments where cells 
undergo potentially harmful alterations, such as telomere shortening, oncogene 
activation and mitochondrial stress. Senescent cells have a distinct phenotype 
including: morphological changes, DNA damage, tumour suppressor activity, 
heterochromatic markers, β-galactosidase activity and a distinctive secretome. These 
changes in cell phenotype can be used to identify senescent cells in vitro and in vivo, 
in addition to proliferation readouts. Senescence has a role in both human health and 
disease; in recent years, mechanisms of how senescence contributes to normal 
physiology and disease pathology have been revealed. There is promise in targeting 
senescence for novel disease therapies, however, it is essential to gain understanding 
of the cellular and molecular mechanisms of senescence to progress further in 
therapy development. 
 
1.2 Metabolism in cancer and senescence 
The seminal work identifying altered metabolism in cancer tissues was performed by 
Otto Warburg, the pioneer of cancer metabolism, a century ago. However, only in the 
past decade has there been substantial progress in understanding the functional 
mechanisms that link metabolites to cancer growth. This is largely due to the 
development of new technologies that provide accurate readouts of metabolism, such 
as liquid chromatography mass spectrometry (LC-MS) machines. These technologies 
coupled with new genetic models for different cancers have vastly expanded the 
understanding of the consequences of cancer-specific metabolism and how this may 
be therapeutically targeted (extensively reviewed in a 2016 NRC Focus issue 
(volume 16.10); foreword by Cairns and Mak (2016)). Although senescent cells are 
permanently arrested, they are capable of hypertrophy and remain metabolically 
active. This knowledge, along with the well-established role for senescence in cancer 
pathologies, has caused recent advances in perturbing specific metabolic pathways 
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and determining the function in OIS. In this section, there is a brief overview of how 
metabolism is experimentally investigated using mass spectrometry, followed by the 
fundamentals of cancer metabolism. Next, seminal studies that have contributed to 
deconvoluting the complex function of metabolic alterations in OIS are reviewed. 
Finally, an overview of ceramide metabolism is provided due to this thesis’ work 
implicating ceramides in OIS. Figure 1.3 can be used to aid visualisation of the main 
metabolic pathways (in purple) and related enzymes (green circles) described in this 
section. 
Figure 1.3 Schematic summary of metabolic pathways implicated in cancer 
and senescence (next page) 
Glucose is transported across the extracellular membrane via glucose transporter 1 (GLUT1). 
Glucose is metabolised in the cytoplasm through a multiple-step process called glycolysis. The 
first step of glycolysis is the conversion of glucose to glucose-6-phosphate, catalysed by 
hexokinases (HK). Glucose-6-phosphate is used in the pentose phosphate pathway to yield 
ribose-5-phosphate units for nucleotide (i.e. RNA and DNA) metabolism. Four glycolytic steps 
occur before 3-phosphoglycerate is produced; this metabolite is an essential precursor for serine 
and glycine metabolism and the synthesis of one-carbon units. The final step of glycolysis is the 
conversion of phosphoenolpyruvate to pyruvate, catalysed by pyruvate kinases (PKM). 
Cytoplasmic glycolysis and mitochondrial TCA cycle are linked via a gatekeeper enzyme 
pyruvate dehydrogenase (PDH), that converts pyruvate to acetyl-coA. PDH activity is stimulated 
by PDH-phosphatase 2 (PDP2) and inhibited by PDH-kinase 1 (PDK1). Acetyl-coA enters the 
TCA cycle to synthesise citrate from oxaloacetate. Citrate and acetyl-coA are the main 
precursors for fatty acid synthesis and downstream lipid metabolism (e.g. triglycerides, 
cholesterol, and sphingolipids). The reverse reaction of the next step in the TCA cycle (citrate to 
α-ketoglutarate), catalysed by isocitrate dehydrogenase (IDH), is also important for fatty acid 
synthesis. Glutamine to glutamate metabolism, catalysed by glutaminases (GLS), is an additional 
mechanism for α-ketoglutarate production. The penultimate step before oxaloacetate is 
synthesised to restart the TCA cycle is the hydration of fumarate to malate, catalysed by fumarate 
hydratase (FH). Energy released from the TCA cycle and subsequent oxidative phosphorylation, 
as nicotinamide adenine dinucleotide (NADH) and adenosine triphosphate (ATP), is used for 
cellular processes such as autophagy and protein synthesis (driven by mechanistic target of 
rapamycin (mTOR)).  
Pathways implicated in cancer and/or senescence = purple; specific enzymes implicated in 
cancer and/or senescence = green circles. 
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Figure 1.3 Schematic summary of metabolic pathways implicated in cancer 
and senescence 
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1.2.1 Measuring metabolism 
The metabolome is composed of small molecules (<1500Da) that are the precursors 
of essential cellular macromolecules, providing the foundation of cellular energy 
production, in addition to having their own independent functions. The metabolome 
can be loosely broken down into the following molecules: nucleotides, amino acids, 
carbohydrates and lipids (Kell and Oliver, 2016). Complex metabolic networks link 
these molecules, meaning determining the activity and regulation of the intricate 
pathways has been challenging. In the past decade, there has been huge development 
in mass spectrometry methods for metabolomics and lipidomics (the specific 
detection of lipids). Mass spectrometry can be used to analyse a large range of 
molecules, with high sensitivity and dynamic range. Furthermore, combined 
methods, such as liquid chromatography mass spectrometry (LC-MS), can provide 
more accurate platforms for analysing metabolomes/lipidomes and for identifying 
unknown single molecules (Patti, Yanes and Siuzdak, 2012). First, LC is used for 
enhanced separation of a liquid phase; this has several benefits for example, 
providing a ‘retention time’ to aid identification of similarly sized molecules. Next, 
separated molecules are injected into the MS component; here, many steps occur to 
ionise, detect and identify molecules. Ionisation is required to give molecules a 
charge and allow the MS to detect it using a mass/charge ratio (m/z). Depending on 
the type of MS, different devices can be used to aid ion detection and identification. 
The Q-Exactive mass spectrometer (Thermo) used for lipidomics in this thesis uses 
an ‘orbitrap’ to detect ions, by applying a voltage and measuring the orbit frequency 
of ions. In addition, the Q-Exactive has a ‘quadrapole’ that can be used to filter and 
isolate ions of a specified m/z, when required. Lastly, tandem-MS (MS/MS) can be 
used to fragment ions and aid identification of molecules; the Q-Exactive uses a 
‘HCD cell’ to facilitate fragmentation. 
Untargeted metabolomics is useful for the large-scale detection of metabolite levels 
in novel biological contexts (Patti, Yanes and Siuzdak, 2012). However, findings 
from these untargeted studies always require validation with more targeted analyses, 
to accurately quantify metabolite levels (Chokkathukalam et al., 2014). In addition, 
metabolic pathways can be further interrogated using stable heavy-isotope labelling. 
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This technique uses stable heavy isotopes, such as 13C, to measure the activity of a 
metabolic pathway. Due to the change in mass with heavy isotopes, mass 
spectrometry can reliably detect different isotopologs of the same molecule. 
Generally, the stable heavy isotopes are provided as synthetically made ‘tracers’, 
which will be precursor molecules for the targeted metabolic pathway. For example, 
13C2-glucose can be used to measure glycolysis and the pentose phosphate pathway 
(Lee et al., 1998) and U-13C5-glutamine can be used to measure the TCA cycle 
starting with citrate (Metallo and Vander Heiden, 2013). Using this method, heavy 
isotopes can be traced through a metabolic pathway; so, depending on the activity of 
that pathway, the heavy isotopes will be incorporated into endogenous molecules at 
certain rates. Using an unlabelled control, the percentage of heavy-labelled 
molecules of total levels (i.e. all isotopes) can be calculated to indicate the activity of 
the metabolic pathway. In the next section, studies relevant to cancer metabolism, 
using LC-MS and stable heavy-isotope labelling, are examined. These examples 
demonstrate how powerful this method can be for biological research (also reviewed  
by Johnson, Ivanisevic and Siuzdak (2016)). However, it is important to note than 
careful experimental design and optimisation must be implemented to gain the 
correct information from stable heavy-isotope labelling (Metallo, Walther and 
Stephanopoulos, 2009). 
1.2.2 Cancer metabolism 
Cancer cells have high bioenergetic and biosynthetic demands that are met by 
remodelling of energy-releasing metabolic pathways and increased nutrient 
acquisition. This fundamental process in malignant transformation of cells was first 
hypothesised and illustrated by Otto Warburg in the 1920s. Warburg observed 
tumour slices preferentially metabolise glucose to lactate by glycolysis, which is 
normally observed as a response to hypoxia in normal tissues (Warburg, Posener and 
Negelein, 1924). This occurs even though ATP generation from aerobic glycolysis is 
inefficient compared to oxidative phosphorylation. Warburg postulated this 
phenomenon (referred to as the ‘Warburg Effect’, figure 1.4) was due to 
mitochondrial dysfunction in cancer (Warburg, 1956); however, many studies have 
subsequently suggested the cause and function of the Warburg Effect is far more 
   
   50 
complex. In 2009, Vander Heiden and colleagues hypothesised the Warburg Effect, 
and related cancer-related metabolic reprogramming, occurs to allow sufficient 
production of essential cellular macromolecules (nucleic acids, proteins and lipids) 
that support expansion of cells (Vander Heiden, Cantley and Thompson, 2009). 
Ultimately, this is the basic principle answering why cancer cells require 
reprogrammed metabolism; but how does cancer mechanistically achieve this 
outcome? Below, this question is explored utilising evidence from studies analysing 
glucose, glutamine and one-carbon metabolism in cancer; genetic implications and 
therapeutic opportunities are included where relevant. 
 
 
Figure 1.4 Pathways of glucose utilisation and energy production in normal 
and cancer tissues 
Normal tissues can metabolise glucose to synthesise ATP via two pathways, depending on the 
presence or absence of oxygen: oxidative phosphorylation (yields 36 mol ATP per mol of 
glucose) and anaerobic glycolysis (yields 2 mol ATP per mol of glucose). Cancer tissues convert 
glucose to pyruvate and lactate via glycolysis, regardless of the presence or absence of oxygen – 
this is known as the Warburg Effect. Diagram adapted from (Vander Heiden, Cantley and 
Thompson, 2009). 
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1.2.2.1 Glucose metabolism 
Since Warburg’s original observation of increased aerobic glycolysis, there has been 
identification of many positive and negative regulatory pathways for glucose 
metabolism (reviewed by Hay (2016)). There are many mechanisms by which cancer 
exploits these regulatory pathways to adapt metabolism to their environment, and 
several key examples are described here. First, glucose transport into cancer cells is 
accelerated due to the increased expression and activity of glucose transporters, such 
as GLUT1 in Ras/BRAF mediated cancers (Yun et al., 2009). Small molecule 
inhibitors of GLUT1 have shown to selectively kill cancer cells in vitro (Y. Liu et 
al., 2012), however homozygous deletion of GLUT1 in mice is embryonic lethal 
(Wang et al., 2006), suggesting widespread expression of GLUT1 is essential for 
normal cell function. Interestingly, GLUTs also transport oxidised vitamin C 
(dehydroascorbic acid, DHA). High dose DHA disrupts glycolysis in Ras/BRAF 
colorectal cancer cells (Corpe et al., 2013) and high dose vitamin C has some clinical 
benefit in human cancers (Mikirova et al., 2012).  
Second, cancer-induced increased glucose uptake also facilitates the first committed 
step of glycolysis: the phosphorylation of glucose to glucose-6-phosphate, catalysed 
by hexokinase 2 (HK2). Cancer cells increase expression of HK2 to ensure high 
levels of glucose remain in cells and fluxes through downstream metabolic pathway 
(Patra and Hay, 2013). In adult mice, systemic deletion of HK2 inhibits tumour 
initiation/maintenance and there is no compensatory expression of hexokinase 1 
(Patra et al., 2013). This demonstrates it is possible to perturb a glycolytic enzyme 
for therapeutic benefit. Additionally, hexokinase activity is an inadvertent readout of 
cancer diagnostic/prognostic tool FDG-PET imaging. Cells are radiolabelled with 
glucose analogue [18F] fluoro-2-deoxyglucose (FDG) and using PET imaging, cancer 
cells can be selectively detected by measuring the increased uptake, trapping (i.e. 
HK2 activity) and glycolytic metabolism of FDG (Okazumi et al., 1992; Kelloff et 
al., 2005).  
Third, the final step of glycolysis- the conversion of phosphoenolpyruvate to 
pyruvate, catalysed by pyruvate kinases- is attenuated in cancer. This is mediated by 
the preferential expression of low-affinity and low-activity pyruvate kinase isoform 
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M2 (PKM2) (Christofk, Vander Heiden, Harris, et al., 2008; Christofk, Vander 
Heiden, Wu, et al., 2008). This observation contrasts with the increased flux of 
upstream glycolytic reactions but functions to support biosynthesis of 
macromolecules for cell proliferation. At low activity, PKM2 mediates the diversion 
of glycolytic metabolites from the TCA cycle, into pathways that facilitate the 
biosynthesis of nucleic acids, amino acids and fatty acids (such as the pentose 
phosphate pathway for ribose synthesis) (Christofk, Vander Heiden, Wu, et al., 
2008). Therefore, PKM2 acts as a gatekeeper, that determines if carbon from glucose 
is either metabolised for macromolecule biosynthesis or used for ATP generation by 
oxidative phosphorylation (Vander Heiden, Cantley and Thompson, 2009). Small 
molecule activators of PKM2 (DASA-58 and TEPP-46) limit the diversion of 
glucose to the pentose phosphate pathway and interfere with macromolecule 
biosynthesis in a cancer xenograft model (Anastasiou et al., 2012). This suggests 
pyruvate kinases are a key regulatory node in cancer-driven glycolysis and outcomes 
are activity-dependent.  
Finally, further to alterations to specific glycolytic enzymes, p53 has a regulatory 
role in glucose metabolism through the activation of ‘TP53-inducible glycolysis and 
apoptosis regulator’ (TIGAR) (Jen and Cheung, 2005; Bensaad et al., 2006). In 
normal tumour environments, TIGAR upregulates the pentose phosphate pathway, 
whereas in hypoxic conditions, TIGAR will mediate glycolysis through hexokinase 2 
activation (Cheung, Ludwig and Vousden, 2012). As p53 is the most frequently 
mutated gene in cancers, its role in glucose metabolism regulation is an important 
feature to understand for therapy development.  
1.2.2.2 Glutamine metabolism 
Glutamine is a conditionally essential amino acid, meaning in stressed environments, 
cells have increased glutamine demand which de novo synthesis cannot fulfil (Rubin, 
1990). Subsequent glutamine depletion can result in cell death and glutamine 
dependence in cancer cells (Yuneva et al., 2007). Rapidly dividing cells, including 
cancer cells, have increased glutamine consumption (Windmueller and Spaeth, 
1974). Glutamine provides a central carbon and nitrogen source for cancer cells to 
use for biosynthetic and energetic processes, and support proliferation; how this 
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function of glutamine is altered in cancer is further explored below. First, it is 
important to note the main steps of glutamine metabolism. Glutamine is transported 
into cells via multiple different transporters (Bhutia et al., 2015). In addition, the 
degradation of macromolecules can supply a cellular pool of glutamine, especially in 
Ras-driven cancer (Commisso et al., 2013; Kamphorst et al., 2015). Once in the cell, 
glutamine is converted to glutamate by glutaminases (GLS) (Krebs, 1935). This is 
followed by the conversion of glutamate to α-ketoglutarate by either glutamate 
dehydrogenases (GLUD) or aminotransferases, depending on the cell type involved 
(Moreadith and Lehninger, 1984). The flux of glutamine into the TCA cycle, via α-
ketoglutarate, generates ATP and NADH to support biosynthesis of macromolecules.  
Glutamine has multiple functions that result directly and indirectly of its flux into the 
TCA cycle. For example, glutamine mediates the synthesis of aspartate from TCA 
intermediate oxaloacetate; this regulation is vital for nucleotide biosynthesis and is 
the mechanism by which glutamine depletion initiates S-phase arrest in KRas-driven 
cancer cells (D. Patel et al., 2016). Additionally, increased glutamine flux through 
the TCA cycle stimulates malic enzyme-mediated pyruvate to lactate conversion in 
glioblastoma cells. This releases NADPH that facilitates the use of glucose-derived 
carbon for fatty acid synthesis (DeBerardinis et al., 2007). Furthermore, glutamine 
can be used as an alternative carbon source to support citrate-mediated fatty acid 
synthesis. Reductive carboxylation is a reverse pathway of part of the TCA cycle: 
glutamine-derived α-ketoglutarate is converted to citrate, by NADPH-dependent 
isocitrate dehydrogenases (IDH) (Wise et al., 2011). This process is important for 
fatty acid synthesis in hypoxic tumours, in vitro and in vivo, and supports 
tumorigenesis (Metallo et al., 2012; Mullen et al., 2012; Sun and Denko, 2014). 
The reprogramming of glutamine metabolism is highly dependent on the tissue of 
origin and oncogenic driver (reviewed by Altman, Stine and Dang (2016)). Cells 
transformed with Myc oncogene are highly dependent on exogenous glutamine 
(Yuneva et al., 2007), and have increased protein/mRNA expression of glutamine-
metabolic enzyme GLS (Wise et al., 2008; Gao et al., 2009). Myc overexpression 
and increased glutamine metabolism are also implicated in Kaposi’s Sarcoma-
Associated Herpes Virus (KSHV) infection and subsequent tumorigenesis of 
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Kaposi’s Sarcoma (Sanchez et al., 2015). Moreover, KRas-driven cancers also have 
glutamine dependence (Weinberg et al., 2010; Gaglio et al., 2011), however this is 
mutation dependent, with G12V mutations in lung cancer less dependent than G12D 
and G12C (Brunelli et al., 2014).  
The studies above indicate the complexity of glutamine metabolism and its genetic 
regulators in cancer. Targeting this pathway for therapeutic benefit is challenging, 
but some clinical progress has been made with allosteric inhibitors of GLS. CB-839 
has been shown to have efficacy in humans against triple-negative breast cancer and 
leukaemia (Gross et al., 2014; Jacque et al., 2015). Targeting glutamine in 
combination with other therapies provides an attractive prospect of synthetic 
lethality, with improved outcomes. For example, metformin decreases glucose 
oxidation, leading to increased glutamine reductive carboxylation. Metformin in 
combination with a glutamine metabolism inhibitor attenuates the proliferation of 
prostate cancer cells in vitro and in vivo (Fendt et al., 2013). The synergistic effects 
of targeting glutamine in combination with another therapy is yet to be clinically 
validated in humans. Finally, the use of [18F] fluorinated glutamine has been 
clinically validated for diagnosis of glioma, instead of FDG-PET (Venneti et al., 
2015). This is because the brain has an increased ability to uptake glucose, making 
FDG-PET not specific enough to detect cancer cells (Kelloff et al., 2005).  
1.2.2.3 One-carbon metabolism 
In addition to glutamine, non-essential amino acids serine and glycine are vital for 
cancer cell metabolism. Serine and glycine are the major sources of one-carbon units 
for pathways that support cancer proliferation (reviewed by Yang and Vousden, 2016 
& Newman and Maddocks, 2017). Serine is sourced from: de novo synthesis (using 
glycolysis intermediate 3-phosphoglycerate), extracellular uptake and protein 
degradation (Commisso et al., 2013; Galluzzi et al., 2015; Kamphorst et al., 2015). 
Serine is metabolised to glycine and a methyl group (used as a one-carbon source) by 
serine hydroxymethyltransferase (SHMT). For cancer cell proliferation, SHMT 
expression and activity is required (Jain et al., 2012; Ye et al., 2014). Additionally, 
the serine synthesis pathway (SSP) is upregulated in cancer (Pollari et al., 2011; 
Possemato et al., 2011) and in serine-starved conditions, growth of cancers in vitro 
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and in xenograft models is decreased (Maddocks et al., 2013; Labuschagne et al., 
2014). This evidence suggests serine metabolism, synthesis and catabolism, is 
important for tumorigenesis. Glycine is also another independent source of one-
carbon units, through the glycine cleavage system (GCS). The GCS cleaves a 
methylene group from glycine that is donated to an acceptor molecule, such as 
tetrahydrofolate. Lung cancer and glioblastoma cells exhibit upregulation and 
dependency on GCS enzyme glycine decarboxylase (Zhang et al., 2012; Kim et al., 
2015). However, high glycine levels can be toxic (Rose et al., 1999), therefore the 
GCS functions as a regulator of glycine levels, rather than one-carbon generation, to 
maintain ideal conditions for tumourigenesis.  
The folate cycle is the major pathway that processes one-carbon units for use in 
downstream functions. Dihydrofolate reductase (DHFR) is the central enzyme that 
generates tetrahydrofolate (THF) from folic acid. THF is subsequently methylated 
(mTHF) using one-carbon units, which are later used for many pathways such as 
nucleotide biosynthesis. For example, two one-carbon units are required for the 
conversion of ribose-6-phosphate to inosine monophosphate (IMP), a precursor for 
purine nucleotides (Maddocks et al., 2013; Labuschagne et al., 2014; Kim et al., 
2015). In cancer, this pathway is important: inhibition of serine metabolism results in 
accumulated pre-IMP intermediates, as no one-carbon units are available and results 
in decreased proliferation and purine levels. In addition, one-carbon units can be 
used for DNA/protein methylation, and are implicated in cancer-related epigenetic 
modifications (Maddocks et al., 2016). Finally, one-carbon metabolism also provides 
a pool of reducing co-factors NADH/NADPH, which critically support biosynthetic 
processes (Ducker et al., 2016; Meiser et al., 2016). 
Anti-folates are inhibitors of DHFR and function to prevent THF metabolism and 
subsequently block one-carbon metabolism. The use of anti-folates as anti-cancer 
therapeutics has been established since the 1940s (Farber et al., 1948); however, 
folate metabolism is important for normal cells therefore these drugs, such as 
methotrexate, have harmful side-effects. More recently, targeting one-carbon 
metabolic regulators has yielded therapeutic benefit for certain cancers. For example, 
targeting SSP enzyme phosphoglycerate dehydrogenase can decrease one-carbon 
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metabolism and inhibit in vitro and xenograft cancer cell proliferation (Mullarky et 
al., 2016; Pacold et al., 2016). However, cells that cannot depend on SSP activity 
must acquire serine for one-carbon metabolism from external sources. To this end, 
starving cells of exogenous serine significantly improves survival in different cancer 
mouse models (Maddocks et al., 2017). This study also found KRas-driven models 
of pancreatic and intestinal cancers have increased de novo synthesis of serine, and 
therefore were less susceptible to serine starvation. Thus, understanding the 
dependency of some cancers on exogenous nutrients suggests how diet can 
contribute to cancer progression, and is an important factor to appreciate when 
considering cancer therapies. 
1.2.2.4 Summary 
It is evident from cancer metabolism research discussed here, that metabolism is not 
a simple homeostatic process but rather, a highly regulated, interconnected and 
dynamic network of processes programmed to meet the demands of the cellular 
environment. The reprogramming of metabolism is a vital hallmark of cancer; this 
arises to generate biomass molecules to support cell proliferation, in addition to 
generating the energy to fuel these biosynthesis pathways. There are many genetic 
drivers of cancer metabolism, which could provide novel targets for future cancer 
therapeutics; although, designing small molecules targeting these genes may be 
challenging due to structural similarities between functionally-different isoforms. 
Further, synthetic lethal approaches, combining metabolic inhibition with traditional 
therapies, are being clinically tested for efficacy in humans. Overall, deconvoluting 
the causes of reprogrammed cancer metabolism will lead to future development of 
new cancer therapies. 
1.2.3 Senescence-induced metabolic alterations 
As alluded by SA β-galactosidase activity and increased lysosomal content (Dimri et 
al., 1995; Kurz et al., 2000), senescent cells are highly metabolically active. The 
increased translation and secretion of SASP factors may explain senescence-induced 
metabolic alterations, as cells must re-balance energy supplies to maintain 
proteostasis; this hypothesis is further discussed later in this section. In recent years, 
there have been many studies deconvoluting rewired metabolism in senescence and 
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have identified this as a fundamental functional mechanism for senescence. Four 
main metabolic pathways are examined in this section: glycolysis-TCA cycle, 
proteostasis, nucleotide synthesis and fatty acid metabolism. 
1.2.3.1 Glycolysis and TCA cycle 
In replicative senescence, cells shift glucose metabolism to glycolysis, yet have low 
energy levels as they are serially passaged (Bittles and Harper, 1984; Zwerschke et 
al., 2003). In OIS, cells also have altered activity through glycolytic and TCA cycle 
pathways (Kondoh et al., 2005). Specifically, increased mitochondrial oxidative 
metabolism has been characterised in OIS, thought to allow enhanced energy 
production and meet demand (Dörr et al., 2013; Kaplon et al., 2013). These studies 
have led an exciting time for senescence research, identifying mechanisms that link 
rewired metabolism to OIS and revealing therapeutic benefits of targeting 
metabolism in cancer. Kaplon et al. (2013) identified a metabolic switch controlled 
by pyruvate dehydrogenase (PDH, a gatekeeper linking cytoplasmic glycolysis and 
mitochondrial TCA cycle) in BRAFV600E and RasG12V induced senescence. The 
authors found OIS regulates PDH activity through suppression of PDH-kinase 1 
(PDK1) and activation of PDH-phosphatase 2 (PDP2). The resulting activation of 
PDH increases TCA cycle and oxygen consumption, and maintained OIS state. 
Importantly, the PDK1-PDP2-PDH axis was identified as a tumour suppressor 
mechanism against BRAFV600E mediated melanoma and genetic ablation of PDK1 
expression caused tumour regression in mice with established melanoma. Therefore, 
identification of this metabolic switch in OIS yielded a novel pathway that can be 
beneficially exploited for cancer therapy. Further to this study, Retinoblastoma (RB) 
had been identified as a central mediator for the activation of glycolysis and 
mitochondrial oxidative phosphorylation (OXPHOS) in OIS (Takebayashi et al., 
2015). RB controls the upregulation of glycolytic and OXPHOS gene expression in 
OIS, to actively increase energy production. This provides a potential mechanistic 
link between metabolic remodelling and cell cycle arrest that Kaplon et al. (2013) 
did not ascertain. Finally, senescence induced by chemotherapeutic drug 
cyclophosphamide in a mouse lymphoma model is typified by increased glucose 
consumption and ATP generation (Dörr et al., 2013). This is linked to alterations in 
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proteostasis and renders senescent cells amenable to selective elimination in 
cancerous lesions by blocking glucose utilisation (further discussed in 1.2.3.1). 
Moving into mitochondrial metabolism, loss of fumarate hydratase (FH) can induce 
senescence via accumulation of a newly-identified tumour suppressor metabolite 
fumarate (Zheng et al., 2015). Hereditary mutations in FH can cause a highly 
malignant renal cancer, characterised by decreased enzyme activity and accumulated 
fumarate (a TCA cycle metabolite) (Tomlinson et al., 2002; Pollard et al., 2005). The 
resulting stress from the dysfunctional TCA cycle is overcome by the induction of 
senescence, via oxidative stress mediated succination of glutathione. Zheng et al. 
(2015) identified the mechanism linking fumarate to senescence by utilising 
analytical and computational chemistry. An unusual metabolite, succinated 
glutathione (succinicGSH), is produced from fumarate-induced succination activity, 
and induces persistent oxidative stress and consequently, senescence characterised by 
SA β-gal and p21CIP1 expression. The authors hypothesise fumarate also induces the 
succination and inhibition of Keap1, which in turn frees and activates anti-oxidant 
factor Nrf2 to maintain a viable level of oxidative stress and maintain senescence 
state. Although this study does not provide comprehensive mechanistic data, it 
suggests FH is an important mitochondrial tumour suppressor for renal cancer. 
Senescence driven by FH loss is another example of tumour suppressor gene loss 
inducing senescence (like Pten-loss (Alimonti et al., 2010)); although FH-loss is 
mediated through a different mechanism, involving altered TCA cycle metabolism. 
Malate, another TCA cycle metabolite, has also been implicated in senescence, via 
interactions with p53 (Jiang et al., 2013). Malate can be decarboxylated by two malic 
enzymes (cytoplasmic ME1 and mitochondrial ME2), to yield pyruvate (which is fed 
back into the TCA cycle) and CO2. This reaction is dependent on the reduction of 
NADP+ to NADPH, which is also vital for other metabolic activities relevant to 
senescence, such as lipid biosynthesis and anti-oxidant responses. Jiang et al. (2013) 
found MEs and p53 are reciprocally regulated in senescence: ME expression/activity 
is suppressed by p53, whereas increased ME delays replicative senescence. The 
suppression of MEs is mechanistically linked to senescence induction via the 
concomitant depletion in NADPH, a vital mediator of anti-oxidant responses. This 
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results in accumulated oxidative stress and AMPK-mediated p53 phosphorylation 
and activation. This study concluded p53 plays a central role in coordinating 
metabolic rewiring in response to cellular stress and its mutual metabolic regulation 
is vital for senescence. 
It is important to note here that although these studies represent important 
progression in the understanding of senescence-related metabolic alterations, the use 
of different models of senescence makes interpretation more complex because of the 
sensitive response metabolism has towards stress. It appears metabolic profiles of 
senescence are model-dependent and the context of senescence induction (e.g. 
duration and intensity of trigger) must be considered if these studies are translated 
into clinical settings. 
1.2.3.2 Proteostasis: autophagy and mTOR 
Proteostasis is a homeostatic process to balance the degradation and synthesis of 
proteins. In senescence, several different proteostatic mechanisms have been 
implicated, involving either protein degradation (via autophagy) and synthesis (via 
mTOR control). Autophagy is the process whereby organelles and macromolecules 
are isolated in double-membrane autophagosomes and degraded by fusion with 
lysosomes (autolysosomes). This cellular degradation process is functionally relevant 
to senescence depending on cell system and trigger (Gamerdinger et al., 2009; 
Capparelli et al., 2012; Singh et al., 2012). For example, (Patschan et al., 2008) 
identified autophagy as a cell survival mechanism, determining the fate of stressed 
cells: senescence or death. Other studies have mechanistically linked both activation 
and inhibition of autophagy in senescence. 
First, autophagy and protein synthesis (via master regulator mTOR) are spatially 
coupled in OIS. Narita et al. (2011) hypothesised senescent cells must have a 
mechanism to accommodate both anabolism and catabolism of proteins, to ultimately 
facilitate SASP expression. In RasV12-induced senescence, a distinct compartment 
following the Golgi is formed; in the TOR-autophagy spatial coupling compartment 
(TASSC) autolysosomes and mTOR accumulate. Amino acids and Rag GTPase 
recruit and activate TASSC-localised mTOR, which is required for IL6 and IL8 
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synthesis. Cytoplasmic-derived autophagosomes are recruited to allow autophagy by 
fusing with TASSC-localised lysosomes, and thus providing amino acids to enrich 
mTOR recruitment to the TASSC. This study highlights the importance of both 
anabolism and catabolism for senescence and indicates the mechanism by which 
senescent cells can augment the opposing processes for efficient protein turnover. In 
addition, autophagy-mediated degradation of nuclear envelope proteins is activated 
in OIS (Lenain et al., 2015). Specifically, lamin B1 and lamin A were globally 
targeted for autophagy in BRAFV600E and RasG12V induced senescence, resulting in 
aberrant nuclear morphology. The activation of autophagy, as described by Narita et 
al., (2011) and Lenain et al. (2015), is concomitant with increased lysosomal content 
in senescence; these studies further highlight multiple aspects of cellular metabolism 
need to cooperate to maintain proteostasis in senescence. 
In contrast, senescent cells can also inhibit autophagy, which mechanistically 
functions to upregulate the SASP. Kang et al. (2015) identified transcription factor 
GATA4 as an essential mediator of SASP activation via NF-κB. Senescence stimuli 
and DDR kinases ATM/ATR suppress p62-mediated selective autophagy of GATA4. 
Accumulated GATA4 mediates SASP expression and inflammation through 
TRAF3IP2 and IL1A induction of NF-κB. Also, GATA4 is accumulated in aged 
mouse and human tissues, indicating this mechanism could drive age-related 
detrimental inflammation and inhibition of GATA4 may be of therapeutic benefit. 
Further to this, inhibition of MDM2, a ubiquitin-conjugating enzyme that targets p53 
for proteasomal degradation, can drive senescence (Efeyan et al., 2007). Also, 
abnormal Ras/ERK signalling can activate senescence-associated protein 
degradation, that selectively targets assorted groups of proteins for proteasome 
degradation (Deschênes-Simard et al., 2013). These final two studies indicate other 
protein degradation pathways, other than autophagy, are implicated in senescence.  
To conclude, although autophagy activation occurs during senescence, it appears 
inhibition of specific autophagy components is required for SASP production. 
Although there is a balance of activation and inhibition of protein degradation in 
senescence, there are additional mechanisms to maintain proteostasis through the 
regulation of protein synthesis, as described next. 
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Recently, there has been a focus in the field to examine the mechanisms by which 
senescent cells facilitate the synthesis and secretion of SASP proteins. Two studies 
have characterised mTOR as a central factor for SASP regulation in senescence. 
Both studies found rapamycin (the classical mTOR inhibitor) ablated the SASP but 
did not subsequently affect the cell cycle arrest (Herranz et al., 2015; Laberge et al., 
2015). The two studies utilised different techniques to perturb this observation and 
found different mechanisms by which mTOR regulates the SASP. First, it is 
important to note that mTOR is a master regulator of protein synthesis that mediates 
the translation of mRNAs encoding target proteins. Laberge et al. found IL1α mRNA 
transcript was preferentially translated through mTOR control in senescence. 
Expressed and secreted IL1α then signals through IL1R1 receptor to activate global 
transcription factor NF-κB, which subsequently initiates the transcription of other 
inflammatory SASP factors. In contrast, Herranz et al. found MAPKAPK2 (a 
serine/threonine kinase) mRNA transcript was preferentially translated through 
mTOR and 4EBP1 control in senescence. Using phosphoproteomics, the authors 
identified MAPKAPK2-mediated phosphorylation of RNA-binding protein 
ZFP36L1; in turn, this inhibits ZFP36L1-mediated degradation of SASP transcripts. 
As discussed previously, it has been proposed targeting senescent cells is a novel 
approach to treat a variety of different diseases (reviewed by Childs et al. (2017)). 
These two studies provide essential evidence that specifically targeting only the 
SASP, via mTOR inhibition, could achieve similar therapeutic benefit, especially for 
pathological scenarios with inflammation. 
Similarly, there are additional links to the SASP, proteostasis and therapeutic 
targeting of senescence-related metabolic alterations in cancer. Dörr et al. (2013) 
found therapy-induced senescence (TIS) in a lymphoma mouse model upregulates 
metabolic pathways, including glucose utilisation and SASP production. In this 
model of senescence, the higher energetic demands cause the activation of a 
proteoxic response through an ER stress-UPR-ubiquitination-autophagy cascade and 
consequently tumour development. TIS cells subjected to pharmacological inhibition 
of glucose utilisation and autophagy are targeted for selective elimination through 
caspase-mediated apoptosis. After metabolic elimination of TIS cells, lymphomas 
regress and following treatment outcomes are improved. The authors considered a 
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synthetic lethal-like metabolic targeting of senescent cells for treatment of primary 
lymphoma cancer. First, senescence is induced with chemotoxic drugs. 
Subsequently, senescent cells are selectively removed by targeting their aberrant 
metabolism. This presents a novel and intuitive approach for cancer therapy; it 
exploits first the beneficial effects of senescence in halting cancer and then prioritises 
the removal of senescent cells before the detrimental effects develop.  
1.2.3.3 Nucleotide metabolism 
Another essential metabolic rewiring process for OIS is the suppression of 
deoxyribonucleotide triphosphates (dNTPs) (Aird et al., 2013). Ras-induced 
senescence results in the repression of rate-limiting dNTP synthesis enzyme, 
ribonucleotide reductase subunit M2 (RRM2), through E2F7 transcriptional repressor 
recruitment. Decreased dNTP levels are associated with aberrant DNA replication 
and the DDR in OIS. Furthermore, RRM2 expression is repressed in senescent 
melanocytic nevi and activated in tumorigenic melanoma, and high RRM2 
expression correlates with poor survival in human melanoma patients. In addition, 
further perturbation of this mechanism also implicated deregulation of the pentose 
phosphate pathway (PPP) via G6PD activity in OIS (Aird et al., 2015). As the PPP is 
vital for the synthesis of dNTP precursors and senescence induces TCA cycle 
glucose consumption (Kaplon et al., 2013), together this provides further explanation 
for decreased dNTP levels in senescence. The key mediator of this phenotype was 
DDR kinase ATM; in response to replication stress, ATM coordinates the 
downstream upregulation of p53 and suppression of c-MYC, which initiates 
metabolic reprogramming to repress dNTP synthesis and initiate and maintain cell 
cycle arrest. This presents a novel mechanism that links DNA damage and 
replication stress to metabolic rewiring. 
1.2.3.4 Fatty acid metabolism 
Quijano et al. (2012) uncovered altered lipid metabolism in OIS, using 
comprehensive metabolomics analysis. First, they observed increased levels of 
intracellular long chain fatty acids and fatty acid oxidation in Ras-induced 
senescence. Senescent cells exhibited higher basal rate of oxygen consumption 
mediated by carnitine palmitoyltransferase 1 (CPT1A). This rate-limiting protein 
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allows the transfer of lipids from cytoplasm to mitochondria for oxidation. 
Interestingly, CPT1A depletion negatively affects the pro-inflammatory SASP, again 
indicating metabolic rewiring is essential for proper SASP function. This study also 
revealed OIS and replicative senescent cells have different and unique metabolic 
signatures, suggesting metabolic rewiring is context dependent and requires full 
understanding before pursuing clinical benefits. Further to this, 5-lipoxygenase 
(5LO) has been implicated in senescence, by promoting oxidative stress-mediated 
p53 activation (Catalano et al., 2004). 5LO is an enzyme that metabolises 
arachidonic acid (a fatty acid) to produce lipids such as leukotrienes; these are 
particularly interesting in terms of senescence due to their well-studied role in 
inflammation. 5LO activity is increased in Ras-induced senescence of human 
fibroblasts and mediates the stimulation of oxidative stress. This stimulated 
phosphorylation of p53 at serine 15 and subsequent activation of p53-target p21CIP1. 
In summary, this study identified 5LO as a key intermediate factor for metabolic 
alterations and the activation in senescence. Although no data has been shown to 
implicate leukotrienes in senescence, it is likely leukotrienes provide crosstalk with 
altered lipid oxidation and the SASP, considering the role 5LO has in leukotriene 
synthesis and their role in inflammation.  
1.2.3.5 Summary 
Overviewed here are key studies assessing senescence-related alterations in four 
pathways of metabolism and the downstream mechanisms identifying metabolic 
checkpoints for cell cycle arrest. Senescence can activate glucose and oxygen 
consumption through the TCA cycle and OXPHOS, which are genetically regulated 
by metabolic enzymes. Also, senescence-induced proteostasis is balanced intricately 
between protein degradation (autophagy and proteasome activity) and protein 
synthesis (mTOR activity). Finally, decreased nucleotide synthesis and increased 
fatty acid oxidation are also essential aberrant metabolic pathways for senescence. In 
conclusion, senescence requires a different homeostatic state to replicating cells 
which results in rewiring of glucose, protein, nucleotide and lipid metabolic 
pathways. Together, these studies suggest altered metabolism is an essential program 
for senescence induction and maintenance. 
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1.2.4 Ceramides 
1.2.4.1 Ceramide biosynthesis 
Ceramides are a subtype of sphingolipids and are characterised by an 18-carbon 
monounsaturated backbone (known as ‘18:1-sphingosine’) coupled with a fatty acid, 
via an amide bond. Ceramides are neutral moieties and provide the backbone of 
complex sphingolipids, such as glyco- and galacto-sphingolipids. Ceramides can be 
of varying sizes; in humans, the 18:1-sphingosine backbone is bonded to fatty acids 
with chain lengths of 14-32 carbons (Hannun and Obeid, 2011; Morad and Cabot, 
2013). The synthesis of ceramides occurs by three main pathways: de novo, recycling 
and sphingomyelinase. This section focusses on the de novo and recycling pathways 
(figure 1.5) as the sphingomyelinase pathway can be considered as part of the 
recycling. De novo synthesis of ceramide is initiated by rate-limiting enzyme serine 
palmitoyltransferase (SPT), which catalyses the condensation of serine and 
palmitoyl-CoA (Linn et al., 2001). This produces the sphingoid backbone of 
ceramides, which is reduced from 3-ketodihydrosphingosine to dihydrosphingosine 
by 3-ketodihydrosphingosine reductase (KDSR) (Kihara and Igarashi, 2004). Next, 
dihydrosphingosine is coupled with a fatty acid (e.g. 16:0 palmitic acid) to produce 
dihydroceramide, by one of six ceramide synthases (CERS). The preferred activity of 
specific CERS determines the length and saturation state of the fatty acid (Riebeling 
et al., 2003; Levy and Futerman, 2010). The final step in de novo ceramide synthesis 
adds a 4,5-trans double bond to the sphingoid base, catalysed by dihydroceramide 
desaturase (DEGS) (Causeret et al., 2000). The recycling pathway of ceramide 
synthesis involves the breakdown of ceramides to release sphingosine backbone. 
Ceramide synthases regenerate ceramides using the released sphingosine substrate 
and free fatty acids (Kitatani, Idkowiak-Baldys and Hannun, 2008). There are several 
enzymes capable of degrading ceramide for recycling purposes, such as ceramidases, 
which have pH-dependent activities (Galadari et al., 2006; Xu et al., 2006). In 
addition, there is compartmentalisation of ceramide metabolism (Hannun and Obeid, 
2008); the de novo synthesis pathway occurs in the endoplasmic reticulum whereas 
the recycling synthesis pathway occurs in the lysosome, cytoplasm and endoplasmic 
reticulum. 
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Figure 1.5 Ceramide biosynthesis 
(A) The de novo synthesis of ceramides occurs in the endoplasmic reticulum. The process starts 
with the condensation of palmitoyl-CoA and serine, catalysed by serine palmitoyltransferase 
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(SPT), to produce the sphingoid backbone of ceramides. The next step is a reduction catalysed by 
3-ketodihydrosphingosine reductase (KDSR). The product from this step, dihydrosphingosine, is 
coupled with a fatty acid (on the above diagram the fatty acid donor is 16:0 palmitic acid) to 
produce dihydroceramide. This step is catalysed by one of six ceramide synthases (CERS). The    
final step is the addition of a 4,5-trans double bond to the sphingoid backbone, catalysed by 
dihydroceramide desaturase (DEGS). (B) The recycling pathway of ceramide synthesis relies on 
ceramide degrading enzymes, such as ceramidases, to release the sphingosine backbone. 
Ceramide synthases then convert the free sphingosine back into ceramides and free fatty acids. 
 
1.2.4.2 Ceramide metabolism 
Ceramides have individual functions, as discussed in 1.2.4.3, or can be further 
modified through ceramide metabolism (figure 1.6). Metabolism of ceramide that 
releases sphingosine has the potential to enter the recycling ceramide synthesis 
pathway (figure 1.5.B). Otherwise, sphingosine is phosphorylated to sphingosine-1-
phosphate by sphingosine kinase (SPHK1). Sphingosine-1-phosphate is a signalling 
molecule involved in intracellular, extracellular and nuclear regulatory pathways 
(Fyrst and Saba, 2010). Ceramide-1-phosphate is synthesised by ceramide kinase 
(CERK) and regulates immune cell processes such as mast cell degranulation 
(Mitsutake et al., 2004). Ceramide is also modified by addition of phosphocholine 
catalysed by sphingomyelin synthase (SMS), to form sphingomyelin. The reverse 
reaction is catalysed by sphingomyelinase and is part of the recycling pathway of 
ceramide synthesis. Sphingomyelin is a sphingophospholipid present in plasma 
membranes and is especially found in myelin sheaths of nerve cell axons (Ramstedt 
and Slotte, 2002). It is proposed sphingomyelin is an essential component of 
membrane ‘lipid rafts’ that function to mediate cellular trafficking and signal 
transduction (Simons and Ikonen, 1997). Glycosylceramides are complex molecules 
synthesised by the glycosylation of ceramide using mono- and polysaccharides, 
catalysed by ceramide glycosyltransferases (CGT). Glucosylceramide 
(ceramide+glucose) is the major lipid component of skin, contributing to water 
barrier properties of skin (Messner and Cabot, 2010). Galactosylceramide 
(ceramide+galactose) is a major component of nervous tissue (Coet et al., 1998). 
Mutations in genes involved in the breakdown glucosyl- and galactosylceramide 
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cause Gaucher and Krabbe disease, respectively. These diseases are known as 
lysosomal storage disorders as they are characterised by tissue-specific accumulation 




Figure 1.6 Ceramide metabolism 
There are four main metabolic fates for ceramide (clockwise from top left): conversion to 
sphingomyelin, catalysed by sphingomyelinase (SMS); addition of mono and poly sugar residues 
to synthesise glycosylceramides, catalysed by ceramide glycosyltransferases (CGT); breakdown 
to sphingosine, catalysed by ceramidase (ASAH1) and phosphorylation to sphingosine-1-
phosphate, catalysed by sphingosine kinase (SPHK1); and phosphorylation to ceramide-1-
phosphate, catalysed by ceramide kinase (CERK). R = R-group present depends on the length 
and saturation state of fatty acid added to sphingosine backbone during ceramide biosynthesis 
(see figure 1.5). 
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1.2.4.3 Functions of ceramide 
More sphingolipid species (~200) are present in human plasma than any other lipid 
class (Gonzalez-Covarrubias, 2013). This observation correlates with the large list of 
cellular and molecular functions of sphingolipids, alluded to in the previous sections. 
These functions of ceramide are also determined by the distinct sub-cellular 
localisation of the different pathways of ceramide synthesis, making it difficult to 
define the context of ceramide functions. This section overviews the role ceramides 
play in cellular membranes and cell cycle and death signalling. 
Sphingolipids are amphipathic molecules, containing both hydrophobic and 
hydrophilic regions. Amphipathic lipids form bilayer membranes typical of the 
plasma membrane of cells; however, sphingolipids generally have saturated tails 
which allow them to pack more tightly into ordered regions (van Meer, Voelker and 
Feigenson, 2008). These sphingolipid-rich regions form dynamic microdomains, 
known as ‘lipid rafts’ (Thomas et al., 2004). The rafts are fluid and can float in the 
normal membrane bilayer due to the association of cholesterol with the 
sphingolipids. The rafts act as platforms that mediate assembly of proteins involved 
in cell signalling (Futerman and Hannun, 2004). Ceramide metabolism can promote 
raft formation in specific cellular locations and thus ceramides have a role in 
regulating cell signalling (Gulbins and Kolesnick, 2003).  
Apoptosis is a series of regulated processes that lead to programmed cell death and is 
a physiological response to cellular stress. Apoptosis can be induced by a number of 
factors, such as ionising radiation and tumour necrosis factor alpha (TNFα), and 
correlates with increased ceramide levels (Haimovitz-Friedman et al., 1994; Dbaibo 
et al., 2001). There are two major apoptotic pathways, extrinsic and intrinsic, and 
ceramides have been implicated in both. The extrinsic pathway occurs extracellularly 
and involves the arrangement of pro-apoptotic receptors and corresponding ligands 
(such as TNFα) on the cell surface (Morad and Cabot, 2013). Ceramides form 
platforms on the cell membrane to mediate this receptor clustering (Stancevic and 
Kolesnick, 2010). The intrinsic pathway is the intracellular signal transduction 
mediated by the mitochondria, resulting in the release of pro-apoptotic proteins (such 
as cytochrome c) (Morad and Cabot, 2013). Ceramide induces pore formation in the 
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mitochondrial outer membrane (Siskind, Kolesnick and Colombini, 2002), increasing 
the permeability and therefore regulating release of pro-apoptotic proteins. Cancer 
cells are resistant to apoptosis and there is some work indicating ceramides can be 
used to induce apoptosis for cancer therapy; this is described in further detail in 
1.2.4.4.  
Ceramides also have a regulatory role in cell cycle arrest, with research focussing on 
replicative senescence. Ceramides were first implicated in senescence by Venable et 
al. (1995); in this study, it was found replicative senescent cells have a 4-fold 
increase in ceramide content. Furthermore, exogenous ceramide treatment induces 
senescence in a dose-dependent manner and is mechanistically linked to cell cycle 
arrest by hypophosphorylated RB (Dbaibo et al., 1995). Ceramide can activate 
protein phosphatases (Wolff et al., 1994), and although this appears to link ceramide 
to RB-mediated cell cycle arrest (Castro et al., 2008), the exact mechanism of RB 
regulation in senescence is unknown. Ceramide-mediated senescence is characterised 
by p21 activation and resulting CDK2 inhibition (Lee, Bielawska and Obeid, 2000); 
however, there is contrasting evidence for whether this process is p53-dependent 
(Pruschy et al., 1999; Struckhoff, Patel and Beckman, 2010) or p53-independent 
(Kim et al., 2000). Finally, ceramide can inhibit telomerase, identifying it as an 
upstream regulator of telomere shortening (Ogretmen et al., 2001). Interestingly, 
most of these studies were performed in replicative senescence models yet it was 
concluded ceramide has an essential tumour suppressive role.  
In the early 2000s, there were many publications implicating ceramides in cell cycle 
arrest and although ceramides have been identified as a tumour suppressor, no 
additional characterisation of functional mechanisms concerning ceramides has been 
performed. This complicates making conclusions of how ceramide mediates cell fate; 
it is unknown how it is decided in what anti-proliferative way ceramide responds to 
cellular stress. Balancing ceramide metabolism likely plays a deciding role in cell 
fate, with a threshold of ceramide levels that will mediate either apoptosis or cell 
cycle arrest. 
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1.2.4.4 Ceramide in senescence-related pathologies 
Ceramides have a function in cell cycle arrest, albeit this function is mechanistically 
unclear; therefore, there have been numerous studies alluding altered ceramide 
metabolism in senescence-related pathologies, discussed here. Recently, there has 
been an influx of ceramide-containing anti-aging products that increase skin 
hydration and reduce wrinkles (Guillou et al., 2011). These products boost naturally-
occurring ceramide present in the stratum corneum epidermis layer of human skin, 
which creates a barrier impermeable to water. Furthermore, ceramide synthesis 
enzymes sphingomyelinase and CERS have decreased activity in the inner epidermal 
skin layer of aged mice, suggesting a mechanism for decreased ceramide content in 
aged skin (Jensen et al., 2005). Finally, altered levels of ceramide and 
glycosylceramides have been observed in aged oocytes (Kujjo et al., 2013) and 
neurodegenerative tissues (Mencarelli and Martinez–Martinez, 2013). These studies 
suggest aged cells/tissues have aberrant ceramide synthesis and metabolism, 
opposing with the senescence-inducing molecular function of ceramide (outlined in 
the previous section). This discrepancy could be explained by timing-specific 
functions of ceramide or lack of correlation between expression and activity of 
ceramides in the aging process. 
The genes that encode the six ceramide synthases present in humans were implicated 
in longevity before the function of the gene products was known. CERS1 was first 
identified in a screen of longevity-related genes in Saccharomyces cerevisiae 
(D’mello et al., 1994). Gene deletion resulted in a 50% increase in yeast lifespan and 
thus, the gene was assigned the name Longevity Assurance Gene 1 (LAG1). LAG 
homologs have been identified in human, mouse and Caenorhabditis elegans, 
indicating conservation of the gene in eukaryotes (Jiang et al., 1998). Human LAGs 
are assigned the name: LASS (longevity assurance), however since the function of 
LAG/LASS genes has been identified they are commonly referred to as CERS 
(ceramide synthase) (Pewzner-Jung et al., 2006). Mammalian CERSs have homolog-
specific functions, as outlined in table 1.1. It is unknown why mammalians have six 
CERS with individual activities, however it implies the importance of specific 
lengths of ceramides for system and cell biology. Pewzner-Jung et al. (2006) 
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hypothesised the role of CERSs in longevity is independent from their ceramide 
synthase activity, however work discussed in the previous section and from this 
thesis suggests that ceramide synthesis does have a role for the biology of aging 
through cell cycle control.  
Gene Length of ceramide product Reference 
CERS1 C18-ceramide Venkataraman et al., 2002 
CERS2 C20-/C22-/C24-/C26-ceramide Laviad et al., 2008 
CERS3 C18-/C24-ceramide Mizutani et al., 2006 
CERS4 C18-/C20-ceramide Riebeling et al., 2003 
CERS5 C16-ceramide Riebeling et al., 2003 
CERS6 C14-/C16-ceramide Mizutani et al., 2005 
Table 1.1 Ceramide synthase activity of the 6 mammalian CERS homologs  
 
Cancer cells have altered levels of ceramide, suggesting a role in cancer pathogenesis 
(Ogretmen and Hannun, 2004). For example, ceramide levels are inversely 
proportional to the severity of malignant glial tumours in humans (Riboni et al., 
2002) and ceramide levels are decreased in ovarian tumours (Knapp et al., 2017) and 
breast tumours (Schiffmann et al., 2009) compared to normal tissues in humans. 
Decreased levels of ceramide in cancer correlate with increased expression of 
ceramide metabolic enzymes in certain cancers. SPHK1 expression is required for 
intestinal adenoma cell proliferation in mice (Kohno et al., 2006), whilst acid 
ceramidase is overexpressed in human prostate cancers (Seelan et al., 2000). In 
addition, de novo synthesised C16-ceramide is essential for B-cell receptor induced 
apoptosis of human lymphoma cells (Kroesen et al., 2001). Finally, recent work has 
provided more detailed insight into the mechanism of altered ceramide metabolism in 
cancer. CERS4-synthesised ceramide inhibits TGFβ receptor trafficking and 
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signalling in cancer cells and attenuates tumour metastasis through inhibition of cell 
migration in vivo (Gencer et al., 2017). This suggests the regulation of specific 
ceramide metabolic pathways can determine the fate of cancer cells and provides a 
novel mechanism for targeting cancer in humans. 
There has been some research into establishing the benefit of increasing intracellular 
levels of ceramide in combination with traditional chemotherapies for cancer 
(reviewed by (Li and Zhang, 2015)). There are three ways of increasing intracellular 
ceramide content: activate synthesis enzymes, inhibit metabolism enzymes or 
provide exogenous ceramide. SPT activator PSC-833 increases the sensitivity of 
human carcinoma cells to vinblastine-induced apoptosis (Cabot et al., 1999). CERK 
inhibitor NVP-231 inhibits proliferation of lung cancer cells and subsequently 
induces apoptosis. This effect was more evident when combined with staurosporine 
treatment (Pastukhov et al., 2014). Finally, exogenous ceramide synergistically 
enhances the anti-proliferation effects of docetaxel in murine and human cancer cells 
(Feng et al., 2014). The majority of this research was performed in vitro, therefore 
further work is required to determine the therapeutic benefit of targeting ceramides in 
vivo. Ceramides have decreased bioavailability due to hydrophobic chemical 
properties. There has been development of novel approaches to deliver hydrophobic 
ceramides to human cells, such as nanoliposomes (Watters et al., 2012). These 
approaches have provided a platform to test the effects of exogenous ceramides in in 
vivo cancer models. Indeed, exogenous ceramides delivered in nanoliposomes halt 
leukaemia progression in rats (Liu et al., 2010) and hepatocellular carcinoma growth 
in mice (Tagaram et al., 2011).  
1.2.4.5 Summary 
Ceramides are a sphingolipid species synthesised by de novo or recycling pathways 
and can be further metabolised to create modified ceramide with distinctive 
functions. Ceramides have a variety of different biological functions, mainly as a 
physical component of cellular membranes and as a signalling regulatory molecule 
for cell cycle and cell death processes. Ceramides have been implicated in a number 
of pathological environments, including aging and cancer. Although it is clear 
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ceramides function in senescence, the specific mechanisms and importance of them 
is currently unclear. 
1.2.5 Metabolism in cancer and senescence summary 
Recent improvement in mass spectrometry techniques and accompanying labelling 
methods has facilitated the vast expansion of knowledge in cancer metabolism. Yet, 
the Warburg Effect – the preferential usage of aerobic glycolysis in cancer – was first 
postulated in 1924 and is now believed to be implemented by cancer to drive energy 
and biomass generation. Due to the dynamic nature of metabolism, the mechanisms 
driving the Warburg Effect are complex; they include alterations in glucose, 
glutamine and one-carbon metabolism, in addition to aspects not discussed here, such 
as acetate metabolism (Mashimo et al., 2014; Schug et al., 2016). OIS results in 
metabolic reprogramming of glucose, protein, nucleotide and lipid biosynthesis 
pathways; genes implicated in these pathways provide novel metabolic checkpoints 
to prevent cancer progression and initiate senescence. In addition, it appears 
ceramides are implicated in cancer, due to unbalanced ceramide metabolism 
initiating cellular outcomes: senescence and apoptosis. Finally, alterations in 
metabolic genes and associated metabolites, in both cancer and OIS, have provided 
new avenues for cancer therapeutics that are being assessed for clinical efficacy in 
humans. 
 
1.3 RNA interference and high content screening 
The discovery of RNA interference (RNAi) in 1998, and subsequent technical 
implications for gene silencing, rocketed biological research into the future. In the 
two decades since, RNAi has been used to make fundamental advances in 
understanding how genes regulate biological processes. Although in very recent 
years CRISPR-Cas9 has taken the trendy gene editing top spot, RNAi is still a 
powerful method for perturbing gene expression. Specifically, CRISPR-Cas9 
techniques result in deletion of genes and in the case of essential genes this is 
incompatible with life. Whereas RNAi can be harnessed to specifically regulate the 
expression levels of genes, to retain essential gene function and thus allow cellular 
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readouts. In this section, the molecular mechanisms for RNAi-mediated gene 
silencing and different types of RNAi are described. In addition, the use of high 
content screening (HCS) coupled with RNAi for discovering new genetic regulators 
of physiological and pathological scenarios is overviewed. Finally, examples of how 
RNAi-HCS methods can be used to identify novel OIS regulators are explored. 
1.3.1 RNA interference (RNAi) 
1.3.1.1 Overview of RNAi 
RNAi is an evolutionary-conserved endogenous biological process first discovered in 
C. elegans worms (Fire et al., 1998). The discovery of RNAi and its function has 
revolutionized biological research due to its application for post-transcriptional gene 
silencing. In basic terms, RNAi harnesses gene-specific RNA reagents to initiate the 
degradation of target gene mRNA, resulting in decreased expression of that gene. In 
molecular terms, RNAi is a complex multi-step process that employs many different 
factors (reviewed by Wilson and Doudna (2013)). Briefly, precursor double-stranded 
RNAs (dsRNA) are processed by RNase III protein Dicer to form small dsRNAs (19-
23 nucleotides (nt) in length) with phosphorylated 5’ sites and 2-nt unphosphorylated 
3’ overhangs (Bernstein et al., 2001). The small dsRNAs are also known as small 
interfering RNAs (siRNA), and their use as synthetic reagents for gene silencing is 
described in the next section. The siRNA has a guide strand that associates with 
RNA-induced silencing complex (RISC), and acts as a template to bind target mRNA 
(Hammond et al., 2000; Nykänen, Haley and Zamore, 2001; Haley and Zamore, 
2004). There can be several outcomes of this process, but the post-transcriptional 
gene silencing is the most characterised; the RISC protein Argonaute-2 is activated 
upon siRNA association and cleaves the complementary mRNA sequence, and thus 
effectively silencing the expression of the encoded gene (Hammond et al., 2001; 
Caudy et al., 2003). 
dsRNA mediators of RNAi can activate a non-specific interferon response in 
mammalian cells (Sledz et al., 2003), therefore there has been careful evaluation of 
the suitability of using RNAi in vitro and in vivo. The interferon response is an innate 
immune process that is usually triggered by viral dsRNAs and can initiate sequence-
independent mRNA degradation (Manche et al., 1992; Sledz et al., 2003; Kim et al., 
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2005). To overcome these non-specific effects of RNAi gene silencing, it has been 
determined dsRNAs of less than 23 base pairs (bp) in length are able to bypass the 
interferon response by imitating Dicer-processed siRNAs and enter RNAi 
downstream of the processing events (Elbashir et al., 2001; Reynolds et al., 2006). In 
addition to the length of dsRNAs, the system used to introduce RNAi mediators and 
the targeted cell type must also be evaluated. Overall, there are many obstacles to 
overcome to establish a specific and efficient RNAi method for gene silencing.  
RNAi can be harnessed in multiple different combinations for use in in vitro and in 
vivo systems. Use of individual RNAi sequences can play a vital role in the 
identification of gene function in health and disease states. Whereas, using RNAi 
technology in combination with high-throughput screening can yield systemic 
analysis of many genes at once; it is also possible to screen genome-wide RNAi 
(Ashrafi et al., 2003; Berns et al., 2004; Boutros et al., 2004; Paddison et al., 2004). 
High-throughput RNAi greatly shortens the time it takes to identify genetic 
regulators of a biological process or disease. The rest of this section will examine the 
different types of RNAi that can be used for gene silencing, and how they can be 
combined with high-throughput screening approaches to yield answers to biological 
problems. 
1.3.1.2 Small interfering RNA (siRNA) 
siRNAs were first discovered in plants (Hamilton and Baulcombe, 1999) and soon 
after, synthetically recapitulated in mammalian cells (Elbashir et al., 2001). To 
experimentally target gene expression, siRNA sequences are synthesised following 
optimised design criteria (Leung and Whittaker, 2005), including ensuring the length 
is between 21-23bp, due to issues with long dsRNAs described previously. In 
addition, the introduction of siRNA must be evaluated for individual cell systems. 
There are three main methods of siRNA delivery: lipid-mediated transfection 
(Malone, Felgner and Verma, 1989), electroporation (Neumann et al., 1982) or virus-
mediated infection (Brummelkamp, Bernards and Agami, 2002b). In all cases, 
siRNA-mediated gene silencing in mammalian cells is transient due to their long-
term instability and dilution with every population doubling. So, siRNA delivery 
must be optimised to allow a certain number of siRNA molecules to be introduced 
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resulting in transient gene silencing without toxic effects. Finally, off-target effects 
are common issues with siRNAs due to non-target genes having partially 
complementary sequences to the target gene, and thus are inadvertently targeted. For 
example, 3’ untranslated region similarity has been implicated as the trigger for off-
targeted genes in siRNA-treated human cells (Birmingham et al., 2006). Off-target 
effects can be combated with algorithm-assisted design of siRNA sequences. In 
addition, there are commercially available siRNAs (e.g. Dharmacon ON-
TARGETplus siRNA) that have a patented dual-strand modification that is proven to 
reduce off-target effects. Specifically, a 2’-O-methyl ribosyl modification at position 
2 of the siRNA guide strand reduces the silencing of off-targeted genes and enhances 
specificity to target genes (Jackson et al., 2006). The properties of siRNAs make 
them amenable to high-throughput screening, for example: under optimised 
transfection conditions knockdown is highly efficient and off-target effects can be 
reduced using chemical modifications. However, there are some disadvantages to 
using siRNAs for screening, for example: their transient effects limits assaying for 
short-term phenotypes only and they can be stored for limited amounts of time. 
Nonetheless, if siRNA transfection conditions are optimised for cell type and 
reagents are handled and stored correctly, screening with siRNAs can be a robust and 
reliable technique for identifying genetic regulators of the screened biological 
process. 
1.3.1.3 Short hairpin RNA (shRNA) 
shRNAs are artificial RNAi molecules used to induce stable gene silencing. They are 
generally around 60-70bp in length with complementary sequences at 5’ and 3’ ends; 
once transcribed, these sequences loop back to create a structure defined as the 
‘hairpin’. The shRNAs enter the RNAi pathway via Dicer cleavage of the hairpin, 
which forms siRNAs that associate with the RISC (McManus et al., 2002; Paddison 
et al., 2002). shRNAs can also be designed to stable express siRNA sequences, that 
are normally transiently delivered, in mammalian cells (Brummelkamp, Bernards and 
Agami, 2002a). shRNAs can be introduced to cells by transfection in a plasmid with 
a RNA polymerase III promoter, which initiates the transcription of the shRNA 
sequence once in the cell (McManus et al., 2002). However, this delivery method can 
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have limited uses, depending on the amenability of the target cell to transfection 
(reviewed by Dykxhoorn, Novina and Sharp (2003)); for example, primary cells are 
notoriously difficult to stably transfect. Therefore, shRNAs are often cloned into 
retro- and lenti-viral vector systems, which can be introduced to cells using a virus 
packaging cell line (such as 293T) to create the shRNA-expressing virus. Cells are 
infected with the virus and co-expressed shRNA and drug-selection marker 
sequences are incorporated into host DNA. This allows stably infected cells to be 
selected and expanded, for long periods with continual provision of the selection 
drug (Rubinson et al., 2003; Stewart et al., 2003). One of the first functional studies 
to use viral-mediated shRNA revealed oncogenic K-RasV12 could be specifically 
repressed in human pancreatic tumours cells. This shRNA-mediated silencing 
decreased tumorigenicity whilst wild type K-Ras remained intact (Brummelkamp, 
Bernards and Agami, 2002b). This was one of the first indications that RNAi could 
be therapeutically manipulated for diseases, such as cancer, and in recent years this 
concept has been making progress in the clinic (reviewed by Bobbin and Rossi 
(2016)). 
1.3.2 High content screening (HCS) 
To gain as much information as possible from RNAi screening, the subsequent 
phenotype must be measured using an appropriate assay. With siRNA, this 
phenotype must be short-lived (the 72 hour period subsequent to siRNA transfection 
yields the best knockdown efficiency). With shRNA, this phenotype can be 
repeatedly measured over an indefinite period. In the past 10 years, there has been 
development of the complex technologies that can be coupled with RNAi for high-
throughput experiments, such as high content screening (HCS). Image-based HCS 
provides an excellent automatic platform for multi-parametric image acquisition and 
analysis. There are many assays that can be measured by image-based HCS; these 
include: simple immunofluorescence stains, such as measuring BrdU incorporation 
as a proliferation readout (Gasparri et al., 2004) and complex live cell assays with 
fluorescently labelled chromosomes to report cell cycle progress (Neumann et al., 
2006). In these techniques, DNA can be co-stained using 4’,6-diamidino-2-
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phenylindole (DAPI). This allows assay quantification by using thresholds to 
determine if a cell is negative or positive for the measured phenotype. 
One of the major issues with RNAi coupled with HCS is the generation of large 
amounts of data to be analysed. This has become easier to overcome recently with 
the availability of online software packages, developed for specific types of assays 
(such as ‘web cellHTS2’, (Pelz, Gilsdorf and Boutros, 2010)). Screen analysis aids 
hit identification and classification; generally, hits can be determined using a Z-score 
analysis. Further, it is vital to perform statistics on HCS datasets, to determine how 
the distribution and quality of data is affected, such as the Z’ factor (Zhang, Chung 
and Oldenburg, 1999). The Z’ factor considers the separation between internal 
negative and positive controls to attain data variability and quality metrics. After 
threshold and statistic driven hit identification, hits must be reassessed in an 
independent validation screen; for primary screens using pooled RNAi (usually at 
least 3 different sequences for the same target), validation can be performed using 
deconvoluted RNAs. Overall, if an appropriate assay is used to measure phenotypes 
after RNAi perturbation of cells, quantitative data can be obtained quickly and easily 
using HCS. 
1.3.3 Using RNAi/microscopy approaches to identify regulators of OIS  
Senescence has proven to be very amenable to RNAi experimental approaches; there 
has been great progression in the understanding of senescence regulatory pathways 
using shRNA and siRNA mediated methods. Generally, screens targeting senescence 
employ an assay that identifies a ‘bypass of senescence’ caused by RNAi knockdown 
of a gene essential for senescence. Bypass of senescence can be initially analysed in 
a variety of ways, including: colony formation, proliferation, tumour suppressor 
expression. As discussed earlier, senescence is not defined by a singular phenotype, 
so subsequent validation of screen hits using other senescence markers is required. 
One of the first large-scale RNAi screens to be reported had implications in 
senescence biology and introduced a new method to stably express siRNAs as 
shRNA constructs (Berns et al., 2004). The authors using their RNAi library, 
targeting 7914 genes in mammalian cells, to identify new components of the p53 
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pathway implicated in DNA-damage induced senescence. In 2008, a genome-wide 
shRNA screen was used to identify 17 genes essential for human BRAFV600E-induced 
senescence (Wajapeyee et al., 2008). This screen involved stable transduction of 
shRNA using retrovirus delivery, followed by colony formation and confirmation of 
shRNAs by gDNA sequencing. Robust validation was performed using 
proliferation/apoptosis assays and p16INK4a expression. Subsequently, a role for 
secreted protein IGFBP7 (one of the top screen hits) was identified for the regulation 
of senescence in benign nevi and apoptosis in malignant melanoma. Following, a 
smaller shRNA screen was used to identify regulators of senescence in human 
fibroblasts, utilising retroviral delivery of pooled shRNA in 96-well plate format 
(Acosta et al., 2008). This screen identified CXCR2 as a regulator of replicative 
senescence and OIS; later validation revealed a role for CXCR2 in the regulation of 
SASP chemokine expression through transcription factors C/EBPβ and NF-κB. More 
recently, the combination of RNAi screening with other genomics approaches have 
been utilised to identify novel tumour suppressors vital for BRAFV600E-induced 
senescence (Kaplon et al., 2014). This study performed a near-genome-wide shRNA 
screen to identify RASEF as essential for senescent nevi. Genome-wide DNA 
methylation analysis using next-generation sequencing confirmed hypermethylation 
of RASEF was required for senescence bypass and melanoma progression. 
Furthermore, a genome-wide siRNA screen was used to associate regulators of 
p16INK4a with primary cilium (PC) biology, in a replicative senescence in vitro 
model. Bishop et al. (2010) identified Hedgehog signalling component SUFU 
promotes cell cycle via the suppression of p16INK4a and this was both primary cilium-
dependent and -independent. Together, these studies highlight the effectiveness of 
using RNAi to identify potential regulators of senescence and assist the development 
of new areas of research for the senescence and cancer fields. 
1.3.4 RNAi and HCS summary 
The original Nobel prize winning discovery of RNA interference in 1998 prompted 
the development of a new field for biological techniques to target gene expression. 
RNAi has since been used to extensively examine processes on a genome-wide scale. 
There are some pitfalls to RNAi but these can generally be overcome if delivery 
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technique and assay platform are optimised. Using RNAi to modulate gene 
expression levels instead of gene deletion techniques is advantageous when studying 
essential genes, such as metabolic enzymes. When coupled with high-content 
screening, RNAi is a powerful approach to identify novel regulators of cancer 
associated processes, including oncogene-induced senescence. RNAi is a main 
method exploited for this thesis; methods, results and discussion involving RNAi can 
be found throughout subsequent chapters. 
 
1.4 Thesis aims 
Although senescent cells are stably arrested they maintain active but rewired 
metabolism. From recent studies, it is evident OIS-specific metabolic alterations can 
be targeted for disease therapeutics. In addition, as there are already clinically 
approved drugs implicated in metabolism, metabolic factors provide an attractive 
target for novel disease therapeutics in humans. The main aim for this thesis was to 
identify novel metabolic regulators in OIS, using RNAi and HCS methods combined 
with in vitro cell culture. The next focus was to thoroughly validate screen hits, using 
senescence marker assays and two senescence models. The next aim was to identify 
the function of the top screen hit in OIS, utilising accurate mass LC-MS to 
quantitatively measure metabolism. Lastly, delineating the downstream mechanism 
that links the identified metabolic regulator to OIS cell cycle arrest was the final aim, 
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Chapter Two: Materials and Methods 
2.1 Chemicals and Solutions 
All chemicals and solutions used for this work have been appropriately referenced 
within the text (information includes supplier and product code). All the solutions in 
table 2.1 were obtained from the MRC Human Genetics Unit Technical Services.  
Product Composition 
Phosphate-buffered saline (PBS) Dulbeccos tablets + dH2O 
Tris-buffered saline (TBS) 25 mM Tris-HCl + 137mM NaCl + 
2.7mM KCl, pH7.4 
TBS-tween TBS + 0.05% Tween 20 
IF blocking buffer PBS + 1% Bovine Serum Albumin + 
0.2% Fish Gelatin 
Table 2.1 Regularly used solutions 
 
2.2 Cell culture 
2.2.1 Cell lines and maintenance  
IMR90 and 293T cell lines were obtained from ATCC. All cell lines were 
maintained in Dulbecco’s Modified Eagle’s Medium – high glucose (DMEM; Sigma, 
D5796), supplemented with 10% HyClone Fetal Bovine Serum (Thermo Fisher, 
SV30180.03) and 1% antibiotic-antimycotic (Thermo Fisher, 15240062); henceforth 
referred to as ‘normal media’. All cell lines were incubated at 37°C with 5% CO2. 
Incubators were decontaminated and cultures tested for mycoplasma on a regular 
basis. For passaging, cells were washed once with PBS and detached using trypsin 
(Thermo Fisher, 25300-054). Plates were placed in a 37°C incubator for up to 5 
minutes, to allow full detachment of cells. Detached cells were pelleted using a 
centrifuge at 1000rpm for 5 minutes. Cells were resuspended in fresh media and 
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counted or split 1:4 of the original density. For passaging, cells were cultured in 
10cm plates and for experiments, 6- and 96-well plates were used.  
2.2.2 Freezing and thawing cells 
Confluent plates were trypsinised as described in 2.2.1 and resuspended in 1ml of 
normal media supplemented with 10% DMSO, and aliquoted in cryotubes. Tubes 
were stored at -80°C and stocks of each passage were transferred to liquid nitrogen.  
Cells were thawed by removal from -80°C and 1-2 minutes in a 37°C water bath. 
Thawed cells were diluted 1:10 in fresh media and pelleted using a centrifuge at 
1000rpm for 5 minutes to remove the DMSO. Cells were resuspended in fresh media 
(5ml per tube) and added to 10cm plate pre-aliquoted with 10ml media, being careful 
to distribute the cells across the whole plate. Generally, thawed cells required 2 days 
to recover and then were split as described in 2.2.1. 
2.2.3 Production of stable cell lines 
293T were routinely used as packaging cells to produce retroviruses or lentiviruses 
for infection in IMR90. Figure 2.1 shows a summary timeline for these experiments.  
 
Figure 2.1 Protocol for making stable cell lines 
 
2.2.3.1 293T transfection – production of retroviruses 
The day before transfection, 293T were split 1:4 into 10cm dishes and the next day 
transfections were performed late afternoon. For each dish, 7.5µg GagPol, 2.5µg 
VSVG and 20µg of midi-prepped plasmid was combined with 500µl unsupplemented 
DMEM, vortexed and incubated at room temperature for 10 minutes. In a separate 
tube, a mastermix of polyethyleneimine (PEI; Alfa Aesar, 43896) was prepared and 
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unsupplemented DMEM. 500µl of PEI mastermix was added to each DNA 
preparation, vortexed and incubated at room temperature for 10 minutes. The 
transfection mix was then added dropwise over 293T and carefully mixed. 
Transfected cells were incubated overnight and the media changed the next morning 
(approximately 16-20 hours after transfection) to avoid toxicity from VSVG and PEI. 
Transfected cells were incubated for a further 24 hours to allow retrovirus 
production. GFP was used as a visual control for transfection efficiency. 
2.2.3.2 Retroviral infection of IMR90 
The day before infection (i.e. the day after 293T transfection), IMR90 were split 1:4 
into 10cm dishes. Retroviruses were collected from 293T and filtered through a 
0.45µm membrane into a falcon pre-aliquoted with 4µg/ml polybrene (Sigma, 
H9268). Fresh media was added to 293T and the time noted to start the next round of 
infection after 2½ hours. Media was aspirated from IMR90 and retrovirus-polybrene 
mix was added, and dishes placed back in the incubator. This process was repeated 
twice more. After the third round, 293T were discarded and retrovirus replaced with 
supplemented DMEM on the IMR90. Infection efficiency was assessed 48 hours post 
infection, using GFP, and IMR90 split 1:2 or 1:3 into selective antibiotic – 400µg/ml 
geneticin (G418 sulphate; Thermo Fisher 10131/027), 1µg/ml puromycin (Thermo 
Fisher, A11138) or 2µg/ml blasticidin (Thermo Fisher, A11139). Selection media 
was changed every 48 hours as the uninfected cells died, and cells expanded for 
experiments. 
2.2.4 An inducible cell model for OIS 
OIS was modelled using human diploid fibroblast primary cells line IMR90 with 
expression of 4-hydroxytamoxifen inducible ER:RasG12V or ER:Stop chimaeric 
fusion proteins. The cell lines are referred to throughout this thesis as: IMR90-
ER:Stop (or iStop) and IMR90-ER:Ras (or iRas). An illustration and explanation of 
this model is shown in figure 2.2. To produce these cells, passage 4 IMR90s were 
infected with the ER:Stop and ER:Ras constructs as described in 2.2.4.2 (performed 
by Juan-Carlos Acosta) and expanded to passages 8-15. For expansion of these lines, 
cells were grown in 400µg/ml geneticin. Cells were frozen down at various passages 
or used for experiments. Further infections of shRNAs and overexpression constructs 
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were performed at passage 10-12. To activate RasG12V and induce senescence in 
IMR90, 100nM 4-hydroxytamoxifen (4OHT; Sigma, H7904) was administered (the 
start day of 4OHT treatment is referred to as ‘day 0’). For 4OHT treatment, a 100µM 
stock was diluted 1:1000 in media, added to cells and refreshed every 2-3 days. 
 
Figure 2.2 The ER:Ras system to model OIS in IMR90 cells 
The estrogen receptor (ER) has a hormone-binding domain which, in the absence of estrogen, is 
bound to chaperones. 4-hydroxytamoxifen (4OHT) is an ER antagonist; this means 4OHT will 
bind to the ER similarly to estrogen and displace the chaperones. This system is exploited to 
model OIS, by fusing an oncogenic Ras protein (RasG12V) to the hormone-binding domain of the 
ER (iRas cells). In normal conditions, the ER:Ras fusion protein will remain inactive due to 
chaperone binding. Upon 4OHT treatment, the chaperones dissociate and the ER:Ras fusion 
protein is constitutively activated; RasG12V will exert its downstream oncogenic effects, inducing 
cell cycle arrest and accumulation of senescence markers. For control cells (iStop), the ER is 
fused with a stop codon, meaning there is no protein bound to hormone-binding domain. The 
presence of 4OHT has no effect on the proliferation of iStop cells.  
 
2.2.5 Measuring population doublings 
Population doublings (PD) were used to measure the growth rate of cells over 
numerous passages. The Muse Cell Analyser (Merck Millipore) and Muse Cell 
Count and Viability kit (Merck Millipore, MCH100102) was used to count cells. The 
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Count and Viability reagent contains two DNA binding dyes that were used to stain 
viable and non-viable cells, depending on the permeability and nucleated state of a 
cell. Cells were pelleted as described in 2.2.1 and resuspended in an appropriate 
volume of normal media. A 1:4 or 1:8 mix of cells and Count & Viability reagent 
was prepared and incubated at room temperature for up to 5 minutes. One sample 
was used to set the two gates for the reagent dyes – each dye plot allowed the user to 
set thresholds to eliminate non-viable and non-nucleated cells. The ‘number of 
cells/ml’ value was used to calculate how much volume of the cell resuspension was 
required to re-seed the sample at 500,000 cells per 10cm dish. The ‘total number of 
cells’ (x) value was used to calculate the population doublings using the formula:  
PD=LOG(x/500,2). The PD over numerous passages were added together to evaluate 
the cumulative PD. 
2.2.6 Treatments 
IMR90 were treated with a variety of drugs and compounds as listed here. All 
ceramides and sphingosine were acquired from Avanti Polar Lipids, Inc., and used at 
final concentrations of 1-2µM. Absolute filtered ethanol was used as a vehicle for all 
sphingolipids. NVP-231, a ceramide kinase inhibitor, was acquired from Calbiochem 
(219493) and used at a final concentration of 5µM. SKI-1, a sphingosine kinase 
inhibitor, was acquired from Abcam (142209) and used at a final concentration of 
2µM. Ceranib-1, a ceramidase inhibitor, was acquired from Tocris Bioscience (4448) 
and used at a final concentration of 2µM. DMSO was used as a vehicle for NVP-231, 
SKI-1 and ceranib-1. 
 
2.3 Cloning 
2.3.1 OligoEngine: pSUPER.retro.puro vector system 
The pSUPER RNAi system from OligoEngine allows the stable expression of siRNA 
sequences and long-term suppression of gene expression. This vector system 
contains a polymerase-III H1-RNA gene promoter and a 19-nucleotide target 
sequence (N-19) designed specifically to target mRNA of the target gene, by using 
siRNA sequences known to transiently knockdown the target gene 
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(pSUPER.retro.puro, OligoEngine VEC-PRT-0002). Oligonucleotides pairs are 
designed to contain the N-19 in sense and anti-sense directions, which are separated 
by a 9-nucleotide spacer. These oligos are annealed and cloned into 
pSUPER.retro.puro between unique BglII (5’ end) and HindIII (3’ end) enzyme sites 
(see figure 2.3 for vector map). When the final cloned vector is introduced to cells, 
the two N-19 are predicted to fold back to form a stem-loop structure, which is 
cleaved to produce a functional siRNA.  
2.3.2 Oligonucleotide design 
The oligonucleotide pairs for CERS4 and TP53 are shown in table 2.2. Andrea 
Quintanilla designed the CERS4 oligonucleotides using Serial Cloner 2.6.1 ‘Make 
shRNA’ function. The TP53 oligonucleotides were designed and validated by 
Brummelkamp et al. 2002.  
2.3.3 pSUPER cloning 
The OligoEngine manual for pSUPER.retro.puro cloning was followed and is briefly 
summarised here. The oligonucleotide pairs were annealed using the following 
programme on an Agilent SureCycler 8800:  
4 min @ 90°C --> 10 min @ 70°C --> step-cool to 37°C --> step-cool to 10°C 
Next, 1µg pSUPER vector was linearized by sequential digestion at 37°C: first 
HindIII for 1 hour followed by BglII for a further 2 hours, and heat inactivation at 
80°C for 20 minutes. Next the ligation was prepared: 2µl annealed oligos + 1µl T4 
ligase buffer + 1µl linear pSUPER vector + 5µl dH2O + 1µl T4 ligase. The reaction 
was incubated at 16°C for 3 hours. The ligated vector was transformed into 
competent bacteria (NEB, C2987) and ampicillin resistant colonies grown overnight 
at 37°C. Multiple colonies were picked and mini-prepped (using QIAprep mini kit; 
Qiagen, 27104). To check for positive clones, DNA was digested with EcoRI and 
HindIII as described above and ran on an agarose gel. Positive clones were identified 
by the presence of a 281bp band and were further validated by sequencing. Ligated 
vector DNA was prepared for transfection/ infection by midi-prep (Qiagen, 12945). 
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[species] Abbreviation Oligonucleotide sequence 






TP53                         
[Homo sapiens] 
pRS-shP53      
or shP53 
sense: GACTCCAGTGGTAATCTAC  
anti-sense: GTAGATTACCACTGGAGTC 
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2.4 RNA interference  
2.4.1 shRNA (short hairpin RNA) 
shRNA sequences were cloned into the pSUPER.retro.puro vector (shortened 
hereafter as pRS) as described in 2.3. Retrovirus containing pRS-shRNA sequences 
was produced by 293T transfection and IMR90s infected with three rounds of virus, 
as described in 2.2.4. Knockdown was routinely measured by qPCR and western 
blot. 
2.4.2 siRNA (small interfering RNA) 
2.4.2.1 siRNA sequences 
All siRNAs were ON-TARGETplus reagents purchased from Dharmacon (see table 
2.3 for individual information for commonly used siRNAs). A custom-made pooled 
siRNA library and deconvoluted siRNA libraries were purchased from Dharmacon 
for screening purposes. The custom-made library was designed and shared with 
Andy Finch and Joy Edwards-Hicks, and included a full set of siRNAs targeting lipid 
metabolism listed by Atilla-Gokcumen et al (2014). For full information on the genes 
targeted in the siRNA library, refer to Appendix 1. 
2.4.2.2 siRNA resuspension 
Commonly used siRNAs were routinely purchased as 5nmol in tubes and libraries 
were purchased as 1nmol in 96 well plates. For resuspension, tubes or plates were 
spun at 1000rpm for 5 minutes, in a pre-chilled (4°C) centrifuge, to collect dried 
siRNA in the bottom. 1X siRNA resuspension buffer was prepared by diluting 5X 
buffer (Dharmacon, B-002000) 1:5 with UltraPure RNase-free distilled water (Life 
Technologies, 10977035). Routinely, siRNAs were resuspended to a stock 
concentration of 100µM and incubated for 30-60 minutes at room temperature on an 
orbital shaker and further diluted with 1X buffer to a working concentration of 1µM. 
See table 2.4 for 1X buffer volume required for stock and working concentrations. 
Both 100µM and 1µM siRNA stocks were stored at -20°C. 
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Target gene [species] Supplier Sequence 
CERS4                    
[Homo sapiens] 
BOLD denotes individual 
siRNA used for validation 
experiments 
Dharmacon     
(L-014364-00) 





TP53                         
[Homo sapiens] 
Dharmacon     
(L-0003329-
00) 





CDKN1A (p21)                   
[Homo sapiens] 
Dharmacon     
(L-003471-00) 





CDKN2A (p16)                   
[Homo sapiens] 
Dharmacon     
(L-011007-00) 




CAGAACCAAAGCUCAAAUA       
Non-Target control          
[N/A] 
Dharmacon     
(D-001810-10) 





Table 2.3 siRNA sequences 
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nmol siRNA 
Volume (μl) 1X buffer required for: 
100μM (stock conc) 1μM (working conc) 
1 10 100 
5 50 500 
Table 2.4 Recommended dilution for siRNAs 
 
2.4.2.3 siRNA reverse transfection 
30nM siRNA were aliquoted into 96 well plates or 6 well plates. Dharmafect 1 
transfection reagent (DF1; Dharmacon, T-2001) was diluted in unsupplemented 
DMEM and added on top of siRNA (see table 2.5 for volumes). The siRNA-DF1-
DMEM mix was incubated at room temperature for 30-60 minutes, whilst IMR90 
were trypsinised and counted. IMR90 were seeded on top of the siRNA-DF1-DMEM 
mix – 1-6x103 cells per well for 96 well plates and 2x105 cells per well for 6 well 
plates. 72 hours post-transfection cells were collected for protein and mRNA analysis 
or fixed for immunofluorescence. On occasion, a repeat transfection was performed 
for a second 72-hour period. For the mid-throughput siRNA library (described in 
2.4.2.1), various automated instruments, including multi-channel electronic pipettes 
and cell plater, were used to aid efficient and consistent siRNA transfection. 
Knockdown was routinely measured by qPCR and western blot. 
 
Plate format 
Volume (μl) of transfection reagent per well 30nM 
siRNA (μl) DF1 Unsup. DMEM Total 
96 wells 0.1 17.4 17.5 3.6 
6 wells 2 348 350 72 
Table 2.5 Transfection conditions 
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2.4.2.4 siRNA transfection during OIS timecourse 
A routine experiment was to reverse transfect siRNAs during a 4OHT timecourse in 
the ER:Ras system. Figure 2.4 shows a summary timeline for this experiment. 
 
 
Figure 2.4 Protocol for siRNA reverse transfection during a typical OIS 
timecourse experiment 
 
2.5 Immunofluorescence and high content analysis 
2.5.1 Antibodies 
Primary and secondary antibodies used for immunofluorescence are listed in tables 
2.8 and 2.9. All antibodies had been previously validated by RNAi knockdown or 
overexpression analysis. Typically, stains were performed in triplicate wells of a 96 
well plate. 
2.5.2 BrdU labelling 
Bromodeoxyuridine (BrdU) incorporation measured by immunofluorescence was 
used as a proliferation readout. 500µM BrdU intermediate stock in unsupplemented 
DMEM was diluted 1:10 in 96 well plates, previously seeded at 1-6x103 cells per 
well. Cells were placed back in the incubator for 17 hours to allow incorporation of 
the synthetic BrdU into the cell DNA. For detection of BrdU incorporation, a 
primary antibody (BD Biosciences, 555627) was diluted 1:2000 with 0.5U/µl DNase 
(Sigma, D4527) and1mM MgCl2. DNase and magnesium co-factor are required to 
unwind DNA and allow the BrdU antibody easier access to the nucleotide. 
Day -1
Split IMR90 
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2.5.3 Staining protocol 
All steps in this staining protocol were performed at room temperature on an orbital 
shaker and all washing steps were performed using a hand-operated liquidator 
(Mettler Toledo). Cells seeded in 96 well plates were washed once with PBS to wash 
the media away. In a fume cabinet, cells were fixed in 30µl 4% paraformaldehyde 
(FD NeuroTech, PF101) for 1 hour, and washed three times with PBS. Cells were 
permeabilised with 30µl 0.2% Triton-X100/PBS for 10 minutes and washed three 
times with PBS. Following permeabilisation, cells were blocked in 30µl IF blocking 
buffer (composition in table 2.1) for 1 hour. During blocking, primary and secondary 
antibodies were prepared in IF blocking buffer and stored on ice (dilutions found in 
tables 2.8 & 2.9). Immediately after blocking, 30µl of diluted primary antibody was 
added to cells and incubated for 30 minutes. After three PBS washes, 30µl of diluted 
secondary antibody was added to cells and incubated for 45 minutes. From this step, 
plates were wrapped in foil to prevent bleaching of the light sensitive Alexa Fluor 
antibodies. After three PBS washes, 30µl of 1µg/ml 4’,6-diamidino-2-
phenylindole/PBS (DAPI; Molecular Probes, D1306) was used to stain for nuclei and 
was incubated for 20-30 minutes. Cells were washed three times in PBS and exactly 
100µl PBS was added to each well.  
2.5.4 High Content Analysis using the ImageXpress (Molecular Devices) 
Image acquisition was performed at 10X magnification with a fixed number of sites 
per well (between 4-9, depending on cell density). Exposure time and focus were 
optimised for each experiment and was consistent for all wells/plates. Image analysis 
was performed using the Meta Xpress <Multi Wavelength Cell Scoring> analysis. 
Using positive/negative controls, a positive-stain threshold was set and all images 
subjected to positive-stain scoring using the same threshold. Cell number was 
calculated by counting DAPI-positive nuclei. The raw image data was exported and 
further data analysis performed using Excel. Raw images were visualised and 
merged using Image J software. 
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2.5.4.1 Screen image analysis using web cellHTS2  
For robust hit identification the online software package ‘web cellHTS2’ was used 
(Pelz, Gilsdorf and Boutros, 2010). This software provided comprehensive data 
visualization and offers quality control and normalization metrics for the siRNA 
screen. Raw data files were formatted and uploaded as previously described by Pelz 
et al. (2010) and underwent statistical evaluation. 
 
2.6 Western blotting  
2.6.1 Lysate preparation 
Cells were pelleted as described in 2.2.1, resuspended in 1ml PBS and aliquoted in 
1.5ml eppendorfs. Cells were washed in PBS using a bench top centrifuge at 
4000rpm for 5 minutes. The PBS supernatant was removed by aspiration and pellets 
were either lysed or, on occasion, stored at -80°C and thawed on ice for 5 minute 
before lysis. Lysis buffer was prepared by diluting Cell Lysis Buffer (Cell Signalling, 
9803) and cOmplete EDTA-free Protease Inhibitor Cocktail (Roche, 04693159001) 
1:10 with dH2O (i.e. 100µl of each + 800µl dH2O). The composition of the lysis 
buffer is found in table 2.6. Depending on the pellet size, cells were resuspended in 
20-250µl lysis buffer and incubated on ice for 5-10 minutes. Samples were spun at 
14,000rpm for 10 minutes, in a pre-chilled (4°C) centrifuge. The supernatant was 
collected into a fresh tube and protein concentration determined. 
2.6.2 Bradford assay for determination of protein concentration  
Bradford reagent (Biorad, 500-0006) was removed from the fridge 30 minutes before 
use and diluted 1:5 in dH2O. This dilution was stored at room temperature for up to 
one week. A 96 well plate format was used and a standard curve performed for each 
plate, using Pierce BSA Standard Pre-diluted Set (Thermo Fisher, 23208). Before 
aliquoting samples, various dilutions were tested with Bradford in 0.5ml tubes to 
ensure readings were within the standard curve. 2µl of standards and diluted samples 
were mixed with 198µl of 1X Bradford reagent using a multi-channel manual pipette. 
A Biorad iMark microplate reader was used to measure the absorbance at 595nm. 
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Each sample was measured in triplicate and compared to the BSA standard curve 
with known concentrations of protein. Using Excel, the standard curve values were 
plotted and resulting regression formula was used to calculate the sample protein 
concentration. This Bradford assay was shown to be detergent compatible and it was 
not necessary to dilute standards in cell lysis buffer. 
2.6.3 Preparation of samples for SDS-PAGE 
The volume of lysate with desired protein quantity (10-20µg) was calculated. Lysates 
were mixed with 6X Laemmli SDS sample buffer (reducing) (Alfa Aesar, J61337) 
and dH2O to make a final volume of 15-30µl and boiled at 95°C for 5 minutes. 
Generally, samples were prepared fresh and on occasion samples were stored at         
-20°C for up to 3 months. 
2.6.4 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE was used to separate proteins, exploiting the XCell SureLock Mini-Cell 
electrophoresis system (Invitrogen). The composition and percentage of the gel was 
chosen depending on the molecular weight of the protein of interest (see table 2.7). 
When multiple proteins were of interest, gradient gels were used to achieve the best 
separation. Samples were carefully loaded and subjected to electrophoresis at 100-
150V for 1-2 hours, until the blue loading dye reached the bottom of the gel. A broad 
range (11-245kDa) colour prestained protein standard (NEB, P7712) was used to 
determine protein size.  
2.6.5 iBlot dry transfer 
An iBlot dry blotting system (Invitrogen) was used to transfer proteins from SDS-
PAGE gels onto nitrocellulose membrane. Gels were carefully removed from the 
plastic cassette and trimmed using a gel knife. The bottom anode component of an 
iBlot nitrocellulose transfer stack (Invitrogen, IB301002) was placed in the iBlot, and 
gels placed on top of the membrane – with a maximum of two mini gels per transfer 
stack. Filter paper was soaked in dH2O and placed on top of the gels, followed by the 
top cathode component of the transfer stack (electrode side up). After each layer a 
blotting roller was used to remove any bubbles within the transfer stack. The sponge 
was placed in the lid of the iBlot and the lid was shut, ensuring a connection by the 
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red light indicator. Program P3 (20V for 7 minutes) was used to transfer all proteins 
of interest within a range of 11-120kDa. When the program was finished the transfer 
stack was disassembled and cut membranes were blocked in TBS + 5% non-fat milk 
(Marvel) for 1 hour at room temperature. Gels were routinely stained with 
Coomassie Brilliant Blue Staining Solution (Biorad, 1610436), for 30 minutes at 
room temperature and washed in tap water overnight until bands were visible. On 
occasion, when an appropriate loading control was not performed, stained gels were 
imaged using a LiCor Odyssey-SA.  
2.6.6 Antibodies 
Where necessary, membranes were cut to blot using multiple antibodies. Membranes 
were incubated in primary antibody overnight at 4°C on a rocker (see table 2.8 for 
details of primary antibody conditions). After three 10 minute washes with TBS-
tween (0.05% tween), the membranes were incubated with a horse radish peroxidase 
(HRP)-conjugated secondary antibody for 1 hour at room temperature (see table 2.9 
for details of secondary antibody conditions). After another three 10 minute washes 
with TBS-tween (0.1% tween), ECL was used to visualise bands. 
2.6.7 Enhanced chemiluminescence (ECL) 
Equal volumes of ECL solution A and solution B (GE Healthcare, RPN2209) were 
mixed. Where necessary, ECL Prime (GE Healthcare, RPN2232) was used for more 
sensitive visualisation. Membranes were placed on a clean surface, typically 
smoothed out cling film on a normal lab bench. ECL was added to the membrane 
(typically 1.5ml for each full size membrane) and incubated for 5 minutes at room 
temperature. As the HRP is conjugated directly to the secondary antibody, the light 
emitted from the oxidation reaction with the ECL substrate will only occur if the 
protein the antibody detects is present. Membranes were placed in a suitable cassette 
and exposed to X-ray film, normal or sensitive (SLS, MOL7016 and GE Healthcare, 
28906837), for an appropriate time and developed using an X-ray processor. 
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Component Concentration in 1X 





Sodium pyrophosphate 2.5mM 
β-glycerophosphate 1mM 
Sodium orthovanadate 1mM 
Leupeptin 1μg/ml 
Table 2.6 Composition of Cell Lysis Buffer (Cell Signalling, 9803) 
 
 
Gel type Num. of wells Running buffer Used for 
NuPAGE Novex 























Small – medium 
proteins                 
(11-100kDa) 
Table 2.7 Gels used for SDS-PAGE (all Thermo Fisher Scientific) 
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Target Molecular Weight (kDa) Species Supplier Dilution 
p16INK4a 16 Mouse Santa Cruz     56330 
WB- 1:5000 
(5% milk)    
IF- 1:500 
p21CIP1 21 Mouse Sigma    P1484 
WB- 1:3000 
(5% milk)    
IF- 1:200 
p53 53 Mouse Santa Cruz     126 
WB- 1:2000 
(5% milk)    
IF- 1:100 
IL6 25 Goat R&D AF206NA 
WB- 1:1000 
(1% BSA)   
IF- 1:100 
IL8 11 Mouse R&D   MAB208 
WB- 1:1000 
(1% BSA)   
IF- 1:100 
IL1β 15-30 Mouse R&D   MAB201 
WB- 1:5000 
(1% BSA)   
IF- 1:100 
RB-total 110-116 Mouse BD Bio 554136  
WB- 1:1000 
(5% milk) 
PP1 38 Goat Santa Cruz 6108 
WB- 1:1000 
(1% BSA)    
pST/Q - Rabbit Cell Signalling 2851 IF- 1:100 
ϒH2AX - Mouse Millipore  05636 IF- 1:2000 
Table 2.8 Primary antibodies used for western blotting (WB) and 
immunofluorescence (IF) 
   






Target Supplier Dilution Diluent 
Mouse-HRP Sigma A2554 WB- 1:10,000-40,000 Same as primary  
Rabbit-HRP Sigma A0545 WB- 1:10,000-40,000 Same as primary 
Goat-HRP Santa Cruz 2020 WB- 1:5000-10,000 Same as primary 




A11029 IF- 1:1000 




A11032 IF- 1:1000 




A11034 IF- 1:1000 




A11037 IF- 1:1000 
IF blocking buffer 
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2.6.8 Testing CERS4 antibodies 
To analyse the expression of CERS4 protein in IMR90 cells several primary 
antibodies detecting human CERS4 were tested, summarised in table 2.10. 
Optimisation was attempted by changing antibody concentrations, loading excessive 
amounts of cell lysates (up to 100µg) and using long exposure times (>1 hour). 
Despite this, CERS4 protein could only be detected in IMR90 cells cloned for 
CERS4 overexpression (figure 2.5). In addition, the antibodies listed below were 
tested using an immunofluorescence protocol (as described in 2.5). However, no 
fluorescence signals were detected in any cells, including the CERS4-overexpression 
cells (data not shown). From this it was concluded CERS4 protein levels are below 
the threshold of detection by western blotting in the inducible OIS model. This data 
relates to the results in 4.1 and is further discussed in 7.4.1. 
 
Antibody (supplier code) Species Dilution 
Santa Cruz C-19 (65112) Goat 1:1000 (5% milk) 
Santa Cruz D-6 (376497) Mouse 1:100 (5% milk) 
Sigma (SAB4301210) Rabbit 1:500 (5% milk) 
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Figure 2.5 CERS4 protein levels detected in IMR90 cells by western blotting 
Three CERS4 antibodies (Santa Cruz C-19, D-6 and Sigma) were tested for western blot 
detection of CERS4 in the following cell lysates: (A) IMR90 with CERS4 overexpression (lanes 
1-2) and iRas with shCERS4 knockdown (Day 10 of 4OHT) (lanes 3-5). Empty vector controls 
were used where appropriate (labeled ‘ev’). 20µg lysate was separated by SDS-PAGE, using a 4-
12% Bis-Tris gel. (B) iStop and iRas at day 4 and 8 of 4OHT (lanes 1-4) and IMR90 with CERS4 
overexpression (lane 5). 60µg lysate was separated by SDS-PAGE, using a 4-12% Tris-Glycine 
gel. Both: numbers on left represent ladder bands (kDa); representative of 1 experiment; gels 
were stained with Coomassie to use as a loading control (images not shown). 
4OHT = 4-hydroxytamoxifen, ev = empty vector, shC4 = pRS-shCERS4 (knockdown), C4 = 
MSCV-CERS4 (overexpression), WB = western blot, arrows = CERS4 bands. 
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2.7 RB-PP1 co-immunoprecipitation 
Cells seeded in 10cm dishes were washed three times with cold PBS, on ice. The 
following lysis buffer was prepared: 25mM HEPES pH 7.5, 0.5% NP40, 150mM 
NaCl, 1.5mM MgCl2, 1mM EDTA and 1mM BME. Protease and phosphatase 
inhibitors were added fresh for every preparation. Depending on confluency, 400-
1000µl lysis buffer was used to lyse cells directly on dishes for 10-20 minutes, on 
ice. Lysates were spun at 14,000rpm for 10 minutes, in a pre-chilled (4°C) 
centrifuge. The pellet was discarded and 5-10% supernatant was collected for an 
input control. Immunoprecipitation Dynabeads Protein G (Invitrogen, 10003) were 
washed three times with lysis buffer without protease and phosphatase inhibitors. For 
equilibration, 10µl washed beads (per IP) were incubated with RB antibody or IgG 
control (table 2.10 for information), and rotated for 1-2 hours at 4°C. The remaining 
lysate was added to the to the equilibrated beads and rotated for 4-6 hours at 4°C. 
The beads were pelleted by magnetism and 5-10% supernatant was collected to test 
efficiency of the IP. The remaining supernatant was discarded. The pelleted beads 
were washed three times with lysis buffer without protease and phosphatase 
inhibitors. After the final wash, as much supernatant as possible was removed and 
proteins eluted from beads using SDS loading buffer. All collected samples were 
boiled and subjected to western blotting of RB and PP1 as described from 2.3.4. 
Target Application Species Supplier Dilution 
RB IP Rabbit Santa Cruz     50 
IP- 5μg per 
IP 
IgG control IP Rabbit Santa Cruz 2027 
IP- 5μg per 
IP 
PP1 WB Goat Santa Cruz 6108 WB- 1:1000 
RB-total WB Mouse BD Bio 554136  WB- 1:1000  
Table 2.11 Antibodies used for RB-PP1 co-immunoprecipitation (IP)  
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2.8 Quantitative real-time polymerase chain reaction (qPCR) 
All steps for this qPCR protocol were performed on a clean surface and sterile filter 
tips (Rainin) were used for all pipetting steps.  
2.8.1 RNA extraction 
Cells were pelleted as described in 2.2.1 and washed once with PBS. Cells were 
lysed using the QIAshredder (Qiagen, 79654) and RNA extracted using RNeasy Plus 
Mini Kit (Qiagen, 74134), both as per manufacturer’s instructions. DNA 
contamination was prevented by using the gDNA Eliminator Spin Columns. 
Extracted RNA was eluted in RNase-free dH2O and quantified using a NanoDrop 
2000C. 
2.8.2 cDNA synthesis using reverse transcriptase 
A 50ng/µl intermediate stock of each RNA sample was prepared. For each set of 
reactions, an RNA pool (total concentration = 50ng/µl) was made to use as a no-RT 
control. qScript cDNA SuperMix (QuantaBio, 95048) was used as the reaction buffer 
and was composed of dNTPs, RNase inhibitor and a qScript reverse transcriptase. 
For each 40µl reaction, 8µl 5X qScript was mixed with 20µl RNA intermediate stock 
and 12µl RNase-free dH2O. For the no-RT control, qScript was replaced with RNase-
free dH2O. Reactions were briefly centrifuged and underwent cDNA synthesis in an 
Agilent SureCycler 8800. The programme for cDNA synthesis was as follows: 
5 min @ 25°C --> 30 min @ 42°C --> 5 min @ 85°C --> 	 @ 4°C  
2.8.3 qPCR  
qPCR primers were designed by myself, Andrea Quintanilla and Juan-Carlos Acosta 
using the NCBI ‘Pick primers’ tool (see table 2.10 for sequences). It was selected 
that primers span an exon-exon junction to ensure only the coding region was 
amplified.  Primers were synthesised by Sigma and resuspended in RNase-free dH2O 
to make 100µM stocks. For each set of triplicate wells, a 50µl mastermix was 
prepared (the value in brackets indicates the final reaction concentration): 25µl 
SYBR Select (1X; Thermo Fisher, 4472908) + 0.5µl forward primer (100nM) + 
0.5µl reverse primer (100nM) + 21µl RNase-free dH2O + 3µl cDNA (75ng). 15µl of 
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each reaction was carefully aliquoted into triplicate wells of RNase-free 96 well 
plates (Star Lab, E1403-7700) and briefly centrifuged to ensure all the reaction was 
pooled at the bottom. qPCR was performed on the Applied Biosystems StepOne Plus 
Real-Time PCR System, using the following programme:  
10 min @ 95°C --> x40 cycles (15s @ 95°C --> 30s @ 60°C --> 15s @ 72°C) --> 
15s @ 95°C.  
After the cycling stage, a melt curve for each primer set was generated by heating 
from 60-95°C in 0.3°C increments. Using the StepOne software, a threshold cycle 
(Ct) was manually defined in the mid-linear phase of the amplification and Excel 
used for data analysis. The relative expression of target genes was calculated by 
normalising to housekeeping gene β-actin using the formula 2-DCt.  
 
Target Forward & Reverse primers 
β-actin           
(housekeeping gene) 
F: CATGTACGTTGCTATCCAGGC                                                          
R: CTCCTTAATGTCACGCACGAT 
ASAH1 F: TGGGAAAGAAAGATGTCATGTG                                                      R: CACACAACCTTCCCCAGACT 
CDC6 F: GTTCAATTCTGTGCCCGCAA                                        R: TAGCTCTCCTGCAAACATCCAG 
CDC7 F: CTCGGTAGGTGGGGATCTCT                                        R: GAGATGCAAAATGCCAGGGTT 
CDK1 F: CTTGGCTTCAAAGCTGGCTC                                         R: GGGTATGGTAGATCCCGGCT 
CDK2 F: CGAGCTCCTGAAATCCTCCTG                                     R: GGCGAGTCACCATCTCAGCAA 
CDKN1A (p21) F: CCTGTCACTGTCTTGTACCCT                                       R: GCGTTTGGAGTGGTAGAAATCT 
Table 2.12 qPCR primers used to quantify human mRNA expression 
(continued next page) 
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Target Forward & Reverse primers 
CDKN2A (p16) F: CGGTCGGAGGCCGATCCAG                                          R: GCGCCGTGGAGCAGCAGCAGCT 
CDKN2B (p15) F: AATGCGCGAGGAGAACAAG                                        R: CCATCATCATGACCTGGATCG 
CERK F: ATCGTTGTTGGGGACTCGCT                     R: GGGACACGGAGTAGCGAAGG 
CERS4 F: ATCAGACCAGGAGGCAAGTG                                      R: GGCCTCACAGAACTTCTTGGT 
GBA F: TTGCAGGGCTAACCTAGTGC                                        R: GGCTTGGGACATTCCTCTCT 
IL6 F: CCAGGAGCCCAGCTATGAAC                                       R: CCCAGGGAGAAGGCAACTG 
IL8 F: GAGTGGACCACACTGCGCCA                                       R: TCCACAACCCTCTGCACCCAGT 
MCM2 F: GTGGATAAGGCTCGTCAGAT                                       R: GTCGTGGCTGAACTTGTT 
ORC1 F: ACATACCCTCACGAAGGTGC                                        R: GCAGAAACATGCAGCCTCAG 
PCNA F: GGTTACTGAGGGCGAGAAGC                                      R: GACCGGCTGAGACTTGCGTA 
SMPD2 F: CCGAATACAATCGACAGAAGG                                     R: CCTGTCCACTCCTTCAGCA 
SPHK1 F: TTGCAGCTCTTCCGGAGT                                              R: CTCCAGACATGACCACCAGA 
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2.9 Transcriptomics 
2.9.1 AmpliSeq targeted RNA sequencing 
Edinburgh Clinical Research Facility Genetics department performed AmpliSeq 
transcriptomics sequencing of RNA (extracted as described in 2.8.1). A protocol 
provided by the CRF is briefly summarised here. All products used were supplied by 
Thermo Fisher. RNA samples were assessed for quality and were quantified. cDNA 
was prepared by reverse transcription of RNA samples and then target genes were 
amplified for 12 cycles of PCR using the Ion AmpliSeq Human Gene Expression 
Core Panel (A26325). This panel contains 20,802 amplicons (41,604 primers) of 
approximately 150 bases in length in a single pool. Ion Torrent sequencing adapters 
and barcodes (4474517) were ligated to the amplicons and adapter-ligated libraries 
were purified using AMPure XP beads. Libraries were quantified by qPCR. Libraries 
were then diluted to 100pM and combined in 3 equimolar pools of 8 for template 
preparation. The Ion PI Hi-Q OT2 200 Kit (A26434) was used for template 
preparation, followed by sequencing with the Ion PI Hi-Q Sequencing 200 Kit 
(A26433) and Ion PI Chip Kit v3 (A26771) The Ion Proton (#2456290-0449) 
platform was used for sequencing; and coupled with the AmpliSeqRNA plugin, was 
used for analysis of the sequencing output. Summary reports for each sequencing run 
provided a large amount of data including sequencing run summary, reference 
alignment statistics, plug-in summary and a detailed list of software version numbers 
used in each analysis step. 
2.9.2 Babelomics 5 RNAseq data analysis 
The sequencing output from AmpliSeq transcriptomics was subjected to analysis 
using the Babelomics 5 ‘RNA-seq class comparison’ tool (Alonso et al., 2015). For 
this analysis, the normalization method used was TMM and Benjamini and Hochberg 
multiple-test correction was used to calculate the False Discovery Rate and adjusted 
p-value (<0.05). The resulting statistic values were further interrogated to indicate 
differential gene expression compared to the OIS control. Gene Set Enrichment 
Analysis was used to assign Gene Ontology (GO) to the dataset and gain information 
on the pathways significantly changing between compared conditions. 
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2.10 Senescence Associated β-galactosidase activity assay 
Cells were seeded at 5x104 cells per well in 6 well plates and cultured for 48-72 
hours. Prior to fixation, a solution of PBS with 1mM MgCl2 was prepared and 
adjusted to pH 5.6-6.0.  Media was aspirated, cells washed twice in PBS and fixed 
with 0.5% glutaraldehyde/PBS (Sigma, G5882) for 10-15 minutes in a fume cabinet. 
During fixation, the X-gal solution was prepared as shown in table 2.12 and 
incubated in a 37°C water bath for up to 30 minutes to avoid crystal formation and 
precipitation. The fixed cells were washed three times in PBS/MgCl2. The pre-
warmed X-gal solution was added to the cells and incubated at 37°C for 6-24 hours, 
depending on the development of the blue precipitate. 
 Stock (20X) Final (1X) Supplier 
K3Fe(CN)6 100mM 5mM Sigma 60299 
K4Fe(CN)63H2O 100mM 5mM Sigma 60279 
X-gal solution 20mg/ml 1mg/ml Thermo Fisher R0941 
Table 2.13 Composition of X-gal solution, diluted in PBS/MgCl2 pH5.6-6.0 
 
2.11 Crystal Violet colony formation assay  
Cells were seeded at 5x104 or 1x105 cells per 10cm dish and cultured for 7-20 days. 
Colony formation was monitored and growing controls compared to senescent cells 
were used to determine when to fix cells. For fixation, cells were washed twice in 
PBS and fixed with 0.5% glutaraldehyde/PBS (Sigma, G5882) for 1 hour in a fume 
cabinet. The fixed cells were washed three times in PBS and left to dry at room 
temperature for at least 24 hours. Dried dishes were stained with 0.2% crystal 
violet/water solution at room temperature for 3-4 hours. The crystal violet was 
collected (to be re-used) and dishes washed with tap water, and left to dry overnight. 
Images of the dried dishes were taken using a normal scanner. For quantification, 
stained dishes were dissolved in 1% acetic acid at room temperature for 4 hours. The 
595nm absorbance of the dissolved crystal violet was measured using a 
spectrophotometer. 
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2.12 Lipidomics 
2.12.1 Compounds used to measure sphingolipid metabolism  
For metabolic flux analysis of sphingolipid metabolism, IMR90 were treated with 
several compounds listed here. Typically, IMR90 were seeded in 10cm dishes or 6 
well plates and starved with DMEM+1% FBS. Starvation was used to keep the basal 
level of metabolism low. To analyse de novo sphingolipid biosynthesis, IMR90 were 
treated with 0.8mM 2,3-13C2-serine (Sigma, 605174) for 6 hours. dH2O was used as a 
vehicle for 2,3-13C2-serine. For analysis of sphingolipid recycling pathway, IMR90 
were treated with 2µM 17:1/8:0-ceramide (Avanti, 860645) for 3 hours. Absolute 
filtered ethanol was used as a vehicle for 17:1/8:0-ceramide. 
2.12.2 Lipid extraction 
To extract lipids from cells a biphasic method based on the Bligh and Dyer method 
(Bligh and Dyer, 1959) was performed and is briefly summarised here. All solvents 
were HPLC grade: water (VWR, 83645), propan-2-ol (VWR, 84881), chloroform 
(Alfa Aesar, 22920) and methanol (Fisher, M/4000/14). Cells were scraped in 1ml 
PBS and pelleted in a pre-chilled bench top centrifuge (4°C) at 800g for 10 minutes. 
Cell pellets were washed with 1ml fresh PBS and centrifuged for 2 minutes. The 
cells were resuspended in 100µl PBS and transferred to a glass test tube. A 
chloroform/methanol (1:2) solution was prepared and 375µl added to the cells and 
vortexed. The tubes were agitated vigorously for 30-45 minutes at 4°C. Next, 125µl 
of each chloroform and water were sequentially added. Tubes were vortexed after 
each addition. The two phases were separated using a centrifuge at 1000rpm for 5 
minutes (room temperature). Using a glass Pasteur pipette, the lower phase was 
transferred into a flat-bottomed 2ml glass vial (Supelco, 29651) and dried under 
nitrogen. Dried lipid extracts were stored at 4°C. 
To prepare samples for LC-MS, the following reconstitution buffer was used: 
acetonitrile/propan-2-ol/water (60:30:5). For extracts from 10cm dishes, 100µl 
reconstitution buffer was added and mixed/vortexed well before aliquoting 30µl into 
a total recovery 1.2ml glass vial (Supelco, 29658). For extracts from 6 well plates, 
50µl reconstitution buffer was added and mixed/vortexed well before aliquoting 25µl 
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into a total recovery 1.2ml glass vial. The remaining lipid extracts were dried under 
nitrogen and stored at 4°C in case another sample was later required.  
2.12.3 Liquid Chromatography Mass Spectrometry (LC-MS) 
Reconstituted lipid extracts were separated on a Kinetex 1.7u C18 100Å column 
(Phenomenex) using a Thermo Ultimate BioRS HPLC maintained at 45°C. Mobile 
phases were: [A] acetonitrile/water (60:40) + 10mM ammonium formate and [B] 
propan-2-ol/acetonitrile (90:10) + 10mM ammonium formate. A flow rate of 
0.3ml/min was used and the following multi-step gradient established:   
20-97%B gradient for 8 min --> 97%B 2 min --> 20%B 2 min [12 min total] 
Separated lipids were eluted into a Thermo Q-exactive mass spectrometrer and 
acquired in positive ion mode with an ion range of 400-1000m/z or 250-1000m/z.  
2.12.4 Data analysis 
Raw LC-MS data was analysed using Thermo Xcalibur Qual/Quan Browser 
software. Sphingolipid ion peaks were confirmed by fragmentation and standards 
(with Joy Edwards-Hicks). Quan Processing methods were created for quantitative 
data analysis: peak areas of defined sphingolipids were extracted from raw data files. 
Peak areas were normalised to Total Ion Count (TIC) or internally normalised by 
calculating % label for labelling experiments.  
2.12.5 University of Highlands & Islands (UHI) Lipidomics 
Global lipidomics and quantitative analysis of ceramides were initially performed at 
the Lipidomics Research Facility at the UHI. Prof Phil Whitfield, Dr Mary Doherty 
and Seshu Tamireddy performed the extractions, LC-MS and data analysis. UHI are 
acknowledged throughout the relevant results sections. For all analyses, cells were 
solvent extracted according to Folch’s method (Folch et al, 1957).  
2.12.5.1 Global lipidomics 
The extracted lipids were analysed by LC-MS in positive and negative ion modes 
using a C18 column and acetonitrile/water/propan-2-ol gradient. All analyses were 
performed on a Thermo Exactive Orbitrap mass spectrometer coupled to a Thermo 
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Accela 1250 UHPLC system. The raw LC-MS data were processed with Progenesis 
CoMet v2.0 software (Non-linear Dynamics) and searched against HMDB 
(http://www.hmdb.ca/) and LIPID MAPS (www.lipidmaps.org/) for identifications. 
The processed data were then subjected to multivariate statistical analysis using 
SIMCA-P v13.0.2 (Umetrics). 
2.12.5.2 Quantitative ceramide analysis  
The extracted ceramides were isolated by silica solid phase extraction 
chromatography. C17:0 ceramide and C12:0 dihydroceramide (Avanti Polar Lipids) 
were included in the experimental system as internal standards. LC-MS/MS analyses 
were performed in positive ion mode on a Thermo TSQ Quantum Ultra triple 
quadrupole mass spectrometer equipped with a heated electrospray source and 
coupled to a Thermo Accela 1250 UHPLC system. The ceramides were separated on 
a Kinetex 2.6µm C8 column (100 x 2.1 mm) (Phenomenex), maintained at 40°C. 
Mobile phases were: [A] 10% acetonitrile + 90% water + 0.1% formic acid and [B] 
acetonitrile + 0.1% formic acid. A flow rate of 500µl/min was used and the following 
multi-step gradient established:   
80%B gradient for 1 min --> 80-100%B gradient for 15 min --> 100%B 1 min --> re-
equilibration to starting conditions [20 min total] 
The data were acquired and processed using Thermo Xcalibur software v2.1. The 
concentration of the ceramide molecular species was determined by comparison to 
calibration curves generated with C16:0 and C24:1 standards (Avanti Polar Lipids). 
Total ceramide concentrations were calculated from the summed concentrations of 
all the monitored molecular species. The values were normalised to cellular protein 
content determined using the Coomassie Plus Protein Assay (Pierce Biotechnology). 
 
2.13 Metabolic Assays 
Protocols for these assays were optimised for 96 well plate format with image 
acquisition and analysis performed on the ImageXpress (2.5.4). 
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2.13.1 Click-iT Lipid Peroxidation Assay (Molecular Probes, C10446) 
25µM Linoleamide Alkyne (LAA) reagent was added to cells previously seeded at 1-
6x103 cells per well, and incubated at 37°C for 2 hours. Cells were fixed, 
permeabilised and blocked as described in 2.5.3, and protected from light throughout 
this staining protocol. During 1 hour blocking, the LAA reaction cocktail was 
prepared as described by the manufacturer’s instructions. After three PBS washes, 
125µl of the prepared LAA reaction cocktail was added per well and incubated for 30 
minutes at room temperature on an orbital shaker. After three PBS washes, cells were 
stained for DAPI, followed by a final PBS wash before image acquisition.  
2.13.2 LipidTox Phospholipidosis and Steatosis Detection Assay 
(Molecular Probes, H34158) 
LipidTox Red Reagent was diluted 1:3000 in supplemented DMEM and 100µl added 
to cells previously seeded at 1-6x103 cells per well, and incubated at 37°C for 24 
hours. Cells were fixed as described in 2.5.3, and protected from light throughout this 
staining protocol. Immediately after fixation, cells were stained for DAPI as 
described in 2.5.3. During the DAPI incubation, LipidTox Green Reagent was 
prepared 1:1000 in PBS. After three PBS washes, 100µl of the diluted LipidTox 
Green Reagent was added per well and incubated for 30 minutes at room temperature 
on an orbital shaker. The LipidTox Green Reagent was not washed off before image 
acquisition. FITC and TxRED filters were used for acquiring the green steatosis stain 
and red phospholipidosis stain, respectively.  
 
2.14 Statistics 
For all experiments with 3 biological replicates (indicated in figure legends), 
significance calculations were performed using two-tailed Student’s t-test or one-way 
ordinary ANOVA. These calculations were done using Microsoft Excel and 
GraphPad Prism 7 software. 
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Chapter Three: Identification of novel metabolic 
regulators of OIS by siRNA screening 
As described in 1.2, altered cellular metabolism provides an attractive target for 
cancer therapies. In addition, it has been argued OIS can be specifically targeted to 
promote its anti-cancer features (reviewed by Acosta and Gil (2012)). The first aim 
for this thesis was to identify new metabolic regulators of OIS, by utilising a high-
content screening platform coupled with an siRNA library targeting 553 genes, 
encoding metabolic enzymes and transcription factors. Essential metabolic genes for 
OIS were identified by siRNA knockdown causing a ‘bypass of OIS’, measured by 
BrdU incorporation as a proliferation readout. In this chapter, the results from the 
primary siRNA screen and subsequent validation are described. 
 
3.1 Primary siRNA screen 
3.1.1 Screen design and workflow 
The primary siRNA library was custom-made from Dharmacon and was designed 
and shared with Andy Finch and Joy Edwards-Hicks. The library was composed of 
pooled siRNA sequences – four different sequences per gene. A total of 553 genes 
involved in a variety of metabolic pathways were targeted in this primary screen 
(figure 3.1.A). Appendix 1 provides a list of genes targeted in the primary screen. 
The workflow of the siRNA screen was optimised by Priya Hari for a different 
project and is overviewed in figure 3.1.B. Briefly, the cells used throughout were 
IMR90-ER:Ras and IMR90-ER:Stop (or iRas and iStop, see figure 2.2 for details on 
the ‘ER’ system used to model OIS in IMR90). For the primary screen, IMR90-
ER:Ras were administered 4OHT and subjected to reverse transfection onto siRNAs 
after 2 and 7 days of 4OHT. Plates were fixed and stained for BrdU incorporation by 
immunofluorescence 72 hours post-transfection. Images were acquired and analysed 
using the ImageXpress High Content Analysis microscope. Raw data underwent 
normalization metrics and were converted to Z-scores for robust hit identification 
using online software package Web CellHTS2 (Pelz, Gilsdorf and Boutros, 2010). 
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IMR90s are amenable to BrdU incorporation as a proliferation readout and as cell 
cycle arrest is a major hallmark of OIS, it was decided BrdU incorporation was a 
good initial readout for OIS in the siRNA screen. siRNA targeting TP53 was used as 
a positive control of bypass of OIS (figure 3.1.C, right panel). 
3.1.2 Screen results for day 5 time point 
Control (Non-Target and siTP53) raw data was checked to ensure the cells were 
behaving as expected with the addition of 4OHT. Figure 3.1.C indicates the images 
and raw percentages of BrdU incorporation. Next, the raw data for ‘plates as 
replicates’ were processed through Web CellHTS2. Normalisation (using the 
‘median’ method) and quality control metrics indicated a robust screen output for the 
day 5 time point. Box plots showed the distribution of raw data (pink) and after 
normalisation (blue) for the three replicates (figure 3.2.A). For plate 6 there were 
only two replicates due to a practical issue with the experimental procedure. Z’ 
Factor plots indicated good separation between negative (red) and positive (blue) 
controls and all replicates had a Z’ Factor of >0.2, which is of reasonable quality for 
an siRNA screen (figure 3.2.B). Heatmaps for each plate, except 6, indicated good 
correlation (>0.8) between the three replicates (figure 3.2.C). The scatter graph 
comparing the two replicates of plate 6 showed minimal variation (figure 3.2.D). 
Next, the Z-scores for each siRNA were extracted from the Web CellHTS2 analysis. 
Initially, a Q-Q plot showed most data within the theoretical normal distribution 
(dotted line) and hits were identified by the data deviating from the dotted line at <-2 
sample quantile (figure 3.3.A). The red circles indicated all the positive controls (i.e. 
siTP53) within the screen. Z-scores were converted to positive numbers to better 
represent the positive effect siRNAs have on OIS state. Significant hits were 
identified as having a Z-score of >2.0, corresponding to an approximate p-value 
<0.05 (figure 3.3.B). The higher the Z-score the more likely the siRNA was truly 
causing a bypass of senescence. TP53 was the top hit at day 5 followed by ceramide 
synthase 4 (CERS4); a further 13 genes were identified as possibly essential for OIS 
(figure 3.3.C).  
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Figure 3.1 Primary siRNA screen design and workflow 
(A) Table summarising the metabolic pathways targeted by Dharmacon ON-TARGETplus 
siRNAs in the custom-design library. (B) An overview of the workflow for siRNA screening. See 
main text for further detail. (C) Representative immunofluorescence images and quantification 
(% positive cells, bottom right) of BrdU incorporation in IMR90-ER:Stop and IMR90-ER:Ras 
transfected with indicated siRNA.  
4OHT = 4-hydroxytamoxifen; BrdU = bromodeoxyuridine 
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Figure 3.2 Normalisation and quality control metrics for day 5 screen data 
(A) Distribution box plots for raw (pink) and normalised (blue) data. Note: there were only two 
replicates for plate 6. (B) Z’ Factor plots and values (top right) for negative (red) and positive 
(blue) controls. (C) Heatmaps showing correlation between the three replicates of each plate 
(except 6). (D) Scatter graph showing variation between the 2 replicates for plate 6 (a 
correlation heatmap could not be generated for two replicates).  
 
   
   115 
 
 
Figure 3.3 Identification of 14 genes possibly essential for OIS 
(A) Q-Q plot comparing sample quantiles and theoretical normal distribution quantiles (dotted 
line = normal distribution). (B) Z-scores plot (converted from the Q-Q data) with a zoom on the 
positive hits with a Z-score of >2.0 (right panel). (C) Table summarising the 14 positive hits with 
a Z-score of >2.0. Note the top hit is the positive control TP53. 
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3.1.3 Screen results for day 10 time point 
The raw data for ‘plates as replicates’ were processed through Web CellHTS2 to gain 
normalisation and quality control metrics, as with day 5. Box plots showed the 
distribution of raw data (pink) and after normalisation (blue) for the three replicates 
(figure 3.4.A). For this time point all plates had three replicates. Z’ Factor plots 
indicated poor separation between negative (red) and positive (blue) controls and all 
replicates had a Z’ Factor of <-0.1 (figure 3.4.B). This could be due to the robust 
nature of established OIS, resulting in the positive control siRNA against TP53 not 
bypassing senescence as well as at day 5. Heatmaps for each plate indicated 
correlation of >0.4 between the three replicates (figure 3.4.C), signifying poor 
reproducibility between plates. Only two significant hits were identified as having a 
Z-score of >2.0, TP53 and CERS4 (data not shown).  
To overcome this replication issue, the Web CellHTS2 analysis was repeated with 21 
‘individual plates’, rather than ‘plates as replicates’. This was to ensure hits were not 
missed due to one replicate being variable; hits were identified when two or more 
individual plates had Z-scores >2.0. Distribution box plots of 21 individual plates 
showed raw (pink) and normalised (blue) data with similar patterns to the first 
analysis (figure 3.4.D). The Z’ Factor was not improved when plates are considered 
individual rather than replicates (-0.36, figure 3.4.E). Z-scores were converted to 
positive numbers and significant hits were identified as having a Z-score of >2.0 for 
two or three of the individual plates, corresponding to an approximate p-value <0.05 
(figure 3.5.B-C). Like day 5, TP53 was the top hit followed by CERS4; a further 4 
genes were identified as possibly essential for OIS (figure 3.5.D). There were more 
siRNAs with a Z-score 1.5-2.0, which is indicative of essentiality but not statistically 
significant (data not shown); however, these were not included in further analysis 
due to increased variation between the replicates.  
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Figure 3.4 Normalisation and quality control metrics for day 10 screen data 
(A) Distribution box plots for raw (pink) and normalised (blue) data. (B) Z’ Factor plots and 
values (top right) for negative (red) and positive (blue) controls. (C) Heatmaps showing 
correlation between the three replicates of each plate. (D) Distribution box plots of 21 individual 
plates show raw (pink) and normalised (blue) data. (E) ‘Individual plates’ Z’ Factor plots and 
values (top right) for negative (red) and positive (blue) control 
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Figure 3.5 Identification of 5 genes possibly essential for OIS – using no 
replicates normalisation 
(A) Q-Q plot comparing sample quantiles and theoretical normal distribution quantiles of 
analyses with replicates (left) and no replicates (right) (dotted line = normal distribution). (B) Z-
scores plot (converted from the ‘no replicates’ Q-Q data). (C) Zoom on the positive hits with a Z-
score of >2.0, for 2 or 3 replicates. (D) Table summarising the 5 positive hits with a Z-score of 
>2.0, for 2 or 3 replicates. 
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3.1.4 Summary 
This section has shown it is possible to identify metabolic regulators of OIS using 
siRNA loss-of-function screening. Using data analysis platforms, 16 genes encoding 
metabolic enzymes have been identified that, when targeted for knockdown by 
siRNA, bypass OIS. This indicates these 16 genes are possibly essential for OIS, 
listed in figure 3.6. 14 genes were identified at day 5 (middle and purple sections, 
figure 3.6), 5 at day 10 (middle and yellow sections, figure 3.6) and 3 were common 
at both day 5 and 10 (middle section, figure 3.6). A summary of the gene IDs, 
function and day 5/10 Z-scores is represented in table 3.1. The next step was to 
validate these significant hits in a secondary siRNA screen. 
 
 
Figure 3.6 Summary of genes identified as possible regulators of OIS from 
the primary siRNA screen 
 
   















Table 3.1 Summary of primary screen results, including the function of genes identified as possible regulators of OIS 
Gene ID Gene function 
Z-score 
Day 5 Day 10 
Average Rep 1 Rep 2 Rep 3 
AGPAT1 Converts lysophosphatidic acid (LPA) → phosphatidic acid (PA)  0.53 2.63 2.22 
BID Death agonist that mediates mitochondrial damage induced by caspase-8 2.61    
CERS4 Ceramide synthase 5.38 2.09 2.12 4.82 
DLST Converts 2-oxoglutarate → succinyl-CoA + CO2 (TCA cycle) 4.06 2.32 1.42 2.06 
GBA Cleaves the beta-glucosidic linkage of glycosylceramide 2.73 2.30 1.70 2.11 
GCLC First rate-limiting enzyme of glutathione synthesis 3.09    
KEAP1 Promotes proteasome-dependent degradation of NRF2 2.55    
LPCAT4 Converts lysophosphatidic acid (LPA) → phosphatidic acid (PA) 2.41    
MAT1A Adenosyl moiety of ATP + methionine → SAM + tripolyphosphate  2.25 0.82 2.12 
NAMPT Nicotinamide + 5-PP-1-PP → nicotinamide mononucleotide 2.17    
PTDSS1 Catalyzes the formation of phosphatidylserine from either PC or PE 2.67    
RPS6KB2 Phosphorylates the S6 ribosomal protein and EIF4b 2.16    
SGK1 Kinase activation of potassium, sodium, and chloride channels 2.08    
SIRT5 Mono-ADP-ribosyltransferase activity 2.63    
SLC7A11 Transports cystine into cells in exchange for glutamate 2.17    
UMPS Catalyzes the final two steps of the de novo pyrimidine biosynthesis 2.22    
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3.2 Secondary siRNA screen 
3.2.1 Screen design and workflow 
Pooled siRNAs targeting the 16 genes identified from the primary siRNA screen 
were deconvoluted and custom-made in two 96-well plates from Dharmacon.  
Deconvolution meant the four different siRNAs in the primary screen pool were 
placed in individual wells. The experimental workflow of the secondary screen was 
identical to the primary screen and is overviewed in figure 3.7. For the data analysis, 
the following criterion for hit selection was used: only those genes with two or more 
siRNAs bypassing senescence were validated. In addition to BrdU incorporation, 
p16INK4a and p21CIP1 immunofluorescence staining was included for further 
validation of bypass of OIS. 
 
 
Figure 3.7 Secondary siRNA screen design and workflow 
siRNA pools were deconvoluted into four individual siRNAs with different sequences targeting 
the same gene. iRas were administered 4OHT and subjected to reverse transfection onto siRNAs 
after 2 days. Plates were fixed and stained for BrdU incorporation, p16INK4a and p21CIP1 
expression by immunofluorescence 72 hours post-transfection. Images were acquired and 
analysed using the ImageXpress High Content Analysis microscope. For data analysis and hit 
identification, a validation criterion for each stain was selected. See main text for further detail. 
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3.2.2 Screen results 
3.2.2.1 BrdU 
First, deconvoluted Non-Target siRNA controls were tested to check for any 
differences compared to the pooled Non-Target (figure 3.8). The raw data indicated 
that the four NT individual controls performed similarly, and NT4 was selected as a 
control for the main secondary screen. siRNAs targeting p53 (siTP53) and p21 
(siCDKN1A) were also tested in iRas cells to confirm their suitability as positive 
controls. 
 
Figure 3.8 Deconvoluted Non-Target siRNA effect on BrdU incorporation 
compared to the siRNA pool 
At day 2 of 4OHT, iStop and iRas cells were transfected with siRNA controls (negative = Non-
Target; positive = siTP53 and siCDKN1A) for 72h. At day 4, cells were subjected to a 17h BrdU 
pulse, and then fixed and stained for BrdU incorporation using immunofluorescence. BrdU 
positive cells were quantified and % positive cells calculated (n=1, ±S.D). 
4OHT = 4-hydroxytamoxifen, BrdU = bromodeoxyuridine. 
 
Next, to evaluate the whole secondary screen, a summary heatmap was created for 
the three replicates of each plate (figure 3.9). It was clear the reproducibility between 
replicates was good for both plates. Compared to the siTP53 positive control there 
were three strong hits: CERS4, KEAP1 and LPCAT4. For robust validation of 
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significant hits, one-way ANOVA for both plates were calculated using the senescent 
control as the comparison parameter (i.e. iRas+NT). The criterion to validate hits 
was: genes with two or more individual siRNAs with significant senescent rescue. 
All the siRNAs causing a significant (p<0.05) bypass of senescence are shown in 
figure 3.10. 14 of the original 16 genes identified in the primary screen matched the 
validation criteria, further indicating siRNA screening is a robust technique for use in 
this system. It was striking to see two siRNAs close to siTP53 efficiency at 
bypassing OIS (siCERS4_1 and siKEAP1_3). CERS4 was the only gene with all 
four siRNAs significantly bypassing OIS; this highlights CERS4 as the top hit and 
was further validated in a variety of OIS assays (data in Chapter 4). 
 
 
Figure 3.9 Heatmap representing a summary of the raw data for three 
replicates of each plate 
After following the siRNA screening protocol (summarised in figure 3.7), % BrdU positive cells 
were calculated for each deconvoluted siRNA. A heatmap was generated to show the variability 
between replicates for each siRNA. Negative (NT4) and positive (siTP53 and siCDKN1A) 
controls are shown in the first three columns. The darker blue indicates higher BrdU positivity 
(scale bar on right). 
BrdU = bromodeoxyuridine, NT = Non-Target. 
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Figure 3.10 Validated hits with significant bypass of senescence 
Hits were validated if they matched the following criteria: genes with two or more individual 
siRNAs with significant senescent rescue, measured as BrdU incorporation. Significance was 
calculated using the one-way ANOVA function in GraphPad. The legend, bottom right, specifies 
the cell conditions (n=3, ±S.E.M., ordinary one-way ANOVA (GraphPad)). 
BrdU = bromodeoxyuridine. 
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3.2.2.2 p16 & p21 
To further validate the hits, the secondary screen was independently repeated and 
siRNA-transfected cells stained with p16INK4a and p21CIP1 antibodies. In a control 
plate, knockdown of p16INK4a and p21CIP1 proteins was assessed (figure 3.11.A-B, 
note: siRNAs targeting p16INK4a and p21CIP1 are annotated as their gene names, 
CDKN2A and CDKN1A respectively). The effect of CDKN2A and CDKN1A 
knockdown on BrdU incorporation was marginal (figure 3.11.B). This suggested 
there were discrepancies with the experimental system, possibly due to low 
efficiency siRNA transfection or inadequate 4OHT treatment. Still, the experimental 
plates were stained and analysed to further validate hits confirmed in 3.2.2.1.  
For both p16INK4a and p21CIP1 staining, there was an experimental issue with one 
replicate of plate 2 (figure 3.12.A/3.13.A, yellow boxes). This further indicated this 
experiment was not consistent or conclusive. However, there were several genes with 
significant decreases in both p16INK4a and p21CIP1 expression after siRNA 
knockdown, and most of these genes correlated with those validated by BrdU 
incorporation (figure 3.12.B/3.13.B). For example, the top hit from the BrdU screen 
siCERS4_1 resulted in a highly significant bypass in p16INK4a and p21CIP1 expression. 
The second hit from the BrdU screen siKEAP1_3 and a second siKEAP1 also 
significantly bypassed p21CIP1 expression. Additionally, two siRNAs targeting 








   




Figure 3.11 Knockdown of CDKN1A and CDKN2A diminished p21CIP1 and 
p16INK4a protein expression and marginally bypassed senescence 
At day 2 of 4OHT, iStop and iRas cells were transfected with specified siRNA for 72h. At day 5, 
cells were fixed and subjected to immunofluorescence staining for (A) p16INK4a expression, (B) 
p21CIP1 expression and (C) BrdU incorporation (after a 17h pulse of BrdU). Positive cells for 
each stain were quantified and % positivity calculated (n=1, ±S.D.) 
4OHT = 4-hydroxytamoxifen, BrdU = bromodeoxyuridine, NTP = Non-Target pool. 
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Figure 3.12 p16 screen further validated 4 hits as bypassing senescence 
(A) After following the siRNA screening protocol (summarised in figure 3.7), % p16INK4a positive 
cells were calculated for each deconvoluted siRNA. A heatmap for each plate was generated to 
show the variability between replicates for each siRNA. Negative (NTP) and positive (siTP53, 
siCDKN2A and siCDKN1A) controls are shown in the first three columns. The lighter blue 
indicates lower p16INK4a positivity and likely a non-senescent state (scale bar on right). An 
experimental issue with replicate 2 meant some data from plate 2 were lost (indicated by the 
yellow boxes). (B) Hits were further validated if they caused a significant rescue in p16INK4a 
expression, in addition to increased BrdU incorporation. Significance was calculated using the 
ordinary one-way ANOVA function in GraphPad. The table summarises the significant hits from 
the p16 screen. 
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Figure 3.13 p21 screen further validated 5 hits as bypassing senescence 
(A) After following the siRNA screening protocol (summarised in figure 3.7), % p21CIP1 positive 
cells were calculated for each deconvoluted siRNA. A heatmap for each plate was generated to 
show the variability between replicates for each siRNA. Negative (NTP) and positive (siTP53, 
siCDKN2A and siCDKN1A) controls are shown in the first three columns. The lighter blue 
indicates lower p21CIP1 positivity and likely a non-senescent state (scale bar on right). An 
experimental issue with replicate 2 meant some data on both plates were lost (indicated by the 
yellow boxes). (B) Hits were further validated if they caused a significant rescue in p21CIP1 
expression, in addition to increased BrdU incorporation. Significance was calculated using the 
ordinary one-way ANOVA function in GraphPad. The table summarises the significant hits from 
the p21 screen. 
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3.2.3 Functional annotation of screen hits 
The 14 validated screen hits were functionally annotated and grouped based on 
similarity using the DAVID Bioinformatics Resource 6.8 ‘Functional Annotation’ 
tool (Huang, Sherman and Lempicki, 2008). The list of validated genes was inputted 
as Homo sapiens ‘Official Gene Symbols’ and analysed for enriched GO terms and 
KEGG pathway maps. There was significant enrichment of genes involved in lipid 
biosynthetic processes, such as phospholipid and ceramide biosynthesis (table 3.2). 
Although this was a small group of genes, this analysis still indicated that lipid 
metabolism is implicated in OIS and warrants further interrogation. Furthermore, 
there was enrichment for genes involved in oxidative stress response; this group also 
included KEAP1, a regulator of NRF2-mediated response to oxidative stress, but this 
did not group with the 3 genes annotated in GO:0006979 by DAVID (table 3.2). 
GO term Process Count Genes p-value 




GO:0008654 Phospholipid biosynthesis 3 PTDSS1, LPCAT4, 
AGPAT1,  
0.016 
GO:0046513 Ceramide biosynthesis 2 CERS4, GBA 0.050 
GO:0006979 Oxidative stress response 3 GBA, GCLC, 
SLC7A11 
0.047 
Table 3.2 GO terms enriched in the validated gene list 
 
3.2.4 Summary 
In this section, 14 of the 16 hits identified in the primary screen were validated, by 
deconvoluting pooled siRNAs and staining for BrdU incorporation and 
p16INK4a/p21CIP1 expression. This suggested the 14 genes have a vital role in OIS 
metabolism (table 3.3 for overview). When analysed by functional annotation, it was 
found 5/14 genes were mapped to lipid metabolism and 4/14 genes were mapped to 
the oxidative stress response.  
   





Gene ID KEGG Pathway Classification 
Validation 
BrdU p16 p21 
AGPAT1 Glycerolipid metabolism    
CERS4 Sphingolipid metabolism    
DLST Citrate cycle (TCA cycle)    
GBA Sphingolipid metabolism    
GCLC Glutathione metabolism    
KEAP1 Ubiquitin mediated proteolysis    
LPCAT4 Glycerophospholipid metabolism    
NAMPT Nicotinate and nicotinamide metabolism    
PTDSS1 Glycerophospholipid metabolism    
RPS6KB2 Signalling pathways    
SGK1 Signalling pathways    
SIRT5 Sirtuins    
SLC7A11 Amino acid transport    
UMPS Pyrimidine metabolism  not tested 
 
Table 3.3 Summary of secondary screen results, including the top KEGG 
pathway classification for each gene 
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3.3 Chapter summary 
In this chapter, the aim was to identify novel metabolic regulators of OIS using high-
content siRNA screening. 16 genes were found bypassing OIS after pooled siRNA 
knockdown and 14 were validated by deconvoluting siRNAs. Additional screening 
for p16INK4a/p21CIP1 expression was used to further characterise some of the hits. Of 
these 14 essential OIS genes, there was a significant enrichment of genes involved in 
lipid biosynthetic processes, such as the top hit ceramide synthase 4 (CERS4). 
siRNA targeting CERS4 caused a significant bypass in BrdU incorporation (with 4 
siRNAs) and p16INK4a/p21CIP1 expression (with 1 siRNA). 
From this data, it can be concluded lipid metabolism has an important role regulating 
OIS that has not been extensively studied in current literature. In the following 
chapters investigations are directed to further validate CERS4 during OIS and 










   
   132 
Chapter Four: Validation of CERS4 as an 
essential lipid metabolic regulator for OIS 
In chapter 3, lipid metabolism was identified as an important process for OIS and 
CERS4 as a key enzyme for this association. Results from the siRNA screen requires 
thorough validation, therefore the next aim for this thesis was to extensively validate 
CERS4 as a regulator of OIS. As described in 1.1.2, OIS has a heterogeneous 
phenotype, thus there are many assays to measure the senescent state of a cell. Here, 
readouts for proliferation, SA β-galactosidase activity and tumour suppressor and 
SASP activation (by western blotting and qPCR) were measured. In addition, the 
effect of CERS4 knockdown was tested in a replicative senescence model. Lastly, 
pharmacological inhibition of ceramide metabolism was tested to see if targeting 
ceramides can induce senescence in normal cells. This chapter describes the results 
from these experiments utilising RNAi genetic knockdowns of CERS4, 
pharmacological manipulation of ceramide metabolism and senescence assays. 
 
4.1 Knockdown of CERS4 robustly bypasses OIS 
4.1.1 Transient CERS4 knockdown rescues proliferation and SA β-
galactosidase activity 
To investigate the correlation between knockdown efficiency and effect on 
senescence, mRNA expression of CERS4 in OIS, after targeting expression with 
siRNA, was analysed. Knockdown efficiency of four siRNAs (i.e. those 
deconvoluted from the pooled siRNA used in the primary screen) was measured by 
qPCR 72 hours post transfection. At the mRNA level, CERS4 expression was 
approximately 50% downregulated in iRas compared to iStop (figure 4.1.A, compare 
first two bars); although this suggested a decrease in CERS4 activity in OIS, this was 
not the case, as described in Chapter 5. The discrepancy between CERS4 mRNA 
expression and activity is discussed in 7.4.1. siRNA no.1 had the best mRNA 
knockdown efficiency followed by no.3 and 4 (figure 4.1.A). siRNA no.2 did not 
knockdown CERS4 mRNA (figure 4.1.A, compare bar 2 and 4). Unfortunately, 
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protein levels of CERS4 could not be detected with the antibodies tested (figure 2.5). 
Importantly, all four siRNAs targeting CERS4 significantly increased BrdU 
incorporation (figure 3.10), correlating with the efficiency of siRNA knockdown 
(figure 4.1.A). Therefore, for further experiments, just siRNA no.1 and pooled 
siRNA were used to keep experiments resourceful and practical. IMR90 were 
targeted for siRNA knockdown of CERS4 at day 5 and day 8 (see figure 2.3 for 
experimental outline) and proliferation, as measured by BrdU incorporation, was 
significantly restored at both time points (figure 4.1.B). In addition, targeting CERS4 
with siRNA strongly reduced SA β-galactosidase activity (figure 4.1.C).  
4.1.2 Generation of an shRNA targeting CERS4 that recapitulates siRNA 
knockdown 
To support data from transient RNAi, stable RNAi was tested by producing a 
retroviral vector (pSUPER.retro.puro, hereafter referred to as pRS) that allows the 
long-term expression of siRNA sequences. The cloning method from OligoEngine is 
described in 2.3, and was performed with Dr Andrea Quintanilla. When vectors were 
cloned, IMR90 were infected as described in 2.2.4 and experiments to test the 
effectiveness of the stable knockdown were performed. Firstly, the knockdown 
efficiency of the cloned shRNA was extremely good (figure 4.2.A). Corresponding 
to the siRNA experiments, CERS4 mRNA expression was ~50% downregulated in 
iRas compared to iStop (figure 4.1.A, compare first two bars). As with the siRNA 
knockdowns, proliferation was significantly rescued when measuring the cell content 
by crystal violet staining (figure 4.2.B) and BrdU incorporation (figure 4.2.C). The 
activation of senescence marker SA β-galactosidase activity was also decreased at 
day 8 of OIS when the expression of CERS4 was depleted (figure 4.2.D). 
4.1.3 Summary 
In this section, confirmation that knockdown of CERS4 expression robustly bypasses 
OIS is shown. This was measured using proliferation readouts and SA β-
galactosidase activity. The next objective for this section was to establish the 
importance of CERS4 for OIS by analysing tumour suppressor pathways and the 
SASP. As discussed in 1.1.2, the expression of these components is essential for OIS 
progression. 
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Figure 4.1 Targeting CERS4 with siRNA depleted CERS4 mRNA levels, 
increased proliferation and decreased SA β-galactosidase activity 
(A) 4OHT-treated iStop and iRas were transfected with control (NTP) and deconvoluted siRNAs 
targeting CERS4 for 72h. RNA was extracted, cDNA synthesised and qPCR used to detect mRNA 
levels of CERS4. β-actin was used as a housekeeping gene (n=1, ±S.D.). Next, 4OHT-treated 
iStop and iRas were transfected with siCERS4 no.1 and controls; Day 8 cells were transfected 
twice as described in figure 2.3. These cells were: (B) subjected to a 17h BrdU pulse, fixed and 
stained for BrdU incorporation using immunofluorescence. BrdU positive cells were quantified 
and % positive cells calculated (n=3, ±S.E.M., two-tailed Student’s t-test). (C) fixed and stained 
for SA β-galactosidase activity. SA β-gal positive cells were quantified from images and % 
positive cells calculated (right graph) (n=3, ±S.E.M., two-tailed Student’s t-test, representative 
images). 
4OHT = 4-hydroxytamoxifen, BrdU = bromodeoxyuridine, NTP = Non-Target pool, siC4 = 
siCERS4. * = p≤0.05, ** = p≤0.01, *** = p≤0.001, **** = p≤0.0001. 
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Figure 4.2 Stable mRNA knockdown of CERS4 rescued proliferation and SA 
β-galactosidase activity 
iStop and iRas infected with ev and shC4 were plated into 4OHT at day 0 for OIS analysis at 
various time points (indicated on figures). (A) mRNA expression levels of CERS4 were measured 
by qPCR. β-actin was used as a housekeeping gene (n=3, ±S.E.M., two-tailed Student’s t-test). 
(B) Cells were subjected to a 17h BrdU pulse, fixed and stained for BrdU incorporation using 
immunofluorescence. BrdU positive cells were quantified and % positive cells calculated (n=3, 
±S.E.M., two-tailed Student’s t-test). (C) Cell content over long-term OIS (>10 days 4OHT) was 
measured using crystal violet staining and quantified by measuring the absorbance of dissolved 
CV at 595nm (right graph) (n=3, ±S.E.M., two-tailed Student’s t-test, representative images).    
(D) Cells were fixed and stained for SA β-galactosidase activity. SA β-gal positive cells were 
quantified from images and % positive cells calculated (right graph) (n=1, ±S.D.). 
4OHT = 4-hydroxytamoxifen, BrdU = bromodeoxyuridine, ev = pRS-empty vector, shC4 = pRS-
shCERS4, CV = crystal violet. * = p≤0.05, **** = p≤0.0001. 
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4.2 CERS4 regulates p53 and p16 tumour suppressor 
pathways 
To investigate if CERS4 has a role in the regulation of essential tumour suppressor 
pathways in OIS, protein levels of p53 and p16INK4a pathways were assessed after 
genetic targeting of CERS4 expression. First, protein expression of p53, p21CIP1 (a 
tumour suppressor downstream of p53) and p16INK4a was measured by 
immunofluorescence and western blot. shRNA knockdown of CERS4 resulted in 
significant (p≤0.0001) decrease in p53, p21CIP1 and p16INK4a levels as measured by 
immunofluorescence (figure 4.3.A, images; 4.3.B, quantification). siRNA 
knockdown of CERS4 resulted in decreased p53 and p21CIP1 expression at day 5 and 
8 as measured by western blot (figure 4.3.C, compare lanes 3-4 and 8-9). 
Next, to determine if CERS4 is required for the transcription of essential tumour 
suppressor pathways in OIS, qPCR was used to measure to mRNA levels of 
CDKN2A (p16), CDKN2B (p15, a tumour suppressor analogous to p16) and 
CDKN1A (p21). At day 8 of 4OHT, mRNA expression of CDKN2A, CDKN2B and 
CDKN1A were significantly (p ≤0.001) decreased when CERS4 was depleted by 
shRNA (figure 4.4). This expression data for tumour suppressors suggests that 
CERS4 is an essential mechanistic component of OIS induction and/or maintenance. 
Here, CERS4 has been confirmed fundamental for the expression of tumour 
suppressor pathways in OIS, by perturbing CERS4 expression and measuring the 
protein and mRNA levels of p53/p21 and p16/p15. Next, the involvement of CERS4 
in another essential OIS effector programme, the SASP, was examined.  
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Figure 4.3 CERS4 knockdown significantly reduced expression of tumour 
suppressors 
iStop and iRas were infected with empty vector (ev) and a stable shRNA targeting CERS4 
expression (shC4). Cells were selected with puromycin and plated into 4OHT at day 0 for tumour 
suppressor expression analysis at day 5. (A) Images of immunofluorescent staining for p16INK4a, 
p21CIP1 and p53 proteins. (B) Quantification of images in (A) using the HCS software 
MetaXpress (n=3, ±S.E.M., two-tailed Student’s t-test). (C) iStop and iRas were subjected to 
reverse transfection with Non-Target and siCERS4 at day 2 of 4OHT. Cell pellets were collected 
and lysed on day 5, and subjected to western blotting to detect p21CIP1 and p53. Briefly, 20µg 
lysate was separated by SDS-PAGE, using a 4-12% Bis-Tris gel. Proteins were transferred onto 
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a nitrocellulose membrane and blocked with 5% milk. Antibodies for blotted proteins were 
incubated on the membranes and ECL used to visualize the bands (representative of 3 
independent experiments). β-actin was used as a loading control (NOTE: the western blot for β-
actin in figure 4.3.C was the same for the β-actin in figure 4.5). 
4OHT = 4-hydroxytamoxifen, BrdU = bromodeoxyuridine, ev = empty vector (pRS), shC4 = 





Figure 4.4 CERS4 knockdown significantly reduced transcription of tumour 
suppressors 
iStop and iRas infected with ev and shC4 were analysed for tumour suppressor transcription at 
day 8 of 4OHT. RNA was extracted, cDNA synthesised and qPCR used to detect mRNA levels of 
genes encoding p16, p15 and p21. β-actin was used as a housekeeping gene (n=3, ±S.E.M., two-
tailed Student’s t-test). 
4OHT = 4-hydroxytamoxifen, ev = empty vector (pRS), shC4 = pRS-shCERS4 *** = p≤0.001, 
**** = p≤0.0001. 
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4.3 CERS4 regulates the SASP 
As described previously, the expression of the SASP is a vital program for OIS. To 
examine the role for CERS4 in SASP regulation, the expression of well-known 
SASP proteins IL1β, IL6 and IL8 was analysed by western blot. It is important to 
note here SASP expression is a phenotype of established OIS and can only be seen 
from ~day 5 of 4OHT treatment. CERS4 knockdown strongly ablated the expression 
of SASP proteins IL1β, IL6 and IL8 at day 8 (figure 4.5, compare lanes 8-9). 
Targeting CERS4 expression also prevented the initial accumulation of IL1β and IL6 
at day 5 (figure 4.5, compare lanes 3-4), further suggesting CERS4 is essential for 
OIS progression. p53 knockdown did not regulate the expression of SASP factors 
(figure 4.5, lanes 5&10, as previously hypothesised by Coppé et al. (2008). 
To investigate the role of CERS4 in the regulation of additional SASP factors, 
transcriptomic analysis was performed. Biological triplicate RNA samples were 
extracted from iStop/iRas with Non-Target and iRas with CERS4 siRNA, at day 5 
and 8 of 4OHT. RNA samples were analysed using targeted RNA sequencing: 
AmpliSeq transcriptomics, performed by Edinburgh Clinical Research Facility (see 
2.9 for methods). Firstly, table 4.1 shows mapped reads and % valid reads per sample 
were above-expected for the analysis (~8million and ≥90%, respectively). Next, gene 
expression analysis was performed using the Babelomics 5 ‘RNA-seq class 
comparison’ tool (Alonso et al., 2015), and comparisons were made related to the 
OIS control (i.e. iRas with Non-Target). The statistic values for 57 SASP factors are 
plotted as % fold change compared to iRas (figure 4.6.A). CERS4 knockdown 
resulted in a strong bypass of SASP transcriptional activation. mRNA expression 
levels of SASP factors IL6 and IL8 were validated by qPCR and again CERS4 
knockdown caused a significant (p<0.0001) ablation of SASP transcription (figure 
4.6.B).  
In this section, by perturbing expression, CERS4 has been identified as essential for 
transcription and protein expression of the SASP in OIS. In the next section, CERS4 
was targeted in a different model of senescence to determine if this metabolic 
enzyme is ubiquitously vital for senescence mechanisms. 
   





Figure 4.5 CERS4 knockdown ablated expression of SASP proteins IL1β, 
IL6 and IL8 
iStop and iRas were subjected to reverse transfection with Non-Target and siCERS4 at day 2 and 
5 of 4OHT. Cell pellets were collected and lysed on day 8, and subjected to western blotting to 
detect IL1β, IL6 and IL8. Briefly, 20µg lysate was separated by SDS-PAGE, using a 4-12% Bis-
Tris gel. Proteins were transferred onto a nitrocellulose membrane and blocked with 5% milk. 
Antibodies for blotted proteins were incubated on the membranes and ECL used to visualize the 
bands (representative of 3 independent experiments). β-actin was used as a loading control 
(NOTE: the western blot for β-actin in figure 4.3.C was the same for the β-actin in figure 4.5). 
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Time point Sample Replicate Chip Mapped reads Valid reads 
Day 5 Stop+NTP 1 1 11,070,707 95.75% 
  2 2 12,592,855 96.31% 
  3 2 10,862,693 95.87% 
 Ras+NTP 1 2 11,162,864 96.57% 
  2 2 11,632,930 96.67% 
  3 2 11,260,321 96.41% 
 Ras+siC4 1 2 12,291,981 95.91% 
  2 2 10,876,947 95.82% 
  3 2 11,447,104 95.51% 
Day 8 Stop+NTP 1 1 10,820,372 95.63% 
  2 3 9,788,997 96.21% 
  3 3 11,925,605 96.33% 
 Ras+NTP 1 3 10,915,829 96.60% 
  2 3 12,836,493 96.41% 
  3 3 11,072,589 96.65% 
 Ras+siC4 1 3 7,421,699 95.76% 
  2 3 12,489,109 96.04% 
  3 3 9,790,041 95.74% 
Table 4.1 Overview of the transcriptomics statistics 
AmpliSeq transcriptomics was performed by Edinburgh Clinical Research Facility on the above 
samples. Briefly, cDNA was prepared by reverse transcription of RNA samples. Target genes 
were amplified and ligated to sequencing adapters to create libraries for next-generation 
sequencing. Sequencing outputs were analysed using the AmpliSeqRNA plugin; the run statistics 
summarised in this table were specified from this analysis. See 2.8 for further details on the 
methods. NTP = Non-Target pool, siC4 = siCERS4. 
   




Figure 4.6 Transcriptomics and qPCR confirmed decreased transcription of 
SASP factors after CERS4 knockdown 
(A) Transcriptomic data analysed using AmpliSeqRNA plugin was subjected to gene expression 
analysis (see table 4.1 for sample info). The Babelomics 5 ‘RNA-seq class comparison’ tool 
(Alonso et al., 2015) was used. For this analysis, the normalization method used was TMM and 
Benjamini and Hochberg multiple-test correction was used to calculate the False Discovery Rate 
and adjusted p-value (<0.05). Here, the statistic values for 57 SASP factors are plotted as % fold 
change compared to the OIS control (i.e. iRas with Non-Target). Next, iStop and iRas infected 
with ev and shC4 were analysed for SASP transcription at day 8 of 4OHT. RNA was extracted, 
cDNA synthesised and qPCR used to detect mRNA levels of: (B) IL6 (C) IL8. β-actin was used as 
a housekeeping gene (n=3, ±S.E.M., two-tailed Student’s t-test). 
ev = empty vector (pRS), shC4 = pRS-shCERS4, NTP = Non-Target pool, siC4 = siCERS4,  
**** = p≤0.0001 
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4.4 CERS4 knockdown delays replicative senescence 
To determine if CERS4 is required for senescence triggered by a different 
mechanism to OIS, CERS4 was targeted for stable knockdown in parental IMR90 
and repeatedly passaged. Population doublings were measured until they reached a 
cell cycle arrest typified by replicative senescence. First, CERS4 mRNA expression 
was decreased throughout the early, mid and late passages, indicating the shRNA 
was active throughout the experiment (figure 4.7.A). Next, the population doublings 
indicated CERS4 knockdown resulted in a partial increase in lifespan compared to 
control throughout the experiment. However, replicative senescence eventually 
overcomes the CERS4 knockdown and cells start to arrest at passage 27 (figure 
4.7.B). In addition, SA β-galactosidase activity was significantly decreased with 
CERS4 knockdown at passage 25, when the control cells were starting to senesce 
(figure 4.7.C). 
As described previously, replicative senescence can have different senescent markers 
due to DNA damage resulting from telomere shortening rather than oncogene 
activation. To analyse this, the expression of tumour suppressors p53, p21CIP1 and 
p16INK4a was measured by western blot (figure 4.8). At passage 24 there was no 
regulation of p53 or p21CIP, suggesting CERS4 has no effect on p53 activation by 
telomere shortening rather than oncogene-induced. Interestingly, p16INK4a expression 
was repressed in CERS4 knockdown as the experiment progressed (figure 4.8.B). 
Together, this data suggests CERS4 is not required for telomere shortening and 
subsequent p53 activation, but is independently required for the activation of the 
INK4a-ARF locus in replicative senescence (concurring with observations made by 
Herbig et al. (2004)).  
Overall, this data suggests CERS4 is essential for replicative senescence, as well as 
oncogene-induced senescence, and may play a role for the activation of the INK4a-
ARF locus in replicative senescence. Next, pharmacological inhibitors of ceramide 
metabolic enzymes were used to target ceramide and the resulting effect on 
senescence was analysed. 
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Figure 4.7 Persistent CERS4 knockdown enforces increased growth in 
IMR90 and delays replicative senescence (legend next page) 
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Figure 4.7 IMR90 were infected with empty vector (ev) and stable shRNAs targeting CERS4 
(shC4) and TP53 (shTP53) expression. Throughout, cells were selected with puromycin and 
pellets collected at each passage for further analysis. (A) mRNA expression levels of CERS4 
were measured by qPCR. β-actin was used as a housekeeping gene (n=2, ±S.D.). (B) Population 
doublings of the three cell types were measured. Briefly, at each passage cells were counted and 
re-seeded at 500,000 cells per 10cm dishes. A formula was used to calculate the P.D. (see 
methods 2.2.5) (n=3, ±S.E.M., two-tailed Student’s t-test).  (C) Cells were fixed and stained for 
SA β-galactosidase activity. SA β-gal positive cells were quantified from images (not shown) and 
% positive cells calculated (n=3, ±S.E.M., two-tailed Student’s t-test, # = n=2 ±S.D.). 
ev = empty vector (pRS), shC4 = pRS-shCERS4, * = p≤0.05, ** = p≤0.01, *** = p≤0.001, ns = 
not significant.  
 
 
Figure 4.8 CERS4 regulated the activation of p16INK4a in replicative 
senescence but not the activation of p53 
IMR90 were infected with empty vector (ev) and stable shRNAs targeting CERS4 (shC4) and 
TP53 (shTP53) expression. Throughout, cells were selected with puromycin and pellets collected 
at each passage for western blot analysis of tumour suppressors p16INK4a, p21CIP1 and p53.  15µg 
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cell lysate was separated on 10-20% Tris-Glycine gels and subjected to western blotting of stated 
proteins. β-actin was used as a loading control. (A) Western blots for passage 24 (representative 
of two independent experiments). (B) Western blot of p16INK4a for different mid and late 
passages. Dotted line indicates a cropped membrane (representative of two independent 
experiments). 
ev = empty vector (pRS), shC4 = pRS-shCERS4. 
 
4.5 Pharmacological inhibition of ceramide metabolic 
enzymes induces a senescence-like cell cycle arrest 
CERS4 is a metabolic enzyme involved in the synthesis of ceramides and as shown 
in this chapter, CERS4 is essential for senescence. Therefore, it can be hypothesised 
ceramides are also vital for senescence, and increased cellular ceramide content may 
be able to induce a stable cell cycle arrest. As summarised by Morad and Cabot 
(2013), sphingosine kinase, ceramidase and ceramide kinase are enzymes that 
degrade or modify ceramide. Inhibiting post-synthesis modification or degradation of 
ceramide theoretically results in accumulated ceramide content and thus a similar 
environment hypothesised for OIS. To ascertain if this hypothesis was correct, 
inhibitors of these three enzymes were tested for their ability to induce senescence 
(figure 4.9.A). For this experiment, parental IMR90s were treated with the inhibitors 
and vehicle controls for 48 hours, and analysed for various senescent markers. 
Firstly, the inhibitor of sphingosine kinase, SKI-1, caused a potent reduction in 
proliferation (figure 4.9.B). There was increased expression of p21CIP1, p53, pST/Q 
and ϒH2AX (figure 4.9.B); and ~5-fold increase in SA β-gal activity (bars 1-2, 
figure 4.9.E). Second, the inhibitor of acidic ceramidase, ceranib-1, caused a 2-fold 
reduction in proliferation and increased expression of p21CIP1and pST/Q (figure 
4.9.C); and a minimal increase in SA β-gal activity (bars 3-4, figure 4.9.E). Finally, 
the inhibitor of ceramide kinase, NVP-231, caused a 6-fold reduction in proliferation 
and increased expression of p21CIP1, p53 and pST/Q (figure 4.9.D); and ~4-fold 
increase in SA β-gal activity (bars 5-6, figure 4.9.E). 
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In summary, this data shows pharmacological manipulation of ceramide metabolism, 
leading to accumulation of ceramides, results in a proliferation arrest in IMR90. This 
coincides with expression of tumour suppressors, DNA damage markers and slightly 
increased SA β-gal activity; overall suggesting a senescence-like stable cell cycle 
arrest. However, this data is not conclusive because the inhibitors were not tested for 
functional activity. Therefore, mass spectrometry is required to confirm levels of 
ceramide after inhibition of these enzymes. 
 
 
Figure 4.9 Drugs targeting ceramide metabolic enzymes cause proliferation 
arrest and expression of senescence markers (legend next page) 
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Figure 4.9 (A) Pathway schematic indicating ceramide metabolic enzymes inhibited by SKI-1, 
ceranib-1 and NVP-231. IMR90 were treated with vehicle (DMSO) and (B) 2µM SKI-1 or (C) 
2µM ceranib-1 or (D) 5µM NVP-231. 48 hours after treatment, cells were fixed for 
immunofluorescence staining of BrdU incorporation (17h BrdU pulse), p16INK4a, p21CIP1, p53 
and DNA damage markers: pST/Q and ϒH2AX. Positive cells were quantified from images (not 
shown) and % positive cells calculated (n=2, ±S.D.). (E) Treated cells were also stained for SA 
β-galactosidase activity. SA β-gal positive cells were quantified from images (not shown) and % 
positive cells calculated. OIS cells (day 10 of 4OHT) were used as a positive control (pink bar) 
(n=1, ±S.D.). 
4OHT = 4-hydroxytamoxifen, BrdU = bromodeoxyuridine. 
 
4.6 Chapter summary 
In this chapter, CERS4 has been extensively validated as a key enzyme for both OIS 
and replicative senescence. CERS4 knockdown by siRNA and shRNA robustly 
bypasses OIS and rescues the following phenotypes: proliferation, SA β-
galactosidase activity and the expression of tumour suppressors and the SASP. Also, 
targeting CERS4 can delay replicative senescence and affects p16INK4a expression but 
not p53/p21CIP1 expression. Finally, pharmacological manipulation of ceramide 
metabolism that, theoretically, accumulates ceramides, resulted in a senescence-like 
cell cycle arrest in IMR90. 
When CERS4 is not present in IMR90, due to genetic knockdown, OIS is bypassed 
and all the typical OIS markers are significantly reduced to control levels. This 
suggests CERS4 function (ceramide synthesis) is mechanistically linked to OIS. In 
the next chapter, the main aim was to probe ceramide metabolism in OIS, using LC-
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Chapter Five: Altered ceramide metabolism in 
OIS is regulated by CERS4 
In the previous chapter CERS4 was thoroughly validated as an essential enzyme for 
OIS progression. The next aim was to gain understanding of the metabolic function 
of CERS4 and how this may be implicated during OIS. As described in 1.2.4, 
ceramides can be synthesized by six ceramide synthases and by two main pathways: 
de novo and recycling. CERS4 preferentially synthesizes ceramides with 18/20/22 
carbon fatty acids, in the de novo pathway (Riebeling et al., 2003). For a 
comprehensive analysis of lipid metabolism in OIS, LC-MS-based lipidomics and 
labelling studies were utilised. In addition, the transcriptomics dataset, described in 
chapter four, was used for pathway expression analysis. In this chapter, data is 
described that indicates OIS results in altered lipid metabolism and CERS4 is 
implicated in these changes. 
The quantitative ceramide analysis was performed in collaboration with Prof Phil 
Whitfield and colleagues at the University of Highlands & Islands (UHI). The 
labelling experiments were performed in collaboration with Dr Andy Finch, Joy 
Edwards-Hicks and Dr Jimi Wills at the Institute of Genetics and Molecular 
Medicine (IGMM). 
 
5.1 Induction of OIS results in a global rewiring of the 
lipidome and increase in ceramide content 
5.1.1 Transcriptomics confirms transcriptional regulation of lipid 
metabolism in OIS 
For initial analysis of lipid metabolism during OIS, the transcriptomic dataset 
(described in 4.3.) was utilised, to determine global mRNA expression of lipid 
metabolic pathways. Gene Set Enrichment Analysis was implemented to identify 
enrichment for lipid metabolism gene sets in OIS, and if gene sets are regulated by 
CERS4. Indeed, for day 8 there were many lipid metabolic pathways upregulated in 
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OIS (figure 5.1), suggesting a transcriptional program regulating lipid metabolism in 
OIS. CERS4 knockdown resulted in strongly significant downregulation of three 
sphingolipid pathways, compared to OIS (figure 5.1, bottom three bars), suggesting 
enzymatic activity is regulated by genetically targeting CERS4 expression. To 
further interrogate the expression of lipid metabolic genes in OIS, the statistic values 
of 8 ceramide metabolic genes were extracted and plotted as % fold change 
compared to iRas (figure 5.2.A). All, apart from GALC and SMPD1/2, showed 
increased expression in OIS and this was dependent on CERS4 expression. These 
results were validated by qPCR and significant increases in expression of GBA, 
ASAH1 and SPHK1 in OIS were shown (figure 5.2.B). Overall, this data suggests 
OIS has altered expression of lipid metabolism gene sets and CERS4 is implicated in 
this transcriptional regulatory program.  
5.1.2 Lipid toxicity is accumulated during OIS 
Lipid toxicity is the abnormal accumulation of cellular lipids, such as fatty acids, 
ceramides and phospholipids, and can be measured as an indicator of altered lipid 
metabolism. As revealed from the bypass-of-senescence siRNA screen, several genes 
in lipid metabolism are implicated in OIS. As a marker for altered lipid metabolism 
and to complement the transcriptomic data, lipid toxicity was measured in OIS and 
cells with CERS4 expression targeted in OIS. Three markers of lipid toxicity were 
used: lipid peroxidation, the oxidative breakdown of lipids; steatosis, the 
accumulation of neutral lipids; and phospholipidosis, the accumulation of 
phospholipids. First, to measure lipid peroxidation a Click-iT reaction was used, 
briefly described here. In the presence of lipid peroxidation, a linoleamide alkyne 
(LAA) substrate oxidises to form reactive aldehyde that binds protein or DNA. The 
aldehyde-protein/DNA adducts are incubated with a fluorescent azide in the presence 
of copper; the alkyne-containing adducts bind azide to form a stable product that is 
visualised with a fluorescent microscope. Next, phospholipidosis and steatosis are 
co-stained using fluorescent dyes with high affinity for phospho- and neutral lipids. 
Figure 5.3 shows the activation of OIS strongly induced lipid peroxidation, steatosis 
and phospholipidosis, and knockdown of CERS4 reduced this response. This data 
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suggests CERS4 contributes to the lipotoxic response in OIS. Next, LC-MS-based 





Figure 5.1 Transcriptomics confirmed regulation of lipid and ceramide 
metabolic programs during OIS 
Babelomics 5 ‘RNA-seq class comparison’ and ‘Gene Set Enrichment Analysis’ tools (Alonso et 
al., 2015) were used to compare expression of genes in lipid metabolic pathways for the 
following samples: OIS (iRas) and OIS with targeted CERS4 (iRas-siCERS4). See 2.9 for further 
details on the methods. Here, the difference in expression of the stated pathways between the two 
samples is quantified as a significative adjusted p-value 
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Figure 5.2 Regulation of sphingolipid metabolic transcriptional program by 
CERS4 
(A) Transcriptomic data analysed using AmpliSeqRNA plugin was subjected to gene expression 
analysis. The Babelomics 5 ‘RNA-seq class comparison’ tool (Alonso et al., 2015) was used. For 
this analysis, the normalization method used was TMM and Benjamini and Hochberg multiple-
test correction was used to calculate the False Discovery Rate and adjusted p-value (<0.05). 
Here, the statistic values for 8 ceramide recycling enzymes are plotted as % fold change 
compared to the OIS control (i.e. iRas with Non-Target). (B) iStop and iRas infected with ev and 
shC4 were analysed for transcription of ceramide metabolic enzymes at day 8 of 4OHT, and 
qPCR used to detect mRNA levels of GBA, ASAH1, ERK, SMPD2 and SPHK1. β-actin was used 
as a housekeeping gene (n=3, ±S.E.M., two-tailed Student’s t-test). 
4OHT = 4-hydroxytamoxifen, ev = pRS-empty vector, shC4 = pRS-shCERS4, * = p≤0.05, ** = 
p≤0.01. 
 
   







Figure 5.3 Lipid toxicity is activated in OIS 
iStop and iRas infected with ev and shC4 were analysed for lipid toxicity at day 5 of 4OHT. See 
2.12 for full methods. (A) Lipid peroxidation was measured using a Click-iT assay. Briefly, cells 
were incubated with linoleamide alkyne (LAA) for 2 hours at 37°C. Cells were fixed and 
incubated with a fluorescent azide for 30 minutes, followed by DAPI. The resulting Click-iT 
reaction was measured using the FITC filter of the ImageXpress. Positive cells were quantified 
from images (not shown) and % positive cells calculated (n=1, ±S.D.). (B) Steatosis was detected 
by incubating fixed cells with a FITC-bound reagent with high affinity for neutral lipid droplets, 
for 30 minutes, followed by DAPI. Neutral lipids were detected using the FITC filter of the 
ImageXpress. Positive cells were quantified from images (not shown) and % positive cells 
calculated (n=1, ±S.D.). (C) Phospholipidosis was detected by incubating cells with a TxRED-
bound phospholipid, for 24 hour at 37°C. Cells were fixed and stained with DAPI. Phospholipids 
were detected using the TxRED filter of the ImageXpress. Positive cells were quantified from 
images (not shown) and % positive cells calculated (n=1, ±S.D.). 
4OHT = 4-hydroxytamoxifen, ev = pRS-empty vector, shC4 = pRS-shCERS4. 
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5.1.3 Global lipidomics reveals an OIS-induced rewiring of lipid 
metabolism 
The previous two sections have indicated OIS induces a transcriptional program 
regulating lipid metabolic gene expression and lipotoxic stress. To gain insight into 
whether OIS induces changes to the cellular lipidome, global lipidomics was 
harnessed (in collaboration with UHI). For this analysis, three cell types were used in 
serum-starved conditions: control (iStop), OIS (iRas), and bypass of senescence 
(iRas-E6/E7). For the bypass of senescence cell line, HPV proteins E6 and E7 were 
overexpressed in IMR90-ER:Ras. E6 and E7 are inhibitors of p53 and RB, 
respectively, and therefore the overexpression of E6/E7 prevents the induction of 
OIS through p53/RB inhibition. It is important to note here that all cells for 
lipidomics were cultured in low serum (1% FBS) to keep the baseline of metabolism 
low. For preliminary evaluation of the samples, a Principle Component Analysis 
(PCA) was performed. It was clear from the PCA for both positive and negative ion 
modes that there were clustering of samples depending on variate, i.e. cell type and 
time point (figure 5.4). It was concluded from the PCA that senescent cells have a 
distinct lipidome, that was reversed with a bypass of senescence induced by E6/E7 
expression. 
Next, information about the specific lipid metabolic pathways implicated in OIS was 
acquired from a multivariate statistical SIMCA analysis. This analysis was 
performed to identify the lipid subspecies significantly upregulated in OIS compared 
to control. This data indicated there was a global rewiring of lipid species present 
during OIS (figure 5.5.A) and it was evident iRas had increased ceramide content 
(figure 5.5.A, yellow bars). Previously, CERS4 was validated as a lipid metabolic 
enzyme implicated in OIS and indicated ceramides are associated with OIS. Thus, to 
determine if ceramides are accumulated in OIS, the global lipidomics dataset was 
further interrogated to get predictive data for ceramide content. The abundances were 
normalised against the Total Ion Count of each sample and then normalised to 
control cells to create a heatmap. OIS caused an accumulation of most ceramides 
detected and CERS4 specific ceramides 18:0 and 22:0 were fluctuating the most, 
especially at day 8 (figure 5.5.B). From this data, it was established ceramides are 
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accumulated in OIS; however, using global lipidomics to quantify specific lipids is 
not entirely reliable, therefore targeted and quantitative ceramide analysis was next 
used to develop the global lipidomics observations. 
 
 
Figure 5.4 Principle Component Analysis for positive and negative modes of 
the global lipidomics dataset (legend next page) 
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Figure 5.4 Samples of iStop, iRas and iRas-E6/E7 were collected at day 4 and 8 of 4OHT 
treatment. Global lipidomics was performed on these samples by UHI. Cells were solvent 
extracted according to Folch’s method (Folch et al, 1957). The lipids were analysed by LC-MS in 
positive and negative ion modes using a C18 column and acetonitrile/water/propan-2-ol 
gradient. All analyses were performed on a Thermo Exactive Orbitrap mass spectrometer 
coupled to a Thermo Accela 1250 UHPLC system.  Here, a Principle Component Analysis was 
performed, using the raw LC-MS data, to compare the lipidome of each condition (detailed in the 
legend). 
4OHT = 4-hydroxytamoxifen 
 
 
Figure 5.5 OIS induces a rewiring of the lipidome and accumulates ceramide 
(A) Raw LC-MS data for iStop and iRas at day 8 were processed to identify lipid subspecies and 
subjected to multivariate statistical analysis using SIMCA-P v13.0.2 (Umetrics, Umea, Sweden). 
This analysis was used to identify the most significantly abundant lipid subspecies present in OIS 
compared to control. The number of each subspecies was calculated as a percentage of global 
lipids. The lipid subspecies for both positive and negative ion mode are detailed in the legend. 
(B) Raw LC-MS data for iStop and iRas at day 4 and 8 were processed to quantify common 
ceramides, with 18:1-sphingosine backbones. The abundance data is presented as fold change 
compared to control (iStop, day 4).  
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5.1.4 Quantitative lipidomics confirms changes in ceramide content 
during OIS 
Although the global lipidomics provided a good indication of the lipidome alterations 
OIS induces, identification of specific lipids can be inaccurate due to sub-optimal 
LC-MS parameters. Therefore, targeted and quantitative analysis of ceramides was 
performed to confirm: first, ceramides are accumulated in OIS and second, CERS4 is 
the gene responsible for the activation of ceramide biosynthesis. Control, OIS and 
CERS4-targeted cells (day 4) were subjected to quantitative ceramide analysis using 
a triple quadrupole mass spectrometer; internal standards were used to identify and 
quantify ceramides (in collaboration with UHI). Ceramides with fatty acid lengths of 
18:0 and 22:0 were significantly increased during OIS (pink bars, figure 5.6.A). This 
was likely due to ceramide synthase activity due to the significant rescue when 
CERS4 was inactivated (grey bars, figure 5.6.A). Other saturated and 
monounsaturated ceramides with 18/20/22 fatty acid chain lengths with lower 
abundances were also significantly accumulated during OIS (presented with a 
smaller y-axis range to observe changes, figure 5.6.B). For this group of ceramides, 
only 20:0 was significantly rescued with CERS4 knockdown, although 22:1 had a 
close-to-significance p-value of 0.06 (figure 5.6.B). From the quantitative ceramide 
analysis, it was concluded that the accumulation of ceramides during OIS was 
regulated by CERS4 activity. 
5.1.5 Summary 
In this section, rewiring of lipid metabolism in OIS has been identified by using a 
combination of global lipidomics and transcriptomics. There were high levels of lipid 
toxicity in OIS cells and expression of lipid metabolic pathway genes were 
significantly upregulated during OIS. These observations were dependent on CERS4. 
Quantitative ceramide analysis confirmed increased CERS4-specific ceramide 
products (18/20/22 carbon fatty acids) in OIS. Levels of these ceramides were 
rescued to control levels with CERS4 inactivation. The next aim of this chapter was 
to determine the mechanism of OIS-related ceramide synthesis. 
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Figure 5.6 CERS4-specific ceramides are accumulated in OIS 
Samples of iStop-ev, iRas-ev and iRas-shC4 were collected at day 4 of 4OHT treatment and 
subjected to quantitative ceramide analysis (UHI). Briefly, cells were solvent extracted according 
to Folch’s method (Folch et al, 1957). Ceramides were isolated by silica solid phase extraction 
(SPE) chromatography. Ceramides were identified and quantified by LC-MS in positive ion mode 
using a C8 column and acetonitrile/water/formic acid gradient. All analyses were performed on 
a Thermo TSQ Quantum Ultra triple quadrupole mass spectrometer equipped with a heated 
electrospray source (HESI) and coupled to a Thermo Accela 1250 UHPLC system. Here, the 
concentration of the ceramides was determined by comparison to calibration curves generated 
with C16:0 and C24:1 standards. The values were normalised to cellular protein content.        
(A) Cellular content of more abundant ceramides: 18:0 and 22:0. (B) Cellular content of less 
abundant ceramides: 18:1, 20:0, 20:1 and 22:1 (ALL: n=3, ±S.E.M., two-tailed Student’s t-test). 
4OHT = 4-hydroxytamoxifen, ev = pRS-empty vector, shC4 = pRS-shCERS4, * = p≤0.05, ** = 
p≤0.01, *** = p≤0.001, ns = not significant.  
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5.2 De novo ceramide synthesis increases during OIS 
The de novo pathway is one of the main means for cellular ceramide biosynthesis. 
Stable heavy-isotope labelling is a powerful approach to study the output of 
metabolic pathways. Therefore, it was decided to analyse the de novo synthesis of 
ceramides in OIS by using a heavy labelled serine molecule (2,3-13C2-serine) as a 
substrate for the first essential step of ceramide synthesis (figure 5.7). This technique, 
with accompanying lipid extraction and LC-MS method (described in 2.12), was 
designed and optimised with Joy Edwards-Hicks.  
As part of the set-up, we optimised the best label time to detect 13C2 incorporation 
into ceramides. All stable heavy-isotope labels can saturate a metabolic pathway if 
given to cells for a long enough period. Optimising the label time is a balance 
between not saturating the pathway and being able to observe differences between 
unlabelled and labelled samples. To optimise the 2,3-13C2-serine label, control and 
OIS cells (day 4 of 4OHT) were treated for short (6 hours) and long (48 hours) 
periods with 12C- and 13C2-serine. The difference between the %M+2 (i.e. the 
percentage of 13C2 present in total ceramide) for each label was used to determine 
which treatment time had the largest variance between unlabelled and labelled 
samples. Figure 5.8 shows the %M+2 for four ceramides (18:0/22:0/24:0/26:0), as a 
fold change compared to 12C of each sample. It was clear that the 6 hour treatment 
time resulted in larger changes in %M+2 in labelled samples compared to unlabelled; 
apart from 24:0-ceramide, which yielded similar %M+2 with 6 and 48 hours 
treatment. It was likely the 48 hour treatment time was saturating the de novo 
ceramide synthesis pathway. Therefore, further experiments were performed using a 
6 hour treatment time of serine. 
To determine if the de novo synthesis of ceramides is increased in OIS, the optimised 
labelling was implemented in control, OIS and OIS cells with CERS4 knockdown, at 
both day 4 and 8 of 4OHT. The %M+2 for unlabelled cells (figures 5.9.A&C) 
represents the natural abundance of M+2 ceramides (i.e. <10% of naturally abundant 
ceramides have M+2 masses). The %M+2 for labelled cells indicated OIS induces de 
novo synthesis of all ceramides detected, and this is partially CERS4 dependent 
(figures 5.9.B&D). This occurred at both day 4 (figure 5.9.B) and 8 (figure 5.9.D) of 
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4OHT, suggesting ceramide synthesis is vital for induction and maintenance of OIS. 
In conclusion, by harnessing LC-MS based stable heavy-isotope labelling, the de 
novo pathway has been identified as a mechanism for OIS-related ceramide 
synthesis. In the next section, the other main route of ceramide synthesis, the 




Figure 5.7 Schematic of 2,3-13C2-serine labelling of ceramides 
Heavy labelled serine (2,3-13C2-serine) can be used to label the de novo synthesis of ceramides. 
The two heavy carbons can be traced through the pathway to all ceramide products. CERS4 
catalyses one of the last steps in this pathway: the coupling of dihydrosphingosine with a long 
chain fatty acid to form dihydroceramide. This stable heavy-isotope labelling approach can be 
used to measure the de novo activity of CERS4.  
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Figure 5.8 Optimisation of the serine label treatment time 
iStop and iRas were treated with 12C-serine or 13C2-serine for 6 hours or 48 hours on day 4 of 
4OHT. Cells were collected and lipids were extracted using a biphasic method based on the 
Bligh and Dyer method (Bligh and Dyer, 1959). Ceramides were identified and quantified by LC-
MS in positive ion mode using a C18 column and acetonitrile/water/formic acid/propan-2-ol 
gradient. All analyses were performed on a Thermo Q-exactive mass spectrometrer coupled to a 
Thermo Ultimate BioRS HPLC. The peak areas for M+0 (m/z + no 13C) and M+2 (m/z + two 
13C) 18:1-ceramides, 18:0/22:0/24:0/26:0, were extracted using Thermo Xcalibur Quan 
Browser. The M+2 fold change was calculated compared to each 12C control sample. The legend 
indicates the colours denoting M+2 fold change. Note: first, compare 12C and 13C columns for 
each treatment time; second, compare 6h and 48h clusters. 
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Figure 5.9 OIS induces increased CERS4-dependent de novo synthesis of 
ceramides 
iStop-ev, iRas-ev and iRas-shC4 were treated with 12C-serine or 13C2-serine for 6 hours on day 4 
and 8 of 4OHT. Cells were collected and lipids were extracted using a biphasic method based on 
the Bligh and Dyer method (Bligh and Dyer, 1959). Ceramides were identified and quantified by 
LC-MS in positive ion mode using a C18 column and acetonitrile/water/formic acid/propan-2-ol 
gradient. All analyses were performed on a Thermo Q-exactive mass spectrometrer coupled to a 
Thermo Ultimate BioRS HPLC. The peak areas for M+0 (m/z + no 13C) and M+2 (m/z + two 
13C) ceramides were extracted using Thermo Xcalibur Quan Browser. The %M+2 incorporation 
into ceramides was calculated as a percentage of total ceramide: M+0 and M+2. (A) %M+2 of 
stated ceramides in unlabelled (12C-serine) cells at day 4. (B) %M+2 of stated ceramides in 
labelled (13C2-serine) cells at day 4. (C) %M+2 of stated ceramides in unlabelled (12C-serine) 
cells at day 8. (D) %M+2 of stated ceramides in labelled (13C2-serine) cells at day 8 (ALL: n=2, 
±S.D.). 
4OHT = 4-hydroxytamoxifen, ev = pRS-empty vector, shC4 = pRS-shCERS4. 
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5.3 Ceramide synthesis through the recycling pathway is not 
regulated in OIS 
In addition to the de novo pathway, cells can synthesise ceramides via the recycling 
pathway. To confirm if OIS also has upregulation of the ceramide recycling pathway, 
a 17:1-sphingosine backbone ceramide not usually present in human cells (17:1/8:0-
ceramide, see figure 5.10.A for structure) was used as a substrate for recycling 
enzymes; a similar technique was previously described by Sultan et al. (2005). In 
principle, the 17:1/8:0-ceramide would be broken down into sphingosine and fatty 
acids, and the 17:1-sphingosine reincorporated into newly synthesised ceramides. 
This incorporation of 17:1 can then be measured in lipid extracts using LC-MS. 
First, an optimisation experiment was performed to determine the best treatment time 
for IMR90. IMR90 were treated with 17:1/8:0-ceramide or ethanol vehicle for 1, 3, 
12 and 24 hours and performed lipid extractions (described in 2.12). A 17:1/8:0-
ceramide standard was analysed on the LC-MS to: (1) gain the retention time to aid 
identification and (2) ensure the correct product was supplied (figure 5.10.A). 17:1 
was incorporated into most ceramides detected, apart from ceramide-20:0 (figure 
5.10.B). This could be due to ceramide-20:0 being naturally less abundant (see y-axis 
values). The incorporation peaked after 3 hours treatment of 17:1/8:0-ceramide, 
which was particularly clear for 17:1/18:0 and 17:1/22:0 ceramides (figure 5.10.B, 
panels 1 and 3). To ensure the 17:1/8:0-ceramide treatment was not having a global 
effect on ceramide recycling, peak areas of 18:1-ceramides were also examined. 
There was no difference in 18:1-ceramide peak areas between ethanol and 17:1/8:0-
ceramide treated (figure 5.10.C), further confirming this technique was specifically 
measuring 17:1 incorporation and ceramide recycling pathway output. 
The optimised 3 hour 17:1/8:0-ceramide treatment was repeated in control, OIS and 
OIS cells with CERS4 knockdown at day 4 and 8. The %17:1 incorporation into 
ceramides was calculated as a percentage of total ceramide: 17:1 and 18:1. As 
expected, %17:1 incorporation in ethanol treated cells was low due to the low natural 
abundance of 17:1-ceramides in human cells (figures 5.11.A&C). The %17:1 
incorporation into cellular 17:1/8:0-ceramide was nearly 100% for all three cell types 
and two time points (first three bars, figures 5.11.B&D); this was due to saturation 
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during the treatment time. Looking at the longer 17:1-ceramides, there were no 
significant changes in 17:1 incorporation (figures 5.11.B&D). As with the 
optimisation experiment, there was no 17:1 incorporation into ceramide-20:0 
(compare ethanol to 17:1/8:0-ceramide treated). This data indicates there is no 
regulation of ceramide recycling in OIS and CERS4 is not implicated in this 
pathway.  
 
5.4 Chapter summary 
The aim of this chapter was to examine lipid metabolism in OIS and determine the 
metabolic function of CERS4 in OIS. First, lipid toxicity and expression of genes 
encoding lipid metabolic enzymes were both upregulated in OIS. Using global 
lipidomics, a global rewiring of the senescent lipidome was identified. As CERS4 
was previously identified as essential for OIS, quantitative lipidomics was used to 
confirm accumulated ceramide in OIS. This was dependent on CERS4 expression, 
suggesting CERS4 is functionally responsible for the synthesis of OIS-related 
ceramide. Next, the de novo pathway was identified as the mechanism of OIS-related 
CERS4-dependent ceramide synthesis, using stable heavy-isotope labelling. By 
perturbing the recycling pathway with a modified ceramide, it was found OIS does 
not upregulate this pathway of ceramide synthesis. 
In conclusion, increased ceramide content in OIS is regulated by the de novo activity 
of CERS4. This suggests OIS functionally requires ceramide, for an unknown 
reason. The final chapter focusses on identifying the function of OIS-related 
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Figure 5.10 17:1/8:0-ceramide can be used to measure ceramide recycling 
pathway output 
(A) 17:1/8:0-ceramide has a sphingosine backbone with one carbon less than 18:1-ceramides, 
which are more abundant in human cells. The 17:1/8:0-ceramide standard was analysed by LC-
MS (method below). Next, IMR90 were treated with EtOH or 17:1/8:0-ceramide for 1, 3, 12 or 
24 hours. Cells were collected and  lipids were extracted using a biphasic method based on the 
Bligh and Dyer method (Bligh and Dyer, 1959). Ceramides were identified and quantified by LC-
MS in positive ion mode using a C18 column and acetonitrile/water/formic acid/propan-2-ol 
gradient. All analyses were performed on a Thermo Q-exactive mass spectrometrer coupled to a 
Thermo Ultimate BioRS HPLC. Thermo Xcalibur Quan Browser was used to convert raw data to 
peak areas for (B) 17:1-ceramides and (C) 18:1-ceramides (ALL: n=1, ±S.D.). 
RT = retention time, EtOH = ethanol. 
 
   




Figure 5.11 Ceramide recycling pathway output is not regulated during OIS 
iStop-ev, iRas-ev and iRas-shC4 were treated with EtOH or 17:1/8:0-ceramide for 3 hours on 
day 4 and 8 of 4OHT. Cells were collected and  lipids were extracted using a biphasic method 
based on the Bligh and Dyer method (Bligh and Dyer, 1959). Ceramides were identified and 
quantified by LC-MS in positive ion mode using a C18 column and acetonitrile/water/formic 
acid/propan-2-ol gradient. All analyses were performed on a Thermo Q-exactive mass 
spectrometrer coupled to a Thermo Ultimate BioRS HPLC. The peak areas for 17:1- and 18:1-
ceramides were extracted using Thermo Xcalibur Quan Browser. The %17:1 incorporation into 
ceramides was calculated as a percentage of total ceramide. (A) %17:1 of stated ceramides in 
unlabelled (EtOH) cells at day 4. (B) %17:1 of stated ceramides in labelled (17:1/8:0-cer) cells 
at day 4. (C) %17:1 of stated ceramides in unlabelled (EtOH) cells at day 8. (D) %17:1 of stated 
ceramides in labelled (17:1/8:0-cer) cells at day 8 (ALL: n=3, ±S.E.M.). 
4OHT = 4-hydroxytamoxifen, ev = pRS-empty vector, shC4 = pRS-shCERS4, EtOH = ethanol. 
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Chapter Six: CERS4 and ceramide activate the 
PP1/RB axis of cell cycle regulation 
In the previous chapter, ceramide accumulation resulting from increased CERS4-
driven de novo ceramide synthesis was identified as a vital mechanism for OIS. The 
main aim of this chapter was to uncover the function of OIS-related ceramide, 
downstream of its synthesis. First, functional rescue experiments with exogenous 
ceramide were performed, to see if OIS bypass driven by CERS4 knockdown can be 
reversed. From this data, it was suggested that CERS4 can affect RB phosphorylation 
state, independent of p53/p21/p16, and further experiments were performed to 
explore this hypothesis. Using western blotting and qPCR, RB phosphorylation state 
and downstream effects on E2F target transcription were analysed. Lastly, the 
relationship between protein phosphatase 1 (PP1), RB and CERS4 was investigated 
using co-immunoprecipitation. This chapter describes the results that identify CERS4 
as a metabolic checkpoint, linking altered ceramide metabolism with OIS. 
Dr Andrea Quintanilla optimised and performed the immunoprecipitation 
experiments for this part of the thesis. Her data has been included as it greatly 
enhances this story and the work is acknowledged where applicable.  
 
6.1 Ceramide treatment rescues OIS in CERS4-deficient cells 
6.1.1 Ceramide reverses proliferation and SA β-gal phenotype of 
shCERS4-driven OIS bypass 
It was previously shown, using LC-MS based techniques, CERS4 knockdown 
reduces the functional activity of the enzyme. Next, experiments were performed to 
examine if the function of CERS4 in OIS can be rescued, using ceramide. Exogenous 
18:1/8:0-ceramide (henceforth C8-cer) was used because ceramides with shorter fatty 
acid chains are more cell permeable than longer ceramides. Control, OIS and OIS 
with CERS4 knockdown were treated every 24 hours with 2µM C8-cer or ethanol 
alongside 4OHT. Proliferation and SA β-gal markers were measured to observe the 
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effect of ceramide on the OIS phenotype. BrdU incorporation at day 6 showed a 
significant decrease in proliferation with ceramide treatment, in cells targeted for 
CERS4 knockdown, from 50% to 35% (figure 6.1.A). There was also a significant 
increase in SA β-gal activity, from 7% to 82% (p=0.011), after 8 days of 4OHT and 
C8-cer treatment (figure 6.1.B). Together this data suggests ceramide treatment can 
partially rescue CERS4-mediated effects in OIS. It was previously shown ceramides 
can induce senescence in a different human diploid fibroblast cell line (Venable et 
al., 1995), indicating why ceramide causes a small decrease in proliferation and 
increase in SA β-gal activity control cells. However, these changes were not 
comparable to those occurring with CERS4 knockdown, further suggesting ceramide 
treatment is truly rescuing the OIS bypass. 
6.1.2 Ceramide rescue in CERS4 deficient cells is independent of 
p53/p21 and p16  
Thus far, it was clear ceramide and CERS4 have a functional role in OIS. To 
delineate the functional mechanism of both in OIS, it was hypothesised ceramide 
could be vital for tumour suppressor activation in OIS, as previously shown for 
CERS4. Therefore, the expression of tumour suppressor proteins p53, p21CIP1 and 
p16INK4a were analysed in the rescue experiment, using immunofluorescence and 
western blotting. As expected, expression of p53, p21CIP1 and p16INK4a was 
significantly increased in OIS at day 6 (first pink bar, figure 6.2.A-C), and 
significantly rescued with CERS4 knockdown (first grey bar, figure 6.2.A-C). In 
shCERS4-driven OIS bypass, p53, p21CIP1 and p16INK4a were expressed similarly 
between ethanol and ceramide treatment (compare grey bars, figure 6.2.A-C; and 
compare lanes 5 & 6, figure 6.2.D). In contrast, the expression levels of p53, p21CIP1 
and p16INK4a decreased in OIS with ceramide treatment (compare lanes 3 & 4, figure 
6.2.D; and compare pink bars, figure 6.2.A). Overall, this data suggests CERS4 can 
regulate the expression of tumour suppressors as an indirect consequence of 
regulating cellular senescence.  
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6.1.3 Summary 
In this section, it has been shown exogenous ceramide treatment can rescue the 
effects of CERS4 knockdown (i.e. OIS-bypass), by promoting a proliferation arrest 
and SA β-gal activity. However, this proliferation arrest did not correspond with 
increased expression of tumour suppressors p53, p21CIP1 and p16INK4a. Together, this 
data implicates CERS4 and ceramide in a tumour suppressor-independent 
mechanism in OIS. However, the effect of ceramide treatment on intracellular levels 
of ceramide was not analysed. To ultimately validate the rescue experiments and 
understand the discrepancy between the effect of ceramide treatment on p21CIP1 and 
p53 expression in OIS and CERS4-depleted cells (figure 6.2.D), measurement of 
cellular ceramide content using mass spectrometry is required; this is further 
discussed in 7.4.2. The next section examines another potential functional 
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Figure 6.1 Long-term ceramide treatment partially reverses bypass of 
senescence driven by CERS4 inactivation 
iStop and iRas were infected with empty vector (ev) and a stable shRNA targeting CERS4 
expression (shC4). Cells were subjected to daily 2µM 18:1/8:0-ceramide treatment from day 0 of 
4OHT, and analysed at day 6 and 8. (A) At day 6, cells were subjected to a 17h BrdU pulse, fixed 
and stained for BrdU incorporation using immunofluorescence. BrdU positive cells were 
quantified and % positive cells calculated (n=3, ±S.E.M., two-tailed Student’s t-test). (B) At day 
8, cells were fixed and stained for SA β-galactosidase activity. SA β-gal positive cells were 
quantified from images and % positive cells calculated (bottom right) (n=3, ±S.E.M.). 
4OHT = 4-hydroxytamoxifen, BrdU = bromodeoxyuridine, ev = pRS-empty vector, shC4 = pRS-
shCERS4, EtOH = ethanol, C8-cer = 18:1/8:0-ceramide, ** = p≤0.01. 
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Figure 6.2 Tumour suppressor proteins expression levels are not altered in 
CERS4-deficient cells after ceramide treatment  
iStop and iRas were infected with empty vector (ev) and a stable shRNA targeting CERS4 
expression (shC4). Cells were subjected to daily 2µM 18:1/8:0-ceramide treatment from day 0 of 
4OHT, and analysed for tumour suppressor protein expression. Cells were subjected to 
immunofluorescence staining for (A) p53 (B) p21CIP1 and (C) p16INK4a. Positive cells were 
quantified and % positive cells calculated (ALL: n=3, ±S.E.M., two-tailed Student’s t-test).      
(D) Cell pellets were collected and lysed on day 6, and subjected to western blotting to detect 
p16INK4a, p21CIP1 and p53. Briefly, 20µg cell lysate was separated on 10-20% Tris-Glycine gels 
and subjected to western blotting of stated proteins. β-actin was used as a loading control. 
(representative of 2 independent experiments).  
4OHT = 4-hydroxytamoxifen, ev = pRS-empty vector, shC4 = pRS-shCERS4, EtOH = ethanol, 
C8-cer = 18:1/8:0-ceramide, *** = p≤0.001, **** = p≤0.0001, ns = not significant. 
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6.2 CERS4 is required for RB activation in OIS 
6.2.1 CERS4 regulates expression of E2F target genes 
The previous section showed the expression of tumour suppressors was not necessary 
for CERS4 function in OIS. As described in 1.1.2.3, retinoblastoma protein (RB) is 
also implicated in the cell cycle; RB acts as a checkpoint to regulate the expression 
of E2F target genes, such as cyclin-dependent kinases (CDKs). In proliferating cells, 
phosphorylated RB is inactivated and frees E2F transcription factors to initiate the 
transcription of genes essential for cell cycle progression (figure 1.2). In non-
proliferating cells, hypophosphorylated RB is activated and prevents transcription of 
E2F target genes. Therefore, expression of E2F target genes can be used as a readout 
for RB activity and are an indicator of cell cycle progression (Dick and Rubin, 2013). 
To examine if CERS4 regulates RB activity, the transcriptomics dataset (described in 
4.3) was utilised to determine gene expression of RB/E2F targets. A Gene Set 
Enrichment Analysis (GSEA) comparing CERS4 knockdown to OIS was performed 
by Dr Tamir Chandra (figure 6.3.A). For this analysis, a gene set annotated as targets 
of RB in senescence (designated here as RB_TARGETS_SENESCENCE, described 
by Chicas et al., 2010) was compared to all genes identified in the transcriptomics 
analysis (~15000). The grey bars (bottom panel, figure 6.3.A) represent all genes 
ranked by expression and the black lines (middle panel, figure 6.3.A) represent the 
genes annotated in RB_TARGETS_SENESCENCE. The black lines are accumulated 
in the left side of the graph, which suggests these genes are highly regulated between 
the two conditions. The green line (top panel, figure 6.3.A) represents an enrichment 
score for RB_TARGETS_SENESCENCE. The large left peak indicates there is 
enrichment of RB targets in CERS4 knockdown compared to OIS. To validate the 
GSEA observations, the expression of well-characterised RB/E2F target genes was 
measured by qPCR. These genes included cell cycle regulators CDK1/2 and DNA 
replication genes CDC6/7, PCNA, ORC1 and MCM2. As expected, OIS decreases 
expression of all E2F target genes, apart from CDK2, compared to proliferating 
control (compare black and pink bars, figure 6.3.B). The knockdown of CERS4 in 
OIS resulted in significant increased expression of all E2F target genes (grey bars, 
figure 6.3.B). This data suggests CERS4 can affect the expression of E2F target 
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genes and therefore RB activity. However, this observation could be an independent 
downstream effect of shCERS4-driven OIS-bypass, eluding the actual mechanism 
that links CERS4 and ceramide to cell cycle regulation. Therefore, the next aim was 
to interrogate RB phosphorylation after CERS4 inactivation and rescue with 
ceramide.  
 
Figure 6.3 Transcriptome data indicates CERS4 regulates RB/E2F activity 
(A) Dr Tamir Chandra performed a GSEA on the transcriptomic dataset, to analyse the 
enrichment of RB/E2F target genes compared to the total number of genes (~15000). (B) For 
validation of GSEA in (A), iStop and iRas infected with ev and shC4 were analysed for 
transcription of E2F target genes at day 8 of 4OHT. qPCR was used to detect mRNA levels of 
stated genes. β-actin was used as a housekeeping gene (n=3, ±S.E.M., two-tailed Student’s t-
test). 
* = p≤0.05, ** = p≤0.01. 
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6.2.2 CERS4 regulates RB phosphorylation in OIS and replicative 
senescence 
As discussed previously, RB has a key role in cell cycle regulation and can interact 
with many other cell cycle proteins, including other tumour suppressors. CERS4 
knockdown had a significant negative effect on expression of p53, p21CIP1 and 
p16INK4a, although ceramide treatment did not rescue this phenotype (figure 6.2). The 
transcriptomic data in the previous section indicated RB activity is regulated by 
CERS4, so the next aim was to analyse the phosphorylation state of RB, in cells with 
CERS4 knockdown. This phosphorylation state was measured by western blot for 
total RB; a low percentage gel was used to observe separation of RB (~110kDa) 
from pRB (110-116kDa). Total RB was measured for the following experiments as 
RB has many different phosphorylation sites (Rubin, 2013) and it was impractical 
and expensive to test each specific phosphorylated RB. 
First, in control cells and iRas with no 4OHT, RB is mostly phosphorylated (lanes 1-
3, figure 6.4.A). Upon 8 days of 4OHT treatment, iRas cells hypophosphorylate and 
activate RB (lane 4, figure 6.4.A), correlating with the decreased expression of 
RB/E2F targets (pink bars, figure 6.3.B). CERS4 knockdown results in similar 
phosphorylation of RB to controls (lane 5, figure 6.4.A), correlating with the 
increased expression of RB/E2F targets (grey bars, figure 6.3.B). In addition, RB 
phosphorylation state during shCERS4-driven delayed replicative senescence was 
measured. In was clear at passage 24, where the population doublings between empty 
vector and shCERS4 were most different (figure 4.7.B), depleting CERS4 resulted in 
phosphorylated RB (compare lanes 1 & 2, figure 6.4.B). This indicated the control 
cells were starting to senesce whilst cells with CERS4 targeted were delaying 
senescence.  
Together, this data indicates CERS4 does regulate RB activity and this corresponds 
with regulation of RB/E2F target expression during senescence. Next, RB 
phosphorylation state after ceramide treatment was examined to functionally link 
CERS4 and ceramide to RB activation in senescence. 
 
   





Figure 6.4 CERS4 inactivation mediates RB phosphorylation in OIS 
For detecting total RB by western blot, cell pellets were collected and lysed on stated days of 
4OHT treatment. For both (A) and (B), cell lysates were separated on 6% Tris-Glycine gels. 
Proteins were transferred onto a nitrocellulose membrane and blocked with 5% milk. Antibody 
for total RB (BD Biosciences, 554136) was incubated on the membranes and ECL used to 
visualize the bands. β-actin was used as a loading control and a 100-130kDa molecular weight 
marker was used for band identification purposes. (A) iStop and iRas were infected with empty 
vector (ev) and a stable shRNA targeting CERS4 expression (shC4). On day 8 of 4OHT, cell 
lysates were subjected to western blotting of total RB, as described above (20µg cell lysate). 
Representative of three independent experiments. (B) IMR90 infected with empty vector (ev) and 
stable shRNAs targeting CERS4 (shC4) and p53 (shP53) expression were serially passaged. At 
passage 24, cells were pelleted and subjected to western blotting of total RB, as described above 
(15µg cell lysate). Representative of three independent experiments. 
4OHT = 4-hydroxytamoxifen, ev = pRS-empty vector, shC4 = pRS-shCERS4. 
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6.2.3 Ceramide reverses CERS4-driven RB phosphorylation state   
Although data thus far indicates CERS4 has a role for RB hypophosphorylation in 
senescence, the rescue experiment with exogenous ceramide (described in 6.1) was 
repeated to confirm the functional mechanism CERS4 has in OIS. First, cells 
transiently targeted for CERS4 inactivation were treated for 24 hours with 2µM C24-
cer or DMSO on day 4 of 4OHT. C24-cer was used to see if longer chain ceramides, 
more specific to CERS4 activity, could have the same effect as short chain ceramides 
(i.e. C8-cer used in figure 6.2.D). Initially, the previous observation that CERS4 can 
regulate RB phosphorylation in OIS was confirmed when comparing the DMSO 
treated cells (compare lanes 1/3/5, figure 6.5.A). Also, C24-ceramide treatment 
rescued RB phosphorylation in CERS4 knockdown cells (compare lanes 5 and 6, 
figure 6.5.A).  
Next, RB phosphorylation was analysed in ceramide-treated passage 24 cells derived 
from those in figure 6.4.B. Cells were re-seeded and treated for 24 hours with 2µM 
C8-cer or ethanol. C8-cer (short-chain ceramide) was used for all subsequent 
experiments because titration and effects were more reproducible, possibly due to 
increased cell-permeability, compared to long-chain ceramide. Ethanol treated cells 
showed the same RB phosphorylation as the previous experiment (compare lanes 1-
2, figure 6.4.B to lanes 1/3/5 figure 6.5.B). C8-ceramide treatment did not have any 
effect on RB phosphorylation state in the three cell types tested (compare EtOH to 
C8-cer, figure 6.5.B). This suggests CERS4 and ceramide do not function via RB to 
regulate replicative senescence.  
RB phosphorylation data from figure 6.4.A were recapitulated in separate 
experiments examined at day 6 of 4OHT: control and CERS4 knockdown cells have 
phosphorylated RB (lanes 1/5, figure 6.6); OIS cells have hypophosphorylated RB 
(lane 3, figure 6.6). These cells were also subjected to daily treatment of 2µM C8-cer 
or ethanol. Ceramide treatment with CERS4 knockdown appeared to cause 
dephosphorylation of RB (compare lanes 5 & 6, figure 6.6.A). This effect was much 
clearer in a replicate experiment (figure 6.6.B).  
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In conclusion, this section has confirmed CERS4 is functionally required for RB 
hypophosphorylation during OIS but not replicative senescence. This suggests the 
requirement of CERS4 to function in senescence is dependent on the initial trigger.  
 
 
Figure 6.5 Short-term ceramide can reverse RB phosphorylation state in OIS 
cells but not replicative senescent cells 
For detecting total RB by western blot, cell pellets were collected and lysed on stated days of 
4OHT treatment. For both (A) and (B), cell lysates were separated on 6% Tris-Glycine gels. 
Proteins were transferred onto a nitrocellulose membrane and blocked with 5% milk. Antibody 
for total RB (BD Biosciences, 554136) was incubated on the membranes and ECL used to 
visualize the bands. β-actin was used as a loading control and a 100-130kDa molecular weight 
marker was used for band identification purposes. (A) iStop and iRas were subjected to reverse 
transfection with Non-Target and siCERS4 on day 2 of 4OHT and 24h 18:1/24:0-ceramide 
treatment on day 4. On day 5 of 4OHT, cell lysates were subjected to western blotting of total 
RB, as described above (15µg cell lysate). Representative of 1 experiment. (B) IMR90 infected 
with empty vector (ev) and stable shRNAs targeting CERS4 (shC4) and TP53 (shTP53) 
expression were serially passaged. At passage 24, cells were re-seeded, cultured for 48 hours 
and treated with 2µM 18:1/8:0-ceramide for 24 hours. Cells were then pelleted and subjected to 
western blotting of total RB, as described above (10µg cell lysate). Representative of three 
independent experiments. 
4OHT = 4-hydroxytamoxifen, NTP = Non-Target pool, siC4 = siCERS4, ev = pRS-empty vector, 
shC4 = pRS-shCERS4, shP = pRS-shTP53, EtOH = ethanol, C8-cer = 18:1/8:0-ceramide, C24-
cer = 18:1/24:0-ceramide. 
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Figure 6.6 Long-term ceramide reverses RB phosphorylation state in 
CERS4-driven OIS bypass 
iStop and iRas were infected with empty vector (ev) and a stable shRNA targeting CERS4 
expression (shC4). Cells were subjected to daily 2µM 18:1/8:0-ceramide treatment from day 0 of 
4OHT, and analysed for total RB expression by western blot. Briefly, 20µg cell lysate was 
separated on a 6% Tris-Glycine gel. Proteins were transferred onto a nitrocellulose membrane 
and blocked with 5% milk. Antibody for total RB (BD Biosciences, 554136) was incubated on the 
membranes and ECL used to visualize the bands. β-actin was used as a loading control and a 
100-130kDa molecular weight marker was used for band identification purposes. This was 
repeated as three independent experiments; two are presented here: (A) First replicate 
experiment (20µg cell lysate). (B) Second replicate experiment (10µg cell lysate). 
4OHT = 4-hydroxytamoxifen, ev = pRS-empty vector, shC4 = pRS-shCERS4, EtOH = ethanol, 
C8-cer = 18:1/8:0-ceramide. 
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6.2.4 Summary 
Here, it was confirmed that CERS4 is required for RB hypophosphorylation and 
subsequent E2F inhibition in OIS and replicative senescence. Using stable and 
transient knockdown of CERS4, transcriptomics was used to interrogate RB/E2F 
target gene expression and RB phosphorylation state was extensively examined by 
western blotting for total RB. Lastly, ceramide rescue experiments confirmed CERS4 
is functionally required for RB hypophosphorylation during OIS but not replicative 
senescence. In the final section, it was aimed to identify the mechanism by which 
CERS4 regulates RB. As it was suggested in 6.1, CERS4 and ceramides likely 
function in OIS independently of tumour suppressors p53/p21 and p16, therefore 
hypotheses were explored involving interactions with other regulators of RB. 
 
6.3 CERS4 drives PP1-dependent activation of RB 
From the previous two sections, it was hypothesised CERS4 is functionally linked to 
OIS via RB phosphorylation and subsequent E2F target transcription. From the 
literature, it was found ceramide is an activator of protein phosphatases (PPs) 
(Chalfant et al., 1999). PPs are regulators of RB and therefore provided a possible 
link between CERS4 and ceramides and cell cycle regulation. Considering this, the 
following hypothesis was assumed (illustrated in figure 6.7): senescence induced by 
oncogenic RasG12V promotes CERS4-mediated de novo ceramide biosynthesis and 
results in accumulated ceramide. OIS-related ceramide can activate PP to 
hypophosphorylate RB. RB is then able to bind and inhibit E2F, resulting in no 
transcription and expression of cell cycle proteins. It was preliminarily hypothesised 
PP1 being the specific protein phosphatase involved due to previous studies 
examining RB-PP1 binding (Hirschi et al., 2010; Choy et al., 2014). Furthermore, 
PP1 has been implicated in a mouse model of ras-induced senescence (Castro et al., 
2008). To initially address this hypothesis, co-immunoprecipitation (IP) experiments 
were performed to determine if PP1 and RB can bind during OIS, and if CERS4 is 
required for this interaction. These experiments were performed by Dr Andrea 
Quintanilla. To initially test the possible interaction of RB and PP1 in OIS, IP 
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conditions for RB and PP1 were optimised using control and OIS cells at day 8 of 
4OHT (figure 6.8.A). As a positive control, a western blot for total RB was tested to 
show RB was being pulled down efficiently (top blot, figure 6.8.A). A western blot 
for PP1 revealed a band in OIS cells, indicating binding of RB and PP1 specifically 
during OIS (bottom blot, compare lanes 3 & 4, figure 6.8.A). On these blots the 
arrow denotes non-specific IgGs. Next, to analyse the role of CERS4 in RB-PP1 
binding, the IPs were repeated with cells targeted for CERS4 knockdown. Again, this 
IP showed OIS-specific RB and PP1 binding and this was dependent on CERS4 
expression (middle blot, compare lanes 8 & 9, figure 6.8.B). This data links CERS4 
to PP1 that binds RB and regulates RBs E2F inhibitory function, specifically in OIS. 
This is robust evidence supporting the hypothesis that CERS4 can regulate the 
activation of PP1 and RB in OIS. Although, the rescue experiment with ceramide 
must be performed to confirm this function of CERS4 in OIS. 
 
6.4 Chapter summary 
The aim of this chapter was to identify the function of CERS4 and ceramide in OIS. 
Firstly, it was shown exogenous ceramide can rescue shCERS4-driven OIS bypass 
and is thus a functional metabolite in OIS. However, ceramide did not rescue 
p16INK4a, p21CIP1 and p53 expression, suggesting a functional mechanism 
independent of tumour suppressors. Exploring other potential mechanisms, it was 
found targeting CERS4 in OIS restored E2F target gene expression (a downstream 
readout for RB activity) and resulted in an accumulation of phosphorylated RB, in 
OIS and replicative senescence. Ceramide treatment rescued sh/siCERS4-mediated 
RB phosphorylation in OIS bypass, further indicating its functional role for OIS. 
Finally, co-immunoprecipitation confirmed CERS4-dependent RB-PP1 binding in 
OIS, physically connecting the mediators of cell cycle control in OIS. In conclusion, 
these preliminary results identify CERS4 as an essential metabolic checkpoint for the 
cell cycle arrest in OIS. Ceramide is known to activate protein phosphatases that 
regulate the hypophosphorylation of RB, therefore further experiments are required 
to assess the essentiality of ceramide for the binding of RB-PP1 and resulting 
activation of RB. 
   






Figure 6.7 Schematic summarising the hypothesis that links CERS4 and 
ceramide to the PP1/RB axis 
CERS4-mediated de novo ceramide biosynthesis is upregulated in senescence induced by 
oncogenic RasG12V. Accumulated OIS-related ceramide activates protein phosphatases to remove 
phosphates from inactivated RB, yielding hypophosphorylated RB. RB is then able to bind and 
inhibit E2F, resulting in no transcription and expression of cell cycle proteins. This process is 
results in the induction and maintenance of senescence. The red text and arrows indicate the 
hypothesis. 
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Figure 6.8 IP:RB indicates RB and PP1 binding in OIS is CERS4 dependent 
Cells were subjected to immunoprecipitation of RB. Briefly, cells were lysed on ice and pelleted. 
Supernatant was collected and some lysate reserved for an input control. IP Dynabeads Protein 
G (Invitrogen, 10003) were equilibrated in lysis buffer and either RB antibody (sc-50) or IgG 
control (sc-2027) for 1-2 hours. The remaining lysate was incubated with the equilibrated beads 
for 4-6 hours. The beads were collected using a magnet and washed in lysis buffer. After a final 
wash, proteins were eluted from beads using SDS loading buffer (see 2.7 for further detail). 
Collected samples (i.e. input and IP) were analysed for total RB and PP1 expression by western 
blot, as described previously (PP1 antibody = sc-6108). (A) Optimisation of IP. (B) IP repeated 
with CERS4-deficient cells, in control and OIS cells.  
4OHT = 4-hydroxytamoxifen, ev = pRS-empty vector, shC4 = pRS-shCERS4, WB = western blot, 
IP = immunoprecipitation, arrows = IgGs. 
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Chapter Seven: Discussion 
7.1 Summary of results 
As discussed in 1.2.3, senescent cells undergo many metabolic alterations that are 
implicated in cancer progression; therefore, the main focus of this thesis was to 
identify new metabolic regulators of OIS. High-content siRNA screening coupled 
with BrdU immunofluorescence, as a proliferation readout, was used to initially 
identify possible metabolic regulators of OIS; the use of loss-of-function siRNA 
screening is discussed below (7.2). The original primary screen, where 553 genes 
were targeted with siRNA (see Appendix 1), identified 16 genes bypassing 
senescence when knocked-down (figure 3.6 & table 3.1 for summary). 11 genes were 
implicated at day 5, an ‘early’ OIS time point; 2 genes were implicated at day 10, a 
‘late’ OIS time point; and 3 genes were implicated at both time points. Subsequently, 
the 16 genes were validated in a secondary siRNA screen. This involved 
deconvoluting the pooled siRNAs from the primary screen and setting a validation 
threshold of: genes with two or more siRNAs bypassing OIS. In addition to BrdU 
incorporation, p16INK4a and p21CIP1 expression was also assessed for more robust 
validation. 14 of the 16 hits were validated by BrdU incorporation, and a further 4 
and 5 hits showed an effect on p16INK4a and p21CIP1 expression, respectively (table 
3.3 for summary). Functional annotation of the validated hits indicated a significant 
enrichment of genes involved in lipid metabolism, including the top hit ceramide 
synthase 4 (CERS4).  
From chapter 3, it was concluded that lipid metabolism was implicated in regulating 
OIS. As current literature had not extensively studied lipid metabolism in OIS, this 
provided an attractive focus for the remainder of this thesis. In particular, the next 
aim was to thoroughly validate the top screen hit CERS4 as a regulator of OIS. In 
addition to the siRNA, shRNA stably targeting CERS4 expression was generated and 
used to identify the essentiality of CERS4 for a number of senescence markers; gene 
targeting techniques are a topic of discussion below (7.3). Bypass of OIS mediated 
by CERS4 knockdown increased proliferation, reduced SA β-galactosidase activity 
and reduced expression of tumour suppressors (p16INK4a, p15INK4b, p21CIP1 and p53) 
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and the SASP. A transcriptomic dataset was utilised for mRNA expression analysis. 
In addition, CERS4 was implicated in replicative senescence, as knockdown partially 
delayed senescence in serially passaged IMR90. Furthermore, p16INK4a but not 
p53/p21CIP1 expression was affected in this model of senescence; this result is 
discussed in further detail below (7.7.2). Finally, it was hypothesised CERS4 
functions in OIS to increase ceramide synthesis; therefore, this environment was 
recapitulated using pharmacological inhibitors of enzymes that modify ceramide. 
Inhibition of three enzymes resulted in a senescence-like cell cycle arrest in IMR90, 
indicating accumulated ceramide is required for senescence induction. 
Chapter 4 identified CERS4 as an essential lipid metabolic regulator in OIS, 
suggesting ceramide synthesis is mechanistically implicated in OIS. The next aim of 
the thesis was to analyse lipid metabolism in OIS and determine if CERS4 and 
ceramides are functionally implicated. First, the transcriptomics dataset was used to 
identify any lipid metabolic gene sets enriched during OIS. Indeed, a transcriptional 
regulatory program for many lipid metabolic pathways was identified. In addition, 
CERS4 knockdown resulted in significant transcriptional downregulation of 
ceramide metabolic pathways; these surprising observations are further discussed 
below (7.6). Next, LC-MS based global lipidomics identified a rewiring of lipid 
metabolites present in OIS and specifically, ceramides were accumulated. These 
results were validated using targeted and quantitative ceramide analysis; CERS4-
specific ceramides (18-22 carbon length fatty acids) were accumulated in OIS and 
reduced after CERS4 knockdown. Labelling studies were then used to identify the 
mechanism by which OIS-related ceramide is produced. Using stable heavy-isotope 
of serine (2,3-13C2-serine), an increase in flux through the de novo synthesis of 
ceramides pathway was identified in OIS. A modified ceramide substrate (17:1/8:0-
ceramide) was used to demonstrate the activity of the recycling pathway was not 
increased in OIS and thus was ruled out as a mechanism for OIS-related ceramide 
synthesis. The results from chapter 5 concluded that OIS has increased ceramide 
content that is regulated by the de novo activity of CERS4; discussion below 
focusses on ceramide synthases in ceramide metabolism and what other metabolic 
experiments to perform in the future (7.4).  
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The focus of the final chapter was to determine the function of OIS-related ceramide 
in OIS, and how CERS4 may be mechanistically linked to the cell cycle arrest. 
Firstly, to show that ceramide is a functional metabolite in OIS, rescue experiments 
were performed using exogenous ceramide treatment to reverse OIS bypass driven 
by CERS4 knockdown. From these experiments, it was found ceramide could not 
rescue the expression of p16INK4a, p21CIP1 and p53, suggesting their regulation by 
CERS4 is likely a consequence of its actual function in OIS (discussed in 7.7.1). 
Therefore, different downstream mechanisms of CERS4 in OIS were explored. The 
transcriptomics dataset revealed a CERS4-dependent regulation of RB targets (E2F-
driven cell cycle genes) in OIS. Furthermore, RB hypophosphorylation in OIS was 
driven by CERS4 and exogenous ceramide rescued this observation. As alluded 
previously, CERS4 functions independently of p16INK4a, p21CIP1 and p53, so 
interactions with other regulators of RB were explored. It has been previously 
described that protein phosphatase 1 (PP1) initiates RB hypophosphorylation through 
physical binding (Hirschi et al., 2010) and can be activated by ceramides (Chalfant et 
al., 1999). Therefore, it was hypothesised that OIS-related ceramide activates PP1 to 
hypophosphorylate RB and initiate cell cycle arrest through E2F inhibition. To test 
this hypothesis, co-immunoprecipitation was used to show in RB-PP1 binding was 
CERS4-dependent in OIS. Although preliminary, this data connects CERS4 to 
mediators of the cell cycle and suggests CERS4 functions as a metabolic checkpoint, 
through RB in OIS; this data is further discussed below and future work is proposed 
to validate these findings (7.8). In addition, other potential roles in senescence for 
increased ceramide metabolism and CERS activity are discussed in 7.5. 
Figure 7.1 provides a graphical summary of results described here. The remainder of 
this chapter will thoroughly discuss strengths and weaknesses of the data and 
techniques used, future work and the broader implications of these results for human 
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Figure 7.1 Summary of thesis results 
The main finding of this thesis was the identification of CERS4 as a metabolic regulator of OIS. 
Validation studies indicated CERS4 could regulate the four major markers of senescence: 
proliferation, SA β-gal, tumour suppressor expression and SASP expression. Mass spectrometry 
techniques were used to identify the de novo synthesis of ceramides as the mechanism for OIS-
related ceramide production. Ceramide can activate PP1 to physically bind and 
hypophosphorylate RB. The resulting inhibition of E2F blocks downstream transcription of E2F 
target genes involved in the cell cycle and induces senescence. This mechanism revealed CERS4 
regulation of tumour suppressors is a consequence of its role as a metabolic checkpoint. 
Red lines indicate inhibitory functions. Grey arrows indicate inhibited pathways. Black arrows 
indicate active pathways. Question marks indicate unknown mechanisms of activation. 
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7.2 Screening approaches 
RNAi is an established technique for the identification of novel regulators of 
senescence, as described in 1.3.3. The primary siRNA screen performed in this thesis 
used BrdU incorporation as the phenotypic readout of OIS, measured using 
immunofluorescence (3.1). To minimize human error and make the screen as reliable 
as possible, automation was utilised; for example, a liquidator (Mettler Toledo) was 
used for all liquid-handling steps, to minimize pipetting errors. In addition, to ensure 
both siRNA transfection and BrdU staining were reliable each plate of the siRNA 
screen was performed in triplicate. Indeed, replicates of each plate at day 5 had a 
Spearman’s rank correlation coefficient of >0.8 (figure 3.2.C&D). This is a measure 
of the strength of the relationship between replicates. A value between 0 and 1 
represents a positive correlation, however the closer to 0 the value, the worse the 
correlation. Therefore, a correlation of >0.8 for the day 5 replicates indicated good 
reproducibility. To adjust for screen-wide inconsistencies, such as edge effects, plate 
normalisation was implemented (figure 3.2.A & 3.4.A). The selected normalisation 
method used the plate median as a constant comparison for all data within that plate 
(Pelz, Gilsdorf and Boutros, 2010). Another student in the lab, Priya Hari, has 
previously shown the 96-well plates used in a HCS format have minimal edge-
effects. Although it was clear from the original distribution boxplots that there were 
only small screen-wide changes (pink boxes, figure 3.2.A & 3.4.A), normalisation 
was still used to ensure accurate data analysis. Overall, this screening platform was a 
reliable method for assessing ‘early’ OIS-bypass. Of the original 16 genes identified 
in the primary screen, 14 were validated in the secondary screen (table 3.3). Three 
genes (CERS4, GCLC and LPCAT4) were validated by BrdU, p16INK4a and p21CIP1 
expression, indicating these genes are likely to be essential for OIS. 
Although for day 5 the screen yielded excellent results that were validated, the day 
10 data had a number of issues. First, the Z’ Factors indicated poor separation 
between negative and positive controls (figure 3.4.B). This may be explained by the 
nature of established OIS (10 days of 4OHT), which is harder to bypass. The positive 
control targeting p53 struggled to overcome the stable cell cycle arrest, explaining 
the poor Z’ Factor. Second, the day 10 screen data had variable correlations (0.4-0.8) 
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between replicates (figure 3.4.C). As mentioned above, the Spearman’s rank 
correlation coefficient was used to gain information about the reproducibility 
between replicates. Although plate 7 had a good correlation of 0.8, the remainder had 
mediocre correlations. This poor reproducibility could be explained by reduced 
dynamic range; only a small population of cells are bypassing OIS, increasing 
chances for variability. To overcome variability and ensure potential hits were not 
discarded, an alternative data analysis was performed (3.1.3). Using the ‘individual 
plates’ Web CellHTS2 analysis, CERS4 was also identified as the top hit at day 10 
(figure 3.5). Four other genes were also identified using this method of data analysis, 
reinforcing the decision to use this screening protocol. Although there was variation, 
choosing the correct data analysis meant the data could still be used to gain 
significant hits. For future screens of OIS regulators, alternative experimental design 
should be considered; for example, utilising a double siRNA transfection protocol. 
This could pick up different regulators, with functions in OIS implicated after the 
standard 72 hour transfection period. 
CERS4 was chosen for follow-up studies due to a strong Z-score representing OIS-
bypass at both day 5 and 10, and the clear involvement of lipid metabolism in OIS. 
However, there were a number of other genes that could be of interest for further 
examination. For example, GCLC, another hit validated by all three secondary screen 
readouts, encodes the first rate-limiting enzyme of glutathione synthesis. Glutathione 
has previously has been shown to have a vital function in OIS-related oxidative stress 
(Zheng et al., 2015). Additionally, LPCAT4, encoding an enzyme involved in 
glycerolipid synthesis, may contribute to a different avenue of OIS-related lipid 
metabolism. Finally, functional annotation analysis (3.2.3) also found ‘proteolysis’ 
pathways (GO terms: 0030162 & 0008610) significantly enriched in the validated 
genes list (data not shown). This is of particular interest due to the importance of 
proteostasis for OIS, as described in 1.2.3.2. Further validation and mechanistic 
studies concerning these screen hits could expand current knowledge of protein 
homeostasis in OIS. 
This is the first RNAi screen described that specifically targets metabolic factors in 
OIS. Using siRNA in this targeted metabolic screen allowed the regulation of 
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expression levels, rather than complete ablation of genes. Although this method will 
not be optimum for targeting all metabolic factors, a commendable number of hits 
was yielded (~3% of starting number of genes targeted). As described above, some 
genes identified in the primary screen are broadly implicated in metabolic processes 
known to be altered in senescence. However, this is the first functional 
characterisation of an individual metabolic gene identified by RNAi screening. 
Genome-wide screens have been performed on different cellular models of 
senescence (Bishop et al., 2010; Kaplon et al., 2014), however metabolic factors 
have not been identified from these screens. This could be due to difficulty 
recapitulating results in different senescence contexts using different RNAi 
techniques; Kaplon et al. (2014) used shRNAs in BRAFV600E-induced senescent 
human diploid fibroblasts, whilst Bishop et al. (2010) used siRNA in replicative 
senescent human epithelial cells. Furthermore, known metabolic regulators of OIS 
were targeted in the primary siRNA screen but were not identified as hits. For 
example, Kaplon et al. (2013) identified pyruvate dehydrogenase (PDH) as vital for 
regulating increased TCA cycle metabolism in OIS. PDH had a Z-score of -0.99 in 
the day 5 primary screen (data not shown); this Z-score is within non-significant 
variation of the screen median, suggesting targeting PDH for loss-of-function by 
siRNA does not affect Ras-mediated senescence. The discrepancies between this 
thesis and the Kaplon et al. study could be explained by inefficient siRNA 
knockdown of PDH enzymatic activity or again, the different cellular systems used 
to model OIS. As described throughout 1.1, genetic context of senescence can have 
substantial contribution to the resulting cellular phenotype, including rewiring of 
metabolism. RasG12V-induced senescence could present with highly altered lipid 
metabolism rather than glucose metabolism (as seen with BRAFV600E) and this was 
echoed by the enrichment of lipid metabolic genes identified in the screen (table 3.2). 
 
7.3 Targeting CERS4 expression 
As described in 1.3.1, RNAi is a powerful method for targeting the expression of 
genes. The use of siRNAs in the screening was a robust technique for initial 
identification of OIS regulators, as discussed in 7.2. However, siRNAs are notorious 
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at inducing off-target effects, whereby partially complementary non-target genes are 
inadvertently targeted (Jackson and Linsley, 2010). For this work, several tactics 
were used to reduce off-target effects and validate results gained using siRNA. First, 
all siRNAs were chemically modified with a 2’-O-methyl ribosyl at position 2 of the 
sequence (Jackson et al., 2006), to reduce off-target effects (commercially referred to 
as ON-TARGETplus siRNA (Dharmacon)). Second, the siRNA reverse transfection 
protocol was optimised by Priya Hari, for a different screening project. Priya 
optimized conditions such as the siRNA concentration, transfection reagent and time, 
and cell density; if these factors are not correctly optimized, results using siRNA can 
be unreliable and inconsistent. In addition, siRNAs were introduced in IMR90s using 
a lipid-mediated transfection protocol; this could interact with siRNA targeting 
CERS4 to bias lipid metabolism in OIS. Therefore, for validation purposes it was 
essential to test other ways of targeting CERS4 expression (e.g. shRNA). An shRNA 
was generated that stably expressed the siCERS4_1 sequence (figure 4.2). An 
additional shRNA expressing the target sequence from siCERS4_4 was generated 
and showed an OIS-bypass effect measured by proliferation (data not shown); 
however, this was not as striking as the first shRNA and it was decided to proceed 
with one shRNA for further characterisation. Future attempts to knockout CERS4, 
using CRISPR, could provide further verification of CERS4s function in OIS, in 
addition to being more amenable for in vivo experiments (this is further discussed in 
7.9). 
The primary siRNA screen used pooled siRNAs, that were composed of 4 individual 
sequences targeting the same gene. For the secondary screen, the pooled siRNAs 
were deconvoluted and the effects of the individual siRNAs were assessed. With 
CERS4, there were discrepancies between the effect of individual siRNAs on BrdU 
incorporation (figure 3.10), p16INK4a expression (figure 3.12) and p21CIP1 expression 
(figure 3.13). Although CERS4 function in OIS was found to be independent of 
p16INK4a and p21CIP1 (chapter 6 and figure 6.2), this discrepancy warrants further 
discussion due to its implications in siRNA techniques. siCERS4_1 was validated by 
all three readouts, whilst the other three siRNAs were only validated by BrdU 
incorporation. This was likely due to the intensity of the effect on proliferation. 
siCERS4_1 caused a large increase in BrdU incorporation similar to positive control 
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siTP53, meaning this correlated with significantly decreased tumour suppressor 
expression. The other three siRNAs caused a smaller (but significant) increase in 
BrdU incorporation, with small effects, if any, on tumour suppressor expression. This 
observation was likely due to the efficiencies of different siRNAs on targeting 
CERS4 expression. Indeed, mRNA knockdown of the individual siRNAs correlated 
with the effect on BrdU incorporation (compare figure 4.1.A to figure 3.10). 
siCERS4_2 had the least BrdU incorporation and CERS4 mRNA knockdown. 
Accordingly, siCERS4_2 did not affect CERS4 mRNA expression but still 
influenced OIS. Generally, the optimal time for siRNA knockdown is 72 hours post-
transfection, therefore mRNA levels were measured at this time point. The optimal 
transfection time for siCERS4_2 may be shorter and by the time mRNA is measured, 
CERS4 expression is normal but the effect on proliferation remains. To address this 
issue, CERS4 mRNA expression can be assessed at multiple time points post-
transfection of siCERS4_2. Alternatively, the siRNA could be affecting CERS4 
translation without affecting transcription.  
 
7.4 Ceramide synthesis in OIS 
7.4.1 Ceramide synthase expression and activity 
The key result from this thesis was the identification of ceramide synthase 4 
(CERS4) as a regulator of OIS. It was essential to validate this finding, by 
investigating the expression and activity of CERS4 in OIS. First, CERS4 mRNA 
expression levels were measured by qPCR, to gain information about knockdown 
efficiencies and expression in OIS. As shown in figures 4.1.A and 4.2.A, both si and 
shRNA knockdown of CERS4 at day 5 and 8 of OIS were very efficient at reducing 
CERS4 mRNA levels. Unexpectedly, CERS4 expression in OIS was reduced ~50% 
compared to proliferating control, at day 5 and 8 of OIS (figure 4.1.A & 4.2.A, 
respectively). Protein levels of CERS4 could not be measured by four different 
antibodies, tested using western blotting and immunofluorescence methods (figure 
2.5). Western blot optimisation was pushed to the technique’s limits: up to 80µg of 
lysate was loaded onto SDS-PAGEs and up to 2 hour exposure times were 
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performed, and no CERS4 was detected. Although this may be due to poor antibody 
efficiency, it could also be explained by low endogenous levels of CERS4. When 
measuring CERS4 mRNA levels, the Ct values were high (~30 cycles for OIS 
samples, data not shown). This implies the starting amount of CERS4 transcript 
available for translation is low, and therefore protein levels are low. Another 
explanation may be that CERS4 is under strict transcriptional regulation, that is not 
inferred by the experiment timings used in this work. This idea is further discussed in 
7.6. 
Although there is a 50% decrease in CERS4 mRNA expression, there is increased 
CERS4 activity in OIS; CERS4-specific ceramides with 18-22 fatty acid chains are 
accumulated (figure 5.6) due to increased de novo synthesis activity of CERS4 
(figure 5.9.B&D). This large discrepancy between expression and activity could be 
due to several reasons. OIS cells could overcome the transcriptional deregulation of 
CERS4, which occurs as part of the global transcriptional regulation of lipid 
metabolism, by allosterically activating the remaining CERS4 enzyme. Allosteric 
activation involves the binding of a regulatory molecule at a site separate from the 
enzymatic active site. Allosteric activation alters the protein dynamics of the enzyme, 
resulting in conformational changes that enhance the enzymatic activity. This could 
account for faster enzyme kinetics and capacity of a single molecule of CERS4. To 
understand the enzyme kinetics, in vitro enzymology could be performed using 
recombinant CERS4 and ceramide substrate. In addition, the expression of CERS4 
could be increased early on in OIS (not measured here) and be still active when 
ceramide content was measured (day 5), perhaps due to a long half-life. Finally, sub-
cellular ceramide metabolism is highly compartmentalised (Hannun and Obeid, 
2011). CERS4 expression in OIS could be occurring in a different sub-cellular 
location that is not indicated from whole cell lysis. To address this issue, CERS4 
expression can be analysed in different cell fractions (e.g. nuclear, cytoplasmic, 
endoplasmic reticulum/Golgi, vesicles). 
Mass spec experiments measuring ceramide content and de novo flux revealed small 
but significant changes compared to the control. This effect could be explained by 
the fact CERS4 is one isoform out of a family of six ceramide synthases. Although 
   
   193 
OIS preferentially requires 18/20/22-ceramides, the synthesis of ceramides other than 
CERS4-specific products is also upregulated (figure 5.9.B&D). Additionally, there 
was a global rewiring of the lipidome in OIS (figure 5.5). This metabolic data 
suggests that OIS can alter the activity of all ceramide synthases, but specifically 
requires CERS4 to mediate this lipidomic rewiring. Furthermore, the OIS-bypass 
caused by targeting CERS4 is a striking outcome of small changes in the ceramide 
content. This indicates a delicate balance in lipid metabolism, initiated and mediated 
by CERS4, is required for robust OIS. Further interrogation of lipid metabolism 
through an OIS time course could provide further understanding of how CERS4 
mediates lipid rewiring, and how this may be connected to other OIS phenotypes, 
such as SA β-gal. 
The increase in de novo synthesis of ceramides in this OIS model could be related to 
recent work showing increased de novo serine synthesis in Kras-driven pancreatic 
and intestinal cancers in mice (Maddocks et al., 2017). Although the downstream 
mechanisms of ceramide in OIS have been deconvoluted in this thesis, and are 
further discussed below, upstream mechanisms have not been explored. The 
increased synthesis of serine in response to oncogenic Ras could be connected to 
ceramides, as serine is required for the first rate-limiting step of de novo ceramide 
synthesis (figure 1.3). In the Ras-induced senescence model used by Maddocks et al. 
(2017) the increased ceramide content could feedback to increase de novo synthesis 
of serine; this could be initially measured by expression analysis of SSP enzymes 
followed by 13C6-glucose labelling of serine and measurement of 13C6 incorporation 
into ceramides.  
7.4.2 Functional in vitro experiments perturbing ceramides  
A number of experiments were performed in this thesis that perturbed ceramide 
metabolism and measured the outcome on senescence phenotype. First, 
pharmacological inhibition of ceramide metabolic enzymes ASAH1, CERK and 
SPHK1 resulted in a senescence-like cell cycle arrest in parental IMR90 (figure 4.9). 
It was hypothesised inhibition of enzymes that metabolise ceramide results in 
accumulation of unmodified ceramide and induce senescence. However, the effect on 
ceramide levels post-treatment with the inhibitors was not determined. Although the 
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inhibitors have been confirmed in other biological systems (Graf et al., 2008; Draper 
et al., 2011; Gao et al., 2012), lipidomics must be performed to confirm levels of 
ceramide post-inhibition in IMR90 and validate the findings in section 4.5. In 
addition, the inhibitors were tested in the OIS system, however, even low doses 
resulted in cellular stress and death. This suggests ceramide metabolism is indeed a 
highly regulated process in OIS and imbalance results in catastrophic stress.  
Secondly, exogenous ceramide treatment was able to rescue the effects of CERS4 
knockdown in OIS, resulting in decreased proliferation and increased SA β-gal 
(figure 6.1). The effect of high concentration (2µM) ceramide treatment on 
intracellular levels of ceramide was not measured. Therefore, it is unknown if the 
results from the rescue experiments are truly due to ceramide entering the cell and 
compensating for lack of CERS4 activity. To address this issue, mass spectrometry 
should be used to measure ceramide levels in all of the experiments using exogenous 
ceramide. It is important to note that it is unknown how cell-permeable ceramide is. 
This issue was overcome partly by using C8-ceramide – the shorter the fatty acid 
chain the more likely the ceramide will pass through the cell membrane. Future work 
recapitulating these experiments with CERS4-specific ceramides (C18-20) would be 
more relevant and an additional vehicle to encourage cellular uptake of ceramide 
could be used. Finally, there was no rescue of tumour suppressor expression in 
CERS4-depleted cells treated with ceramide. This suggests CERS4 is 
mechanistically independent of tumour suppressors. To confirm this, ceramide 
treatment or CERS4 overexpression on OIS cells with p53, p21CIP1 or p16INK4a 
knockdown should have no effect on OIS-bypass. 
7.4.3 Approaches to measure ceramide synthesis 
As described in 1.2.1, LC-MS is an accurate method to measure metabolites in many 
different biological scenarios. For this thesis, lipids were extracted from cultured 
cells under several different conditions. It was vital to optimise the LC-MS methods 
to gain as much information as possible from the lipidomics experiments (figures 5.8 
& 5.10). Once optimised, all ceramides were identified by the presence of a fragment 
at 264.2682 m/z and retention time. Overall, the LC-MS approaches used in this 
thesis provided accurate readouts of ceramide metabolism. In addition, this is a novel 
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description of ceramide synthesis interrogation in human cells, using a combination 
of 2,3-13C2-serine and 17:1/8:0-ceramide to measure de novo and recycling ceramide 
synthesis, respectively. For future work, deconvoluting the links between glucose 
and lipid metabolism could provide further insight into OIS metabolism rewiring. As 
described in 1.2.3.1, a metabolic switch from glycolysis to the TCA cycle occurs in 
OIS, controlled by PDH activity (Kaplon et al., 2013). This could be linked to 
increased ceramide synthesis through citrate and acyl-CoA; this hypothesis could be 
examined using a glucose with suitably labelled carbon(s) to trace from the TCA 
cycle to ceramides. Furthermore, the accumulation of ceramides could be related to 
increased glucose consumption and subsequent proteoxic response observed in 
therapy-induced senescence by Dörr et al. (2013). Finally, the role of RB as a 
mediator of glucose metabolism in OIS (Takebayashi et al., 2015) may also be linked 
to ceramide metabolism, and warrants further investigation. 
In addition to LC-MS approaches, imaging methods to examine the sub-cellular 
compartmentalisation of ceramide synthesis in OIS could be used to reveal 
mechanistic information about how senescent cells physically accommodate rewired 
ceramide metabolism. This proved to be important for the characterization of the 
TASSC in OIS, described by Narita et al. (2011) (1.2.3.2). The de novo synthesis of 
ceramides occurs in the endoplasmic reticulum, whilst the recycling pathway occurs 
mostly in the lysosomes (Hannun and Obeid, 2008). One would expect, due to 
increased lysosomal content in senescence (Kurz et al., 2000), that the recycling 
pathway is activated; however, this is not the case, as proven with 17:1/8:0-ceramide 
labelling (figure 5.11). Moreover, the function of lysosomal SA β-galactosidase 
activity is unknown and could be linked to ceramide metabolism through complex 
galacto-sphingolipids. Thus, understanding the compartmentalisation of lipid 
metabolism, particularly ceramides, could answer long-standing questions in the 
senescence research field. However, lipids are much smaller than proteins and could 
be technically difficult to image without probes that do not disrupt the local 
environment (Schultz et al., 2010). The recent advance in imaging-mass 
spectrometry (iMS) technologies may avoid such technical issues. iMS resolves m/z 
of molecular species to ion maps of an in situ biological sample (Harkewicz and 
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Dennis, 2011). iMS is generally used on tissues, particularly in clinical settings, but 
there is scope for the technique to identify sub-cellular locations of metabolites. 
 
7.5 Role of ceramide and ceramide synthases in senescence 
It has been concluded from this thesis that CERS4-synthesised ceramide acts in a 
metabolic checkpoint to activate PP1-mediated RB dephosphorylation and initiate 
cell cycle arrest. This mechanism correlates with current mechanistic knowledge 
regarding ceramides and senescence (1.2.4.3). However, an additional hypothesis not 
considered here is the role ceramide plays in cell membranes. Senescent cells are 
generally very enlarged and have increased vesicle content (Serrano et al., 1997). 
Therefore, increased ceramide content, and altered lipidome as a whole, could be 
linked to the considerable production of lipid bilayers for cellular membranes during 
senescence. As reported by Atilla-Gokcumen et al. (2014), atomic force microscopy 
can be used to determine mechanical properties of cell membranes. This approach 
could be used to examine the effect of CERS4 depletion on the cell membrane of 
bypassed cells, compared to both proliferating and senescent cells. In addition, if a 
working CERS4 antibody is available, co-staining with vesicular proteins could be 
used asses the role CERS4 plays in vesicle formation. This could also determine if 
there is a physical link between subcellular location of CERS4-driven ceramide 
synthesis and sites where cellular membranes are required. 
Ceramides have previously been implicated in replicative senescence and aging-
related pathologies. Current knowledge also indicates cancer cells downregulate 
ceramide biosynthesis by overexpressing ceramide metabolic enzymes (1.2.4). 
However, this work is the first indication that ceramide accumulation is a 
characteristic of OIS. This thesis also presents CERS4 as a key mediator of OIS, and 
correlates with the cancer attenuation effect of CERS4-synthesised ceramide reported 
by Gencer et al. (2017). Although in vivo data is lacking (7.9 for further discussion), 
this thesis identifies a promising novel metabolic pathway, regulated by many 
different genes, to further investigate for cancer therapeutic development. 
Furthermore, this work has preliminarily identified other genes encoding metabolic 
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proteins (table 3.3), that may provide additional novel OIS mechanisms to explore 
for cancer therapeutic potential.  
As described in 1.2.4.4, there has been some research in combining traditional cancer 
chemotherapy with increasing ceramide levels. This can be achieved by either 
activating ceramide synthesis enzymes or inhibiting ceramide metabolic enzymes or 
introducing exogenous ceramide. These approaches have shown to increase 
sensitivity of cancer cells in vitro to chemotherapy-induced apoptosis. The work 
from this thesis suggests there is a balance of ceramide metabolism that is 
differentially altered in senescence and cancer. In theory, this metabolic balance 
could be targeted pharmacologically to induce senescence in tumours, in 
combination with induction of senescent cell apoptosis and clearance. This approach 
is similar to the synthetic lethal metabolic targeting of senescent cells in an in vivo 
cancer model, performed by Dörr et al. (2013). For example, NVP-231 is an inhibitor 
of ceramide kinase and results in accumulated unmodified ceramide (although this 
has not been proven by mass spectrometry, 7.4.2). In principle, NVP-231 could be 
used to induce senescence of cancer cells, as already shown for human cell in vitro 
(Pastukhov et al., 2014). The senescent lesion can be subsequently targeted for 
apoptosis and clearance by the immune system. In conclusion, this scientific 
evidence presented in this thesis warrants further work analysing the effect of 
targeting ceramide metabolism for cancer therapy.  
 
7.6 Transcriptional regulation of lipid metabolism in OIS 
It is evident that senescence causes unique gene expression patterns, that are 
regulated by SAHFs (1.1.2.4); however, the global transcriptional regulation of lipid 
metabolism observed in this thesis is remarkable (figure 5.1). Transcriptomics 
revealed OIS modifies transcription of many different lipid metabolic pathways, 
including transport, storage and synthesis. Moreover, targeting CERS4 expression 
significantly reversed this global modification of lipid metabolic pathways, not just 
ceramide-related pathways (figures 5.1 & 5.2). Although, further qPCR validation of 
specific lipid metabolic genes is required; it can be concluded from this data that OIS 
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induces a tightly regulated lipid metabolic gene transcriptional program and CERS4 
is an essential mediator of this regulation. Furthermore, CERS4 has a homeobox 
domain (Holland, Booth and Bruford, 2007), that have well-known transcriptional 
regulatory activity through DNA-binding. This suggests how CERS4 may be linked 
to the regulation of lipid metabolic gene expression in OIS. This function of CERS4 
is discussed further in 7.7.2, in terms of p16 transcription. 
Throughout this thesis, CERS4 has been associated with both the initiation and 
maintenance of OIS. To confirm this, it would be important to analyse both the 
transcriptome and lipidome in a time course of OIS, using comprehensive 
sequencing and mass spectrometry technologies. This could be performed initially in 
vitro using the IMR90-ER:Ras 4OHT-inducible system. Subsequently, an in vivo 
panel of normal, senescent and cancerous tissues (such as the PanINs described in 
7.9) could be utilised to gain data more relevant to humans. A time course would 
yield vital information about the regulation of the transcription of CERS4 and related 
genes, in parallel with their activity. This information should be carefully considered 
if lipid metabolism in OIS becomes a potential target for cancer therapy, to ensure 
the optimum effectiveness.  
 
7.7 Regulation of tumour suppressors by CERS4 
7.7.1 CERS4 function in OIS is independent of p16INK4a, p21CIP1 and p53 
It was evident from the secondary siRNA screen that CERS4 can regulate the 
expression of p16INK4a and p21CIP1 (figure 3.12 & 3.13). Further validation of these 
observations was performed in chapter 4; additionally, CERS4 regulates p53 
protein/mRNA expression and CDKN2B (p15INK4b) expression (figure 4.3 & 4.4). 
The identification of the mechanism that links CERS4 and OIS-related ceramide to 
the cell cycle revealed CERS4-driven regulation of tumour suppressors is a 
consequence of its actual function in OIS. Initially, rescue experiments indicated that 
ceramide, as a functional metabolite of CERS4, can reverse proliferation and SA β-
gal activity (figure 6.1) but not tumour suppressor protein expression (figure 6.2). 
CERS4 was then implicated in the PP1-RB axis of cell cycle regulation (as discussed 
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in 7.8). There could be a number of reasons why and how CERS4 inadvertently 
regulates tumour suppressors in OIS. For example, it is evident that CERS4 is a 
central mediator of the OIS transcriptional program, thus could regulate tumour 
suppressor expression through this function. Additionally, there may be a positive 
feedback mechanism occurring; whereby, p21CIP1 and p53 are activated through the 
DDR and p16INK4a through oncogenic stress. Their expression is reinforced by 
CERS4 (by an unknown mechanism) to ensure the inhibition of CDKs and continual 
hypophosphorylation of RB. Additionally, as CERS4 is essential for the expression 
of the SASP (4.3), it could be mediating an autocrine program contributing to 
senescence maintenance (described in 1.1.2.6). To test this hypothesis, an interaction 
experiment could identify novel binding partners of CERS4 and suggest implicated 
signalling pathways. Further to this, CERS4 could be regulating tumour suppressor 
signalling through its product ceramide, which is a well-established signalling 
molecule (Hannun and Obeid, 2008). Overall, in response to oncogene activation, 
CERS4 can indirectly regulate tumour suppressor expression to maintain the cell 
cycle arrest. This suggests a complex mechanism that links altered metabolism to 
well-characterised OIS programs. 
7.7.2 CERS4 regulation of p16INK4a in replicative senescence 
As described in 1.1.4.2, p16INK4a is a functional biomarker for aged tissues and is 
triggered independently of telomere shortening (Herbig et al., 2004). Therefore, 
p16INK4a expression must be controlled through an alternative mechanism; 
specifically, the INK4A locus (encoding p16INK4a) is transcriptionally regulated 
through histone modifications and polycomb proteins. In this thesis, targeting 
CERS4 expression in IMR90s partially delayed replicative senescence (figure 4.7) 
and resulted in repressed p16INK4a expression (figure 4.8). Due to this works focus on 
OIS and cancer, the regulation of p16INK4a by CERS4 in replicative senescence was 
not examined further. Here, several follow up experiments are hypothesized to 
ascertain the relationship between CERS4 and p16INK4a. First, it would be interesting 
to analyse the effect of targeting CERS4 on CDKN2A mRNA expression during 
replicative senescence. It would be expected that due to the complete reduction in 
p16INK4a protein after CERS4 knockdown, that the transcription of its gene is also 
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repressed. Second, to understand the mechanism of repressed p16INK4a with CERS4 
knockdown in replicative senescence, the function of the homeobox domain of 
CERS4 should be assessed (introduced in 7.6). As stated above, the INK4A locus is 
normally repressed through polycomb proteins, which themselves are recruited 
through homeobox proteins (HOX) (Martin et al., 2013). Chromatin 
immunoprecipitation experiments could be performed to determine (1) if the CERS4 
through its homeobox domain can bind to INK4A promoter DNA and (2) whether 
this functions to inhibit HOX recruitment of polycomb proteins, resulting in 
transcriptional activation of the INK4A locus. Although identified in the replicative 
senescence model, p16INK4a is also regulated by CERS4 during OIS (figure 4.3), 
albeit due to its PP1-activating function. Therefore, understanding the molecular 
mechanisms behind CERS4 regulation of p16INK4a expression could have 
implications for both aging and cancer biology. 
 
7.8 CERS4 regulation of PP1-RB-E2F axis 
It was originally hypothesised that CERS4 could drive RB-PP1 binding using 
previously published evidence; first, ceramides can activate protein phosphatases 
(Chalfant et al., 1999) and second, RB has a docking site for PP1 that inhibits CDK 
binding and facilitates RB hypophosphorylation (Hirschi et al., 2010). Therefore, to 
link these two facts, co-immunoprecipitation was used to show in RB-PP1 can bind 
in OIS in a CERS4-dependent manner (figure 6.8). Although ceramides have already 
been implicated in replicative senescence and cell cycle control (1.2.4), this is the 
first proposed functional mechanism of specifically de novo synthesised ceramide in 
OIS, (summarised in figure 7.1). To verify the role of PP1 in OIS, the ceramide 
rescue experiment (described in 6.1) could be repeated in the presence or absence of 
PP1. If ceramide is indeed activating PP1 to hypophosphorylate RB in OIS, one 
would expect reducing PP1 expression will prevent ceramide from reversing 
shCERS4-driven OIS-bypass. This would also further confirm the tumour 
suppressors are not implicated in CERS4s checkpoint function. Next, repeating the 
RB-PP1 co-immunoprecipitation with ceramide rescue is an essential experiment to 
demonstrate CERS4 is functionally required for this interaction. Additionally, PP1-
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activated RB hypophosphorylation results in the inactivation of E2F-driven 
transcription in OIS, as indicated by mRNA expression of E2F target genes (figure 
6.3). For further mechanistic insight of CERS4s role as a metabolic checkpoint, it is 
vital to determine its necessity for RB-PP1-E2F binding using more complex 
immunoprecipitations. Furthermore, it must be determined which E2F transcription 
factors are implicated in this cell cycle checkpoint. All these experiments must be 
performed with the ceramide rescue for confirmation of CERS4s function. Finally, 
the CDK-driven phosphorylation of RB can occur at multiple different sites and 
different phospho-sites can modulate the function of RB (Dick and Rubin, 2013; 
Rubin, 2013). Therefore, identifying the sites at which RB is phosphorylated in OIS-
bypass driven by CERS4 knockdown could reveal further insight to the overlapping 
checkpoint functions of RB and CERS4. 
 
7.9 In vivo research 
The in vitro experiments performed in this thesis were necessary for the 
identification and validation of CERS4 as a novel regulator of OIS. Importantly, this 
work has also identified the mechanistic function of CERS4 in OIS. However, as 
with all biological processes, OIS can present differently in vivo (described 
throughout 1.1), therefore it is essential to determine if this work can be replicated in 
a relevant cancer in vivo model. Additionally, cultured cells do not represent the 
complex environment of a pre-cancerous lesion. Overall, the use of in vivo models 
will confirm if this work is relevant for human health and disease, and if ceramide 
metabolism is a candidate target for therapy. Until this work is recapitulated in vivo, 
thoughts of how CERS4 and ceramide metabolism may be implicated in human 
cancers are wholly speculative. 
An initial in vivo readout could be used to analyse ceramide metabolism in sections 
of mouse and human senescent tissues. One well-established in vivo model of OIS is 
the pancreatic intraepithelial neoplasms (PanINs) that are a precursor for invasive 
ductal adenocarcinoma of the pancreas (PDAC) (Caldwell et al., 2012; Distler et al., 
2014). Both mouse and human tissue panels that progress from normal tissue to 
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senescent PanIN to cancerous PDAC are available for immuno-staining, and have 
been exploited for several OIS studies (Acosta et al., 2013; Hoare et al., 2016). 
Unfortunately, CERS4 is a poorly characterised gene/protein, thus suitable human 
and mouse antibodies are required for future expression analysis. In addition, CERS4 
appears to have low expression in OIS (figure 4.1.A) but its activity is increased 
(chapter 5). Even if a decent antibody was produced for CERS4 there may not be any 
detectable changes in expression in the PanIN model. Therefore, the use of more 
complex in vivo models may be prudent, for measurement of metabolic activity. 
As described in 1.1.3.2, there are many oncogenes recognised to induce senescence, 
in addition to a specific senescence associated with tumour suppressor loss (PICS). It 
is essential to determine if results from this thesis, that used Ras-induced senescence, 
can be recapitulated in other models of OIS. The mechanisms of OIS are highly 
dependent on genetic context and this must be understood and considered before 
developing therapies targeting ceramide metabolism in cancer. It would be 
particularly interesting to study the role of ceramide metabolism in OIS and obesity-
related cancers, due to the obvious imbalance in lipid metabolism that occurs in 
obese tissues. Finally, ceramides also function in human skin physiology 
(Meckfessel and Brandt, 2014), thus recapitulating results in a BRAF-induced 
senescence model of melanocytic nevi (Michaloglou et al., 2005) could have 
implications for melanoma tumourigenesis. 
Furthermore, this thesis has identified increased ceramide content through the de 
novo synthesis pathway in OIS (figures 5.6 & 5.9). As described in 1.2.4 (figure 1.3), 
the de novo synthesis of ceramides involves a series of reactions catalysed by four 
enzymes; some of these enzymes have many isoforms, like the ceramide synthases. 
Thus, to fully understand the role of ceramide synthesis in OIS, it may be beneficial 
to analyse different de novo ceramide synthetic enzymes. For initial analysis of other 
de novo ceramide synthesis enzymes, the cBioPortal open access platform for cancer 
genomics data (Cerami et al., 2012; Gao et al., 2013) was used to explore genomic 
alterations in human cancers. KDSR was found to be deleted in 19.3% and 8.2% 
cases of human pancreatic and prostate cancers, respectively (data not shown). This 
could be of interest to OIS research for two reasons; first, these two tissues are 
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widely implicated to induce senescence in response to pre-cancerous growth. 
Second, KDSR is encoded by the q21 locus of chromosome 18, closeby to tumour 
suppressor SMAD4 (NCBI, 2004). This may imply de novo synthesis of ceramides is 
genetically deregulated alongside mutated SMAD4, providing the two hits required 
for pancreatic and prostate cancer to progress. KDSR is a single isoform enzyme, 
therefore depleting KDSR levels may result in more striking effects in ceramide 
metabolism and subsequent OIS phenotype than targeting CERS4. KDSR was 
included in the primary screen and had a Z-score of 0.15 at day 5 (data not shown); 
KDSR was possibly not a screen hit due to siRNA inefficiencies. These observations 
suggest using cBioPortal to support in vitro experiments can reveal alternative and 
more intuitive approaches to investigate metabolic pathways. 
Finally, CERS4 is implicated in replicative senescence (figure 4.7-4.8), therefore it 
may be of interest to perform in vivo analysis on aged tissues, such as the BubR1 
progeroid mouse model (Baker et al., 2008). Using the INK-ATTAC mouse (Baker 
et al., 2011) to combine ablation of p16 and CERS4, may provide further insight into 
the role CERS4 plays for p16 regulation in replicative senescence, as discussed in 
7.7.2. 
 
7.10 Final conclusions 
Oncogene-induced senescence is a stable cell cycle arrest, employed to protect cells 
from cancer. Although recently OIS has been an intriguing topic for cancer 
therapeutic research, more insight to the mechanisms that control OIS is required. 
Metabolism of senescent cells is highly altered and metabolic regulators could be 
attractive targets for novel cancer therapies. This thesis aimed to identify novel 
metabolic regulators of OIS and determine the upstream/downstream mechanisms 
that link the identified factors to cell cycle arrest. This thesis has identified and 
validated CERS4 as a regulator of OIS and found increased de novo synthesis 
activity of CERS4, correlating with accumulated ceramides in OIS. CERS4 is 
mechanistically linked to cell cycle via the PP1-RB-E2F axis. CERS4 is also 
required for replicative senescence, suggesting this lipid metabolic checkpoint is 
   
   204 
implicated in aging-related diseases, in addition to cancer. Future work must focus 
on confirming the function of CERS4 and ceramides in OIS using models more 
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Appendix 1 
The table below has information about the 553 genes targeted in the primary siRNA 
screen, described in 3.1.
 
 
Gene Symbol Gene ID 
1 A4GALT 53947 
2 AASDHPPT 60496 
3 ABHD5 51099 
4 ACAA2 10449 
5 ACACA 31 
6 ACACB 32 
7 ACAD11 84129 
8 ACAD8 27034 
9 ACADL 33 
10 ACADM 34 
11 ACADS 35 
12 ACADVL 37 
13 ACER1 125981 
14 ACER2 340485 
15 ACER3 55331 
16 ACLY 47 
17 ACOT8 10005 
18 ACOX1  51 
19 ACOX2  8309 
20 ACOX3  83110 
21 ACSL1 2180 
22 ACSL3 2181 
23 ACSL4 2182 
24 ACSL5 51703 
25 ACSL6 23305 
26 ACSM1 116285 
27 ACSM2A 123876 
28 ACSM2B 348158 
29 ACSM3 6296 
30 ACSS1 84532 
31 ACSS2 55902 
32 ADCY6 112 
   
   
 Gene Symbol Gene ID 
33 ADH1B 125 
34 ADSL 158 
35 ADSS 159 
36 AGER 177 
37 AGK 55750 
38 AGMO 392636 
39 AGPAT1 10554 
40 AGPAT2 10555 
41 AGPAT3 56894 
42 AGPAT4 56895 
43 AGPAT5 55326 
44 AGPAT6 137964 
45 AGPAT9 84803 
46 AGPS 8540 
47 AIFM1 9131 
48 AIFM2 84883 
49 AKR1A1 10327 
50 AKR1B1 231 
51 AKR1C1 1645 
52 ALDH1A1 216 
53 ALDH1A2 8854 
54 ALDH2 217 
55 ALDH3A2 224 
56 ALDH5A1 7915 
57 ALDH8A1 64577 
58 ALDOA 226 
59 ALDOB 229 
60 ALDOC 230 
61 ALG9 79796 
62 ALOX12 239 
63 ALOX12B 242 
64 ALOX15 246 
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65 ALOX15B 247 
66 ALOX5 240 
67 AMD1 262 
68 AMPD1 270 
69 AMPD2 271 
70 AMPD3 272 
71 APRT 353 
72 ARNT 405 
73 ARSG 22901 
74 ASAH1 427 
75 ASAH2 56624 
76 ASAH2C 653365 
77 ASPH 444 
78 ASS1 445 
79 ATG3 64422 
80 ATG7 10533 
81 ATIC 471 
82 ATP5G1 516 
83 AWAT1 158833 
84 AWAT2 158835 
85 B3GALNT1 8706 
86 B3GALT1 8708 
87 B3GALT4 8705 
88 B3GNT5 126792 
89 B4GALNT1 2583 
90 B4GALT1 2683 
91 B4GALT6 9331 
92 BAD 572 
93 BAK1 578 
94 BAX 581 
95 BCKDHA 593 
96 BCL2 596 
97 BCL2A1 597 
98 BCL2L1 598 
99 BCL2L10 10017 
100 BCL2L11 10018 
101 BCL2L13 23786 
102 BCL2L14 79370 
103 BCL2L2 599 
104 BDH1  622 
105 BDH2 56898 
106 BID 637 
107 BOK 666 
108 BPGM 669 
109 C14ORF1 11161 
110 CAD 790 
111 CBR4 84869 
112 CDIPT 10423 
113 CDS1 1040 
114 CDS2 8760 
115 CEPT1 10390 
116 CERK 64781 
117 CERS1 10715 
118 CERS2 29956 
119 CERS3 204219 
120 CERS4 79603 
121 CERS5 91012 
122 CERS6 253782 
123 CH25H 9023 
124 CHDH 55349 
125 CHKA 1119 
126 CHPT1 56994 
127 COQ7 10229 
128 COQ7 10229 
129 COX5A 9377 
130 COX7B 1349 
131 CRLS1 54675 
132 CS 1431 
133 CTH 1491 
134 CYC1 1537 
135 CYCS 54205 
136 CYP2S1 29785 
137 CYP51A1 1595 
138 DEGS1 8560 
139 DEGS2 123099 
140 DGAT1 8694 
141 DGAT2 84649 
142 DGAT2L6 347516 
143 DGKE 8526 
144 DHCR24 1718 
145 DHCR7 1717 
146 DHFR 1719 
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147 DHODH 1723 
148 DHRS7 51635 
149 DLAT 1737 
150 DLD 1738 
151 DLST 1743 
152 DOLK 22845 
153 DOLPP1 57171 
154 DPAGT1 1798 
155 DPM1 8813 
156 DPYSL2 1808 
157 EBP 10682 
158 ECHS1 1892 
159 EIF2AK4 440275 
160 ELOVL1 64834 
161 ELOVL2 54898 
162 ELOVL3 83401 
163 ELOVL4 6785 
164 ELOVL5 60481 
165 ELOVL6 79071 
166 ELOVL7 79993 
167 ENO1 2023 
168 ENO2 2026 
169 ENO3 2027 
170 EPAS1 2034 
171 EPT1 85465 
172 FA2H 79152 
173 FADS1 3992 
174 FADS2 9415 
175 FADS3 3995 
176 FADS6 283985 
177 FAH 2184 
178 FASN 2194 
179 FBP1 2203 
180 FBP2 8789 
181 FDFT1 2222 
182 FDPS 2224 
183 FH 2271 
184 FIG4 9896 
185 FMO2 2327 
186 FOXO1 2308 
187 FOXO3 2309 
188 G6PD 2539 
189 GAL3ST1 9514 
190 GALC 2581 
191 GALNT6 11226 
192 GAMT 2593 
193 GAPDH 2597 
194 GART 2618 
195 GBA 2629 
196 GBA2 57704 
197 GBA3 57733 
198 GCLC 2729 
199 GGPS1 9453 
200 GJA1 2697 
201 GK 2710 
202 GLA 2717 
203 GLB1 2720 
204 GLS 2744 
205 GLS2 27165 
206 GLUD1 2746 
207 GLUL 2752 
208 GMPR 2766 
209 GMPS 8833 
210 GNPAT 8443 
211 GOT1 2805 
212 GOT2 2806 
213 GPAM 57678 
214 GPAT2 150763 
215 GPD1 2819 
216 GPD2 2820 
217 GPI 2821 
218 GPT 2875 
219 GPT 2875 
220 GPX3 2878 
221 GSR 2936 
222 GSS 2937 
223 GSTA1 2938 
224 GSTA2 2939 
225 GSTA3 2940 
226 GSTA4 2941 
227 GSTA5 221357 
228 GUCY1A3 2982 
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229 GUCY1B3 2983 
230 GXYLT2 727936 
231 HADH 3033 
232 HADHA 3030 
233 HADHB 3032 
234 HDC 3067 
235 HEXB 3074 
236 HGPRT 5651628 
237 HIF1A 3091 
238 HK1 3098 
239 HK2 3099 
240 HK3 3101 
241 HMGCL  3155 
242 HMGCR 3156 
243 HMGCS1 3157 
244 HMGCS2 3158 
245 HPGDS 27306 
246 HSD17B4 3295 
247 IDH1 3417 
248 IDH2 3418 
249 IDI1 3422 
250 IDI2 91734 
251 INPP5E 56623 
252 ISYNA1 51477 
253 KDSR 2531 
254 KEAP1 9817 
255 KYNU 8942 
256 LARGE 9215 
257 LCAT 3931 
258 LCLAT1 253558 
259 LDHA 3939 
260 LDHB 3945 
261 LDHC 3948 
262 LIAS 11019 
263 LIPC 3990 
264 LIPE 3991 
265 LIPG 9388 
266 LIPT2 387787 
267 LPCAT1 79888 
268 LPCAT2 54947 
269 LPCAT3 10162 
270 LPCAT4 254531 
271 LPGAT1 9926 
272 LPIN1 23175 
273 LPIN2 9663 
274 LPIN3 64900 
275 LPL 4023 
276 LSS 4047 
277 LYPLA1 10434 
278 LYPLA2 11313 
279 MAN1C1 57134 
280 MAT1A 4143 
281 MAT2A 4144 
282 MAT2B 27430 
283 MBOAT1 154141 
284 MBOAT2 129642 
285 MBOAT7 79143 
286 MCCC2 64087 
287 MCL1 4170 
288 MDH1 4190 
289 MDH2 4191 
290 ME1 4199 
291 ME2 4200 
292 MECR 51102 
293 MGLL 11343 
294 MOGAT1 116255 
295 MOGAT2 80168 
296 MOGAT3 346606 
297 MOXD1 26002 
298 MOXD1 26002 
299 MPC1 51660 
300 MPC2 25874 
301 MSMO1 6307 
302 MTHFD1 4522 
303 MTM1 4534 
304 MTMR3 8897 
305 MTOR 2475 
306 MTR 4548 
307 MVD 4597 
308 MYC 4609 
309 NAMPT 10135 
310 NCEH1 57552 
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311 NDUFA2 4695 
312 NDUFAB1 4706 
313 NDUFB6 4712 
314 NDUFS8 4728 
315 NDUFV2 4729 
316 NEU1 4758 
317 NFE2L2 4780 
318 NMNAT1 64802 
319 NMNAT2 25057 
320 NMNAT3 349565 
321 NQO1 1728 
322 NRF1 4899 
323 NSDHL 50814 
324 NT5E 4907 
325 NUAK1 9891 
326 OCRL 4952 
327 ODC1 4953 
328 OGDH 4967 
329 OLAH 55301 
330 ORMDL1 94101 
331 ORMDL2 29095 
332 ORMDL3 94103 
333 OXSM 54995 
334 P4HA1 5033 
335 P4HA2 8974 
336 PAH 5053 
337 PCK1 5105 
338 PDE5A 8654 
339 PDHA1 5160 
340 PDHA2 5161 
341 PDHB 5162 
342 PDHX 8050 
343 PDK1 5163 
344 PDK4 5166 
345 PDP2 57546 
346 PECR 55825 
347 PEMT 10400 
348 PEX2 5828 
349 PFKFB3 5209 
350 PFKFB4 5210 
351 PFKL 5219 
352 PFKM 5213 
353 PFKP 5214 
354 PGAM1 5223 
355 PGAM2 5224 
356 PGAM4 441531 
357 PGD 5226 
358 PGK1 5230 
359 PGK2 5232 
360 PGLS 25796 
361 PGM2L1 283209 
362 PGS1 9489 
363 PI4K2A 55361 
364 PI4KA 5297 
365 PI4KB 5298 
366 PIK3C2A 5286 
367 PIK3C2B 5287 
368 PIK3C2G 5288 
369 PIK3CA 5290 
370 PIK3CB 5291 
371 PIK3CD 5293 
372 PIK3CG 5294 
373 PIK3R1 5295 
374 PIKFYVE 200576 
375 PIP5K1A 8394 
376 PISD 23761 
377 PKLR 5313 
378 PKM 5315 
379 PLA1A 51365 
380 PLA2G15 23659 
381 PLA2G1B 5319 
382 PLA2G4A 5321 
383 PLA2G4B 100137049 
384 PLA2G4C 8605 
385 PLA2G4F 255189 
386 PLA2G5 5322 
387 PLA2G6 8398 
388 PLCB1 23236 
389 PLCE1 51196 
390 PLD1 5337 
391 PLSCR1 5359 
392 PLSCR2 57047 
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393 PLSCR3 57048 
394 PLSCR4 57088 
395 PNP 4860 
396 PNPLA3 80339 
397 PNPLA8 50640 
398 PPAP2A 8611 
399 PPAP2B 8613 
400 PPAP2C 8612 
401 PPARG 5468 
402 PPARGC1A 10891 
403 PPAT 5471 
404 PPCS 59717 
405 PPIF 10105 
406 PPME1  
407 PPT1 5538 
408 PRKAA1 105787 
409 PRKAA2 5563 
410 PRKACA 5566 
411 PRKAR1A 5573 
412 PRPS1 5631 
413 PRPS2 5634 
414 PSAP 5660 
415 PSAPL1 768239 
416 PTDSS1 9791 
417 PTDSS2 81490 
418 PTEN 5728 
419 PTGS1 5742 
420 PTGS2 5743 
421 PTPLA 9200 
422 PTPLAD1 51495 
423 PTPLAD2 401494 
424 PTPLB 201562 
425 PYCR2 29920 
426 RICTOR 253260 
427 RPE 6120 
428 RPIA 22934 
429 RPS6KB1 6198 
430 RPS6KB2 6199 
431 RPTOR 57521 
432 SACM1L 22908 
433 SAMD8 142891 
434 SAT1 6303 
435 SC4MOL 6307 
436 SC5DL 6309 
437 SCD 6319 
438 SCD5 79966 
439 SDHA 6389 
440 SDHB 6390 
441 SDHC 6391 
442 SDHD 6392 
443 SERINC1 57515 
444 SERINC4 619189 
445 SERINC5 256987 
446 SGK1 6446 
447 SGMS1 25923 
448 SGMS2 166929 
449 SGPL1 8879 
450 SGPP1 81537 
451 SGPP2 130367 
452 SHMT1 6470 
453 SHMT2 6472 
454 SIRT1 23411 
455 SIRT2 22933 
456 SIRT3 23410 
457 SIRT4 23409 
458 SIRT5 23408 
459 SIRT6 51548 
460 SIRT7 51547 
461 SLC16A1 6566 
462 SLC16A3 9123 
463 SLC16A6 9120 
464 SLC16A7 9194 
465 SLC19A1 6573 
466 SLC19A2 10560 
467 SLC1A3 6507 
468 SLC1A4 6509 
469 SLC1A5 6510 
470 SLC20A1 6574 
471 SLC23A2 9962 
472 SLC25A1 6576 
473 SLC25A11  8402 
474 SLC25A13  10165 
   
   241 
475 SLC25A14 9016 
476 SLC25A15 10166 
477 SLC25A20  788 
478 SLC25A27 9481 
479 SLC25A31 83447 
480 SLC25A4 291 
481 SLC25A5 292 
482 SLC25A6 293 
483 SLC26A6 65010 
484 SLC27A1 376497 
485 SLC27A2 11001 
486 SLC2A1 6513 
487 SLC2A4 6517 
488 SLC38A7 55238 
489 SLC38A9 153129 
490 SLC52A1 55065 
491 SLC5A3 6526 
492 SLC5A7 60482 
493 SLC6A15 55117 
494 SLC6A5 9152 
495 SLC6A6 6533 
496 SLC6A9 6536 
497 SLC7A1 6541 
498 SLC7A11 23657 
499 SLC7A2 6542 
500 SLC7A5 8140 
501 SLC7A8 23428 
502 SMOX 54498 
503 SMPD1 6609 
504 SMPD2 6610 
505 SMPD3 55512 
506 SMPD4 55627 
507 SMPDL3A 10924 
508 SMPDL3B 27293 
509 SMS 6611 
510 SOAT1 6646 
511 SPHK1 8877 
512 SPHK2 56848 
513 SPTLC1 10558 
514 SPTLC2 9517 
515 SPTLC3 55304 
516 SQLE 6713 
517 SRD5A3 79644 
518 SREBF1 6720 
519 SREBF2 6721 
520 SSSPTA 171546 
521 SSSPTB 165679 
522 ST3GAL5 8869 
523 ST6GALNAC6 30815 
524 ST8SIA1 6489 
525 ST8SIA3 51046 
526 ST8SIA5 29906 
527 STK11 6794 
528 SUCLA2 8803 
529 SUCLG1 8802 
530 SUCLG2 8801 
531 TAZ 6901 
532 TECR 9524 
533 TGM2 7052 
534 TK1 7083 
535 TK2 7084 
536 TKT 7086 
537 TM7SF2 7108 
538 TP53 7157 
539 TPI1 7167 
540 TSC1 7248 
541 TSC2 7249 
542 TXN 7295 
543 UCP1 7350 
544 UCP2 7351 
545 UCP3 7352 
546 UGCG 7357 
547 UGT8 7368 
548 UMPS 7372 
549 UPP1 7378 
550 UPP2 151531 
551 UQCRC1 7384 
552 VDAC1 7416 
553 YY1 7528 
 
